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Abstract
Molecular Modelling of Immunoglobulin Folds
Stephen M. J. Searle Ph.D Thesis
November 1997
The crystallisation of the T Cell a(3 Receptor (TCR) proved difficult to ac­
complish. Many TCR clones have been sequenced since the receptor was first 
identified in 1984. The main aim of this thesis is the prediction of TCR variable 
region structures using homology modelling techniques and gaining some insight 
into their interaction with MHC-peptide complexes.
The modelling was approached in a series of steps. TCR sequences were com­
pared to antibody sequences. These two classes of structures are both members of 
the immunoglobulin superfamily. Evidence is presented that both TCR a  and f3 
chains show greater homology to antibody k light chains than to antibody heavy 
chains, particularly in the Wa-Y/3 interface residues. A similarity index for com­
paring one set of sequences to two others was devised to aid in the comparison of
iii
TCRs and antibody sequences. An algorithm had previously been developed in the 
laboratory for modelling antibody variable domains. Certain modifications were 
made to this algorithm to allow the use of an antibody light chain dimer frame­
work and also a VLVH hybrid framework for modelling the CDR (32 region which 
appeared more similar to the antibody heavy chain. Before models of the TCR 
were made the modifications to the algorithm were tested on the non-antibody 
immunoglobulin CD4, which has a known crystal structure, so that the accuracy 
of the model could be judged. The algorithm was then used to model TCRs. First 
a set of TCR sequences were modelled for which data relating sequence and func­
tion were available. This provided a means of testing the ability of the algorithm 
to generate models which were consistent with these known facts. Then a TCR 
was modelled and used to predict the identity of a peptide contacting residue in a 
TCR CDR a3 loop which was then confirmed to be important for binding. The 
experimental work was done by L. Wedderbum at the Imperial Cancer Research 
Fund Laboratories (London, UK).
Also during the course of this work many antibody models were produced. It 
became apparent that the CAMAL modelling algorithm did not always produce 
accurate results especially for long CDR H3 loops. Adaptations to the algorithm 
CAMAL which increase its accuracy in modelling antibody CDRs are also pre­
sented.
A brief description of the work done on a new method for humanising murine 
antibodies (resurfacing) is also presented. This method generally requires fewer 
changes to be made to the mouse sequence than CDR-grafting and is therefore
iv
less likely to adversely affect the binding affinity of the antibody.
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Chapter 1
Introduction
The aim of the project was the molecular modelling of T cell receptor (TCR) alp  
dimers, as well as their interactions with their ligands, the major histocompati­
bility complex (MHC) -peptide complexes. At the time (1990) no structural data 
existed for any TCR because of difficulties in solubilising the protein for crystal­
lography. It is only recently that the structure of a complete TCR V region was 
solved [1,2], although the subunits had been crystallised separately in 1994 [3,4]. 
The modelling was an extension to previous work by the Bath group on antibody 
modelling [5-7].
In this introduction the immune system is briefly described and the role of 
the T cell and its receptor within it is explained. In Chapter 2 the sequences of 
TCRs and antibodies are compared. Chapter 3 describes the antibody molecular 
modelling method and adaptations that were made to it in an attempt to improve 
accuracy as well as to allow it to be used for the modelling of TCRs. In Chapter
CHAPTER 1. INTRODUCTION 2
4 an examination is made of the published work on the TCRs, and the modelling 
studies on them are described. Chapter 5 describes the application of antibody 
modelling to humanisation studies. In the final chapter a discussion is made of 
the value and accuracy of molecular modelling in this system. Also the future of 
modelling for TCRs is discussed.
1.1 The Immune System
There are many potential pathogenic microorganisms in the environment, includ­
ing bacteria, viruses and protozoa. Multicellular organisms have developed in­
creasingly more advanced mechanisms through evolution to protect them from 
infection by these entities.
As well as the physical barriers to invasion such as the skin and mucosa, the 
circulation contains many different cells and molecules involved in the elimina­
tion of foreign entities. Some are always present and do not vary in concentration 
in response to an infection. These form the natural immunity (or innate immu­
nity) of the body. Others recognise very specific foreign molecules, which are 
termed antigens, and increase in concentration to enable the rapid elimination of 
the foreign entity. These cells and molecules form the specific immunity of the 
organism [8 ].
On entry of a foreign organism, the initial response is by the natural immune 
mechanisms, before the specific immune response can be activated. These mech­
anisms include phagocytosis by phagocytes and macrophages and the activation
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of the complement system by the alternative pathway. The complement sys­
tem is a group of proteins which form a cascade proteolytic pathway to produce 
a protein complex called the Membrane Attack Complex (MAC) which cre­
ates holes in the cell membrane of invading microbes causing their death (see 
figure 1.1). Complement components can also mark cells for opsonisation by 
phagocytes and macrophages. Natural Killer (NK) cells are involved in immune 
surveillance, screening for tumour or virus infected cells [9]. They cause cell 
death of these abnormal cells by creating pores in their cell membranes.
The specific immune system consists of two main parts. The first is humoral 
immunity. This can be transferred between individuals in the humors (serum and 
plasma), that is without the transfer of cells. The second arm is the cell mediated 
immune response (cellular immunity) which can only be transferred between 
individuals by the transfer of blood leukocytes [1 1 ].
The specific immune response has several characteristics. The first is speci­
ficity which is the ability to identify uniquely a particular protein. The second is 
memory which is the capability of the organism to retain the ability to fight the 
same infection again without having to redevelop the response. This secondary 
response has massively increased effectiveness and often the micro-organism is 
eliminated before symptoms develop. A third is self non-self discrimination 
which is the ability to discriminate self molecules from non self foreign mole­
cules. These can include foreign micro-organisms, and also now tissue grafts or 
transplants. Failure of self recognition leads to autoimmunity [12,13]. In the 
case of tissue grafts self non-self discrimination presents a problem to successful
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Figure 1.1: The complement system. There are two different mechanisms by which the comple­
ment system can be activated; the Classical and the Alternate Pathways. However the two path­
ways both eventually lead to the same final result, the formation of the membrane attack complex 
(MAC). The classical pathway is activated by multivalent antibody antigen complexes, while the 
alternate pathway can be activated by several molecules including microbial cell surface polysac­
charides. Both pathways lead to the production of C3 convertases although these are made up 
of different components in the two pathways. C3b is a component of both C5 convertases which 
proteolyse C5 into C5a and C5b. C5b associates loosely with the cell membrane. This association 
is strengthened by the formation of the C5bC6C7 complex which is highly lipophilic. C8 and 
multiple copies of C9 then bind to the C5bC6C7 complex resulting in the pore forming MAC. 
(Dashed line = proteolytic activity, Line above text = proteolytic complex, Dashed and dotted line 
= activating agent) (adapted from [10]).
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grafting. A fourth is self regulation, which is the capacity to initiate the cor­
rect response at the right time and terminate the response once the infective agent 
has been eliminated. Failure of self regulation can lead to hypersensitivity or 
allergy [14]. The last characteristic is diversity, which ensures that an effective 
response can be mounted against almost any entity [15].
The specific immune system involves two types of cells from the circulatory 
system, B lymphocytes (B cells) and T lymphocytes (T cells). These have, on 
their surface, clonally distributed receptors which can recognise foreign mole­
cules. B lymphocytes produce antibodies that act as specific receptors for intact 
foreign macromolecules which can be free in solution or cell bound. T lympho­
cytes use a different receptor, the T-cell receptor which is more restricted in speci­
ficity, only recognising antigen when presented on another cell. In fact only 
fragments of the original antigen can be recognised when presented along with 
a major histocompatibility complex (MHC) antigen on the surface of another 
cell [16,17].
1.1.1 The Role of B Lymphocytes
B cells have antibodies expressed on their cell surface. These can bind antigen 
which can be internalised and processed for presentation by the MHC. This makes 
the B cell a very good antigen presenting cell (APC) as the antigen is specifically 
taken up. T cell help causes the proliferation of the B cell and differentiation into 
plasma cells which can secrete soluble antibody. The membrane bound antibodies 
on B cells can also act as the recognition component of a protein signalling com­
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plex known as the B Cell Receptor (BCR) [18]. This can stimulate activation of 
the B cell when antigen is bound if accompanied by T cell help.
Soluble antibody can bind to the antigen in solution and cause the activation of 
complement via the classical pathway. Alternatively it can bind to Fc receptors 
on phagocytes and hence target them to specific antigens in a process known as 
opsonization.
1.1.2 The Role of T Lymphocytes
T lymphocytes are primarily involved in the elimination of virally infected cells, 
although they also have an important regulatory capacity in the B-cell antibody re­
sponse to micro-organisms. T lymphocytes are subtyped according to their func­
tion. Those which bind to cells and cause them to die are called cytotoxic T cells, 
while those which bind to specific types of cells (B cells and other lymphocytes) 
termed APCs and enhance B cell proliferation and immunoglobulin production by 
lymphokine secretion are called T helper cells. There are also T cells which, on 
binding to APCs, suppress the immune response to a particular antigen. These are 
called T suppressor cells.
T cells develop from haemopoietic stem cells in the bone marrow. These 
enter the thymus where they complete their development. The T cells are divided 
into two groups distinguished by whether they express alp  TCRs or 7 IS TCRs on 
their cell surface. The alp  TCR expressing T cells constitute about 95% of the T 
cells in the body.
T helper and suppressor cells, as well as recognising antigen, must also be able
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to recognise the cell type as an APC. A set of polymorphic molecules, the MHC 
antigens, are involved in presentation of the antigen. Distributed almost ubiqui­
tously among the tissues of the body are the MHC class I molecules which mark 
cells as “self”. “Non self” cells entering the body such as those from transplants 
are recognised as foreign because they generally have different MHC class I mol­
ecules expressed on their cell surface. This is known as an allotypic response. 
MHC class II molecules have a much more restricted distribution, only being 
found on APCs. The structures of several MHC class I molecules have been deter­
mined by X-ray crystallography [19-21]. The structure comprises a glycosylated 
polypeptide chain of 45kD in non-covalent association with /?2 microglobulin, a 
12kD polypeptide which is also found non-associated in serum. The 45kD chain 
is divided into five domains: three extracellular domains, a transmembrane region 
and a cytoplasmic domain. The two N-terminal domains of this chain form the re­
gion which is involved in antigen presentation to T cells. This consists of a groove 
with a-helix sides and a (3 sheet base which binds a peptide from the processed 
antigen. Figure 1.2 shows an MHC class I molecule with bound peptide. This is 
the region of the molecule where the polymorphic variations are centred.
The tertiary structure of MHC class II is similar to the class I molecules with 
the antigen presented in a similar way. However the primary structure is different, 
with two chains of approximately equal length each forming half of the peptide 
binding site. Several MHC class II proteins have been crystallised [22,23] and 
found to form dimers. There is now some evidence that the dimeric state may be 
important for their signalling function [24].
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Figure 1.2: A schematic diagram of the structure of the MHC class I molecule H-2K6 in complex 
with a peptide from Sendai virus nucleoprotein (residues 324-332) [25]. Diagram created with 
molscript [26],
Pockets have been identified in the binding clefts of both types of MHC which 
are specific for certain amino acid types at fixed positions in the peptides which 
bind.
The breakdown of the antigens and association of peptide occurs within the 
APC [27]. Proteins produced within the cell, such as those of viral origin are 
presented in association with MHC class I molecules whereas those which have 
been endocytosed into the cell are associated with MHC class n  on APCs. This 
allows the different types of cells to be distinguished by the subsets of T cells. 
The cytotoxic T cells mainly recognise cells with MHC class I. They have on
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their surface a receptor, CD8 , which binds to a non polymorphic region of the 
MHC class I molecule. The T helper cells on the other hand are mainly class II 
restricted and have a receptor, CD4, which binds to the MHC class II molecule. 
Although CD4 and CD8 are involved in determining which cells are bound, these 
receptors bind to non-polymorphic regions on the MHC molecules [28]. To give 
specificity for a particular MHC and peptide a receptor is needed which binds to 
both the polymorphic regions on the MHC and to the bound peptide. This is the 
function of the TCR.
1.1.3 7/ S  TCR expressing T Cells
During the early sequencing experiments to find the a  chain a third TCR chain 
type, the 7  chain, was discovered [29]. The role of the 7  chain remained a mystery 
until the S chain was identified and it was discovered that there were two distinct 
types of TCR (at(3 and 7 15) [30]. TCR 7 M expressing T cells form a distinct 
lineage from al(3 TCR expressing T cells. The 7  and 5 TCR sequences are similar 
to the a  and (3 and rearrange in a similar manner. However the function of 7 15 
T cells is uncertain [31]. They do respond to stimuli in similar ways to a/(3 T 
cells, for instance by secreting lymphokines or producing cytotoxic responses. 
However they do not, in general, seem to bind to classical MHC molecules. There 
is some evidence they may bind to non classical MHC possibly without bound 
peptide [32]. Also 7 /5 cells often do not express either CD4 or CD8 (double 
negative cells) , but the TCR chains do appear to be associated with the CD3 
signal transduction complex.
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Figure 1.3: The response to antigen in CD4+ T cells is divided into three stages; the cognitive, ac­
tivation and effector phases. The cognitive phase is the stage at which recognition of MHC bound 
peptide on an APC occurs. Signal transduction through the CD3 complex activates signalling 
pathways within the T cell. This leads to stimulation of interleukin-2 growth factor secretion by 
the T cell that binds to receptors on the cell causing proliferation and differentiation of the T cell 
clone. In the effector phase these cells bring about responses in other cells of the immune system 
by the release of cytokines. Adapted from [10].
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The 7 15 expressing cells may be involved in responses to stress, possibly 
recognising heat shock proteins [33]. It has been suggested that this might pro­
duce an early non-specific response to micro-organism infection before the TCR 
alp  response develops [34]. Another possibility is that they may be involved 
in immune surveillance such as the elimination of tumour cells. In the epithelia, 
there are populations of 7 15 T cells expressing a single TCR. The role of these 
receptors is not certain [31].
1.1.4 Mechanism of Action of T Cells
The first stage in T cell activation is the cell cell contact between the T cell and 
the APC or target cell which initiates signalling [35]. The TCR is probably not 
the main protein responsible for the initial binding phase, this being performed by 
the monomorphic receptors on the cell surface such as CD2 which binds LFA3 on 
the APC and ICAM1 which binds LFA1 on the APC or vice versa.
The signal transduction pathway in T cells is shown in figure 1.5. The binding 
of MHC-Ag induces a signal which is transduced by the CD3 protein complex (see 
figure 1.4) [36]. CD4 has on its C terminus a binding site for a phosphorylation 
enzyme p56/cfc which phosphorylates several src homology 2 (SH2) sites on the 
C terminal domains of CD3. An SH2 site on CD3 £ chain binds phospholipase C 
(PI-PLC7 I) which catalyses the conversion of phosphatidyl inositol 4,5 bispho- 
sphate (PIP2) to inositol (1,4,5) triphospate (IP3) and diacylglycerol (DAG) . 
IP3 stimulates the release of calcium from intracellular vesicles and, possibly, 
also the uptake of calcium from the exterior and the removal of potassium from
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Figure 1.4: The TCR CD3 protein complex. The TCR a//3 and 7 IS chain pairs both form a 
complex with the CD3 complex. CD3 acts as a signal transduction complex detecting binding to 
the recognition TCR component and producing intra-cellular responses. CD3 consists of a 7 , <5 and 
e chains noncovalently associated with the TCR heterodimer. There are conserved complementary 
charged residues in the presumed membrane spanning regions of the chains which may be involved 
in maintaining the complex. There is either a £ chain homodimer or a £ chain 77 chain heterodimer 
associated with CD3 and the TCR.
the cell. DAG causes the activation of protein kinase C which catalyses various 
enzyme phosphorylations leading to gene activation and new protein production.
The genes which are activated depend on the type of T cell. In mouse the T 
helper cells can be divided into two groups based on the cytokines they produce. 
These are TH1 and TH2. Table 1.1 shows the profiles of cytokines produced by 
THl, TH2 and cytotoxic T cells. Within the two T helper cell types IL-2, EFN7 
and TNF/3 are produced exclusively by THl while IL-4, IL-5, IL-6 and IL-10 are











PKC Ca** dependent kinases
phosphorylation-mediated control of 
cellular responses
Figure 1.5: The signal transduction pathway in T cells. The binding to MHC with antigenic 
peptide (Ag) to the TCR induces signalling pathways within the T Cell. These are described in 
detail in the text (adapted from [37]).
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produced only by TH2 cells. These differences lead to different functions for the 
two types of cells. They differ in the isotypes of antibodies with which they can 
give T cell help. TH2 provide help for IgM, IgG3, IgA and particularly IgE. The 
production of IgE requires IL-4. THl can provide help for IgM, IgG3, IgGl and 
IgG2a. IgG2a requires IFN7 for its production. Parasitic worms elicit responses 
which are mainly TH2 based leading to the production of IgE, while responses to 
some bacterial and most virus infections are THl based leading to the production 
of IgG2a. IFN7 is also involved in macrophage activation, and so this is a role of 
THl cells. IL-3 and EL-4 are involved in mast cell growth and IL-5 in eosinophil 
maturation. These are therefore functions of TH2 cells.
In humans, cells with similar cytokine expression profiles to mouse THl and 
TH2 cells do occur. However many human T cells show another pattern of expres­
sion and are classed as THO cells.
EL-2 induces proliferation of cytotoxic T cells. A close association between T 
cell and target cell is required before killing can occur. There may be more than 
one mode of killing. One mechanism is pore formation, produced by the secretion 
of perforins into the intercellular space which form polyperforin multimers in the 
target cell membrane, puncturing it. TNFo; and TNF/3 can also be secreted and 
these cause apoptosis (programmed cell death) of the target cell. Proteoglycan 
(condroitin-5-sulphate) may help to stabilise perforins and protect the T cell from 
their pore forming action during an attack on a target cell. Calcium is also required 
for perforin polymerisation.
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Cytokine CTL Thi TH2
IFN7 ++ ++ -
IL-2 +/- ++ -
TNF^ + ++ -
GM-CSF ++ ++ +
t n f q + ++ +
IL-3 + ++ ++
IL-4 - - ++
IL-5 - - ++
IL-6 - - ++
IL-10 - - ++
Table 1.1: This table indicates the cytokines which are produced by the three mouse T cell types 
THl, TH2 and CTL [37].
1.1.5 Antigen Processing and Presentation
Endogenously produced proteins are proteolysed in the cytoplasm by a protea- 
some encoded in the MHC, or in endoplasmic reticulum (ER) . Peptides pro­
duced in the cytoplasm are transported across the ER membrane by the trans­
porter in antigen processing (TAP) before binding to MHC class I molecules. 
Only peptide bound MHC is expressed at the cell surface (see figure 1.6).
Exogenously produced proteins are endocytosed into early endosomes where 
they are proteolysed. These bind to class II storage vesicles where the MHC class 
II molecules have their binding grooves protected by CLIP protein. The CLIP 
protein is degraded in the vesicle allowing the proteolysed foreign peptides to 
bind in the MHC groove [38].
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Figure 1.6: Endogenously produced protein antigens are broken down by the proteasome into 
peptides which tranfer through the endoplasmic reticulum membrane using the TAP peptide trans­
porter. There they become associated with MHC class I molecules and are transferred via the 
Golgi apparatus to the cell surface where they are screened by T cells. Adapted from [10].
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1.2 The Immunoglobulin Superfamily
A superfamily is a group of proteins which show sequence homology (at least 
15%), usually encoded by a single exon and forming a compact structural unit. 
Each member of the superfamily probably derives from a common precursor by 
divergent evolution. Some examples of superfamilies are the globins, the growth 
factors, the neurotransmitter receptor ion channels and the immunoglobulins.
Membership of the immunoglobulin superfamily is indicated by the presence 
of one or more Ig domains (homology units) of 70-100aa’s homologous to Ig 
Variable (V) or Constant (C) domains. The Ig superfamily comprises proteins 
which in general have receptor functions, many of which are involved in immune 
recognition but some in areas such as endocrine and neuronal recognition. Figure 
1.7 shows some of the members of the Ig superfamily. There are three types of 
Ig domain, the V type (like an antibody V region), the C type (like an antibody C 
region) and the H type (hybrid sharing V and C character). Some proteins contain 
several Ig domains of one or more type [39].
The ancestry of the different types of domain is still a matter of some spec­
ulation. However it is thought that V and C domains split early in Ig evolution 
and that the gene rearrangement mechanism shown in Ab and TCR V regions 
developed early [40]. The low homology between Ig V domains and TCR V do­
mains suggests an early split. The study of Ig evolution is hampered by the gene 
rearrangement mechanism. It is thought that Ig genes are evolving more rapidly 
than other proteins, probably because the antigen recognition role Ab and TCR
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Figure 1.7: Some proteins containing immunoglobulin domains are shown. Each domain is rep­
resented by an arc. The three types of domain are C type (like Ab constant region) which are 
coloured blue, V type (like Ab variable region) which are coloured red and H type (hybrid con­
taining both constant region and variable region character) which are coloured green.
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perform makes rapid adaptation to new antigens vital [41].
1.2.1 Immunoglobulin Structure
The structure of an antibody Fa& was first solved by X-ray crystallography in 1973 
by Poljak et al [42]. Since then the structures of many antibodies and several other 
members of the Ig superfamily have been determined (CD4 [43,44], CD8 [45], 
NCAM, ICAM and MHC). Table 1.2 lists published antibody structures. The Ig 
fold consists of two antiparallel /3-sheets of 4 and 3 (C domain) or 4 and 5 (V 
domain) strands as shown in figure 1.8. They form what is known as a “Greek 
Key” motif. These are brought together to form a compact structure with the 
hydrophobic residues in the (3 strands forming a stable core [46]. The two sheets 
are bonded together by a disulphide bond between two very highly conserved 
cysteines in strands B and F.
Brookhaven Entry Name Resolution (A) Chain Type Reference
3hfl HyHEL-5 2.65 ftAyll [47]
3hfm HyHEL-10 3.0 ftAyl [48]
lbji/2 bji LOC 2 .8 ft/ft
2 fbj J539 1.95 ft/IGA [49]
3fab/7fab NEW 2 .0 ftAyll [50]




lmcp/2 mcp McPC603 3.0 ft/7H[ [53]
3mcg MCG 2 .0 Al/Al [54]
lmcw WEIR/MCG 3.5 Al/Al [55]
2 rhe RHE 1 .6 Al/Al [56]
lrei REI 2 .0 ft/ft [57]
2fb4/2ig2 KOL 1.9 AI/7 III [58]
If 19 R19.9 2 .8 ft/711 [59]
lfdl D1.3 2.5 ft/711 [60]
Imam YS*T9.1 2.5 ft/711
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Brookhaven Entry Name Resolution (A) Chain Type Reference
8 fab HIL 1.8 AI/7 I [61]
lbaf AN02 2.9 ft/7 1 [62]
lhil/lhin/lhim 17/9 2 .0 ftAyll [63]
ligf/2 igf B13I2 2 .8 ftAyl [64]
ldfb 3D6 2.7 /J7 I [65]
ligm POT 2.3 ft/? [6 6 ]
lbbd 8F5 2 .8 ft/? [67]
lncd NC41 2.9 ft/? [6 8 ]
ligi 26-10 2.7 ftAylLA [69]
Iggi 50.1 2 .8 ft/711 [70]
lacy 59.1 3.0 ft/7 1 [71]
lbbj B72.3 3.1 ft/7 lV [72]
lbre BRE 2 .0 ft/ft [73]
lcbv bv04-01 2 .6 6 ft/? [74]
leap 17E8 2.5 ft/? [75]
lfbi F19.3.7 3.0 ft/7 1 [76]
lfgv HUH52-AA 1.9 ft/? [77]
lfig 1F7 3.0 ft/7 1 [78]
lfor FAB17-IA 2.75 ftAyHA [79]
lfpt C3 3.0 ftAyllA [80]
lfrg FAB26/9 2 .8 ftAylLA [81]
lfvc 4D5 2 .2 ft/? [82]
Igig HC19 2.3 A/7 I [83]
ligc MOPC21 2 .6 ft/7 1 [84]
likf 2.5 ft/7 1 [85]
lind CHA255 2 .2 A/7 I [8 6 ]
livl M29B 2.17 ft only [87]
ljel JE142 2 .8 ft/? [8 8 ]
ljhl D l l .15 2.4 ft/7 1 [89]
llmk L5MK16 2 .6 ft/? [90]
lmlb/lmlc D44.1 2 .1 ft/7 1 [91]
lnbv BV04-01 2 .0 ft/? [74]
lnma/lnmb NC10 3.0/2.5 ft/? [92]
lnsn N10 2.9 ft/7 1 [93]
lopg OPG2 2 .0 ft/? [94]
lrmf R6.5 2 .8 ft/? [95]
ltet TE33 2.3 ft/7 1 [96]
lvfa D1.3 1 .8 ft/7 1 [97]
lwtl WAT 1.9 ft/ft [98]
2 cgr 2 .2 ft/711 [99]
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Brookhaven Entry Name Resolution (A) Chain Type Reference
2 dbl DB3 2.9 k/j ILA [1 0 0 ]
2fl9 R19.9 2 .8 ftAyllB [1 0 1 ]
2 gfb CNJ206 3.0 /cAyllA [1 0 2 ]
3bjl LOC 2.3 AL/AI [103]
Table 1.2: List of antibody structures and their fragments whose X- 
ray coordinates are currently available at the time of writing from the 
Brookhaven database of protein structures.
Three of the four loops between strands at one end of the core in the V domain 
of each chain form the antigen combining site in antibodies [104] and probably 
the MHC-peptide binding site in TCRs. These are the loops between B and C 
strands, C’ and C” strands and the F and G strands.
In the TCR a  chain V region structure the C” strand switches from one sheet 
to the other [4].
A single protein chain often contains more than one immunoglobulin domain 
separated by short connecting regions. The chains themselves are often associated 
into multimeric proteins; for example IgG contains four chains, two heavy and two 
light. The heavy chain contains four domains VH CHl and Q^. The light chain 
contains two domains VL and C^ . There are interactions between the VH and VL> 
the Q  and Q^, the and and the Qj3 and Qj3 domains. The interactions 
between the V domains are between the five strand sheets. In the C regions the 
four stranded sheets interact. Other members of the immunoglobulin superfamily 
such as CD8 are multimers with similar pattern of association. Some, however, 
are monomers, for example CD4 which is made up of four Ig domains in a single 
chain.
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Figure 1.8: The arrangement of (3 strands in antibody V and C domains. V Domains have one 
sheet consisting of 5 and one of 4 strands and C domains one of 3 and one of 4 strands. Also 
shown is the disulphide bond between the two sheets.
1.2.2 TCR Gene Arrangement
The polymorphic TCR chains are encoded in four gene loci TCRA (a chain), 
TCRB(/3 chain), TCRG (7 chain) and TCRD (5 chain).
The TCRB chain locus consists of 25 V region segments followed by two 
tandemly arranged groups of 1 D, 6 J and 1 C region. 3’ to the second C region is 
an inverted V region [105]. The TCRG locus in humans is similar to the (5 chain 
locus overall, having two groups of J and C segments. It however lacks D regions 
and has fewer V regions (8). The two tandemly arranged groups of J and C regions 
also contain different numbers of J regions (2 and 3). The TCRD locus is unusual 
in that it is completely enclosed in the TCRA locus. The TCRD locus V region 
gene segments are interspersed amongst the more than 75 a  chain V region genes.
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Figure 1.9: The arrangement of /3 strands in the antibody Vh and Cm domains of 4-4-20 [51]. V 
Domains have one sheet consisting of 5 and one of 4 strands (left). C domains are missing the C’ 
and C” strands having 4 and 3 stranded sheets (right). Diagram created with molscript [26].
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Figure 1.10: Schematic of the human TCR gene complexes. The top line shows the /3 chain 
complex. The second and third the a/5  complex and the bottom line the 7  chain complex. Adapted 
from [1 0 ].
There are 2 D5 regions followed by two J5 regions and a Q  region. 3’ to this is 
an inverted % region [106,107]. The 75 V region genes of the a  locus are 5’ to 
the TCRD locus whilst the 70 JQ regions are 3’ to it. Some of the V region gene 
segments can be used in both a  and 8 chains. The single CQ region is positioned 
3’ to the last JQ region. The arrangement of the loci is illustrated in figure 1.10.
1.2.3 TCR Gene Rearrangement
Gene rearrangement is the general mechanism by which TCRs generate their di­
versity [108]. The first two stages occur at the DNA level by somatic recom­
bination, initially between a D and a J gene segment (/3 and 8 chains only) and 
subsequently between a V and the rearranged D-J (/? and (5) or V and J (a  and
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7 ) gene segments. The DNA between the particular V, D and J regions utilised 
is usually excised during the recombination processes. The processes involved in 
TCR gene rearrangement are shown in figure 1.11.
A primary mRNA transcript consisting of the leader exon, the combined VDJ 
exon, and the region 3’ to this, including the C region gene exons, is transcribed. 
RNA processing (splicing) then generates the LVDJC mRNA transcript which is 
translated to protein.
The mechanism of V, D, J somatic recombination has been studied in detail. 
It involves the protein products of two genes known as recombination activating 
genes (RAG). RAG1 and RAG2 recognise conserved heptamer and nonamer base 
sequences which are separated by either 12 or 23 base pairs. These segments are 
present 3’ to each V region, 5’ and 3’ to each D region and 5’ to the J region seg­
ments. Hybridisation between a pair of heptamer and a pair of nonamer sequences 
leads to recombinase enzyme recognition, and excision of the DNA between the 
two gene segments, as long as the loop contains one 12 and one 23. Excision will 
not occur if two 1 2 ’s or two 23’s are between the two heptamer nonamer pairs.
1.2.4 Immunoglobulin Sequence Diversity
A comparison of the TCR and antibody V domain diversity is shown in table 1.3. 
The smaller number of V segments in TCR compared to antibodies reduces the 
variability possible due to combinatorial association. By contrast, diversity within 
the junctional region is greater for TCRs than for antibodies. This difference 
in distribution of variability led to the suggestion that the junctional region in
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Figure 1.11: The scheme represents the stages involved in producing translated TCR protein from 
the chromosomal DNA. First the DNA in the cell recombines (described in the text) to splice 
together a V, for /3 D, J and a C region into a transcribable gene. This is transcribed and translated. 
Adapted from [10].
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TCRs, that codes for the CDR 3 region in antibodies, is responsible for binding 
to the peptide antigen, while the V gene segments, which have less possibility for 
variability, are involved in binding the MHC molecule. Several investigators have 
examined this possibility by sequencing the receptors from several T cell clones 
reactive against the same MHC and antigen, to determine whether V segment 
usage was conserved [109-113]. The consensus from these studies is that TCRs 
recognising the same antigen often express a limited repertoire of V and J gene 
segments but that there is no complete dependence on a single segment for each 
MHC.
The number of possible TCR sequences is very large and includes many which 
could be reactive against self components and produce adverse autoimmune re­
sponses in the body. To prevent such problems there is a very restrictive selection 
process. This occurs in the thymus, and the major mechanism appears to be clonal 
deletion. It is obviously important that the TCR should be sensitive to the com­
position of the peptide as well as the MHC, so it is necessary to eliminate T cells 
which express TCRs which bind too strongly to MHC. However TCRs with low 
affinity for host MHC would also need to be eliminated as these might not be able 
to discriminate self from non-self MHC alleles [37].
1.3 Summary
T cells form an integral part of the immune system, having two major functions; 
the killing of virally infected cells (cytotoxic T cells) and the stimulation of spe-
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Ig TCR
H K a (3
variable(V) 250-1000 250 1 0 0 25
diversity (D) 1 0  0 0 2
joining(J) 4 4 50 12
Variable region combinations 62,500-250,000 2500
usage of different D and 
J segments
yes yes yes yes
Junctional
variability in 3’ joining 
of V and J
rarely rarely yes no
Diversity D joining in all three 
reading frames
rarely - often
N region diversity V-D, D-J none V-J V-D, D-J
Junctional combinations ~  1 0 u -  1 0 15
Total repertoire ~  1 0 11 ~ 1 0 15
Table 1.3: Table comparing the mechanisms involved in the generation of antibody and TCR 
diversity. Estimates of the total diversity are shown.
cific B cells to produce antibodies (T helper cells). The TCR is vital to the T cell’s 
functioning, acting as a specific receptor for both an antigenic peptide and self 
MHC. Many different TCRs can be generated by the mechanisms of junctional 
and combinatorial diversity, but each T cell expresses only one TCR sequence. 
This provides the specificity of the T cell response. How the TCR itself signals 
that it has bound to an MHC is under intense investigation. However, the cascade 
of signalling reactions which occur within the T cell have been widely studied. 
They cause the T cell to express interleukins as well as receptors for them. These 
compounds cause proliferation of the T cells, and initiate B cell proliferation and 
differentiation.
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1.4 Aims and Objectives
The TCR is a member of the immunoglobulin superfamily. Methods for the ac­
curate prediction of the structure of antibody variable domains exist. This thesis 
describes an approach taken to use homology modelling to produce models of 
TCRs based on methods used to model antibodies. The initial work concentrated 
on making comparisons of TCR and antibody sequences and improving antibody 
modelling. Information from these studies was then used to devise a method for 
modelling TCRs and this method was used to create models of TCRs. The re­
cent publication of the TCR structures has enabled some comparisons to be made 
between models and structure. This work is described in the subsequent chapters.
Chapter 2
Sequence Analysis of 
Immunoglobulins.
2.1 Introduction
The sequence is the starting point for any homology modelling approach. For 
antibodies and TCRs, the diversity generation mechanisms give rise to many dif­
ferent sequences. The structure of all antibody Fv’s so far determined have a very 
similar core structure, varying mainly in the hypervariable loops which form the 
antibody combining site (three from each chain). However, not all the regions 
of sequence between these loops is completely conserved in different V and J 
regions. Those residues which are highly conserved are therefore likely to be 
important for maintaining the structure, or to have some other important func­
tional role. There are several thousand antibody V region sequences published
30
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and several hundred TCR sequences. Therefore sets of homologous sequences 
can provide invaluable information in producing models of the structure.
There are known relationships between sequence and structure and sequence 
and function for antibodies [46,104,114-117]. Studies on antibodies indicate that 
only a proportion of the residues in the sequence interact directly with antigen. Al­
most all of these residues fall into regions of the sequence which are hypervariable 
between antibody sequences. There are three such regions in antibodies; CDR1, 
CDR2 and CDR3. CDRs 1 and 2 are coded for in the V segment of germline 
DNA while CDR 3 encompasses the junctional region including the 3’ end of the 
V segment, the D segment in the antibody heavy chain and TCR (I and <5 chains, 
and the 5’ end of the J segment.
Some residues in antibodies, outside the CDRs in the more conserved frame­
work regions, are almost completely conserved between sequences. Structural 
studies have shown that some of these residues are involved in structurally impor­
tant interactions such as those between the strands and those in the V-C and VL-VH 
interfaces [117,118].
Some structurally important interactions between framework and CDR residues 
have also been found. These lead to the ability to use sequence patterns to divide 
some CDRs into canonical groups [119-122].
The frequencies of residues in CDRs of antibodies is distinctly different to 
the framework regions. Residues such as tyrosine, tryptophan and asparagine 
are more common in the CDRs than the framework. The aromatic residues in 
CDRs are more exposed than is usual while the asparagines are more buried. It
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is thought that the asparagines are involved in structural interactions and the aro­
matic residues provide an important contribution to the binding energy for the 
antibody-antigen interaction [123].
As there are few structures of TCRs, structure-function relationships are less 
certain. However the sequence homology of the two groups of sequences en­
ables the information (such as the positions of CDRs and the roles of conserved 
residues) and techniques (such as variability plots) that have been applied to anti­
body sequences to be transferred to studying TCRs.
The TCR sequences are divided into non overlapping subfamilies based on 
a homology criterion of 75%. These classes have had various naming schemes 
applied to them over the years but recently the mouse and human TCR sequences 
have been assigned a standardised naming scheme by the nomenclature sub-committee 
of the International Union of Immunological Societies (IUIS) [124-126].
A comparison of TCR sequences to antibody sequences has been made by 
Chothia and Lesk [127]. This showed that the TCR V domain sequences were 
consistent with an antibody V type fold. Variability analysis, which identifies 
the regions of family of sequences that are most variable in terms of the residues 
which occur, was performed on TCR sequences by Jores et al [128]. This showed 
peaks of variability in TCRs in regions equivalent to antibody CDRs. An ex­
tra peak of variability was also seen between the CDR 2 and CDR 3 equivalent 
regions in the TCR f) chain. This chapter, rather than repeating this work con­
centrates on specifically identifying which of the antibody chain types is most 
similar to each TCR chain type, in order to identify the best framework to use in
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molecular modelling of TCRs.
2.2 Methods
2.2.1 Sequence Selection
Sequence alignments of antibody light and heavy chains, TCR a  and /3 chains and 
MHC chains are maintained by Kabat and Wu [129]. The “fixed length” file ver­
sions of these alignments were obtained via anonymous ftp from ncbi.nlm.nih.gov 
(mirrored at ftp.ebi.ac.uk) and converted into NBRF format using the program 
MOL [130]. The converter checked for data consistency and several errors were 
found and notified to the database maintainer who posted updates. The NBRF 
format files were analysed in the program SR [131].
Wherever possible sequences were obtained from the Kabat database. When 
a sequence was not obtainable from Kabat the Genbank database was used. Three 
different groups of sequences were selected, the CDR3 regions, the complete an­
tibody V region and the complete TCR V regions. There were many more CDR3 
regions in the Kabat database than complete V regions. When examining the prop­
erties of these regions it is better to include all those which have a CDR3 region 
rather than just those with the complete V region.
2.2.1.1 CDR3 Sequences
All the sequences of a particular chain type were selected, for mouse and human 
separately, from the Kabat database. The next stage in the selection process was to
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discard all sequences in the Kabat database containing any unknown or ambiguous 
residues, for example containing ’X’, ’B \ ’Z’ or ’?’ residues. The rest of the 
sequences were selected.
A subset of sequences was also created in which identical sequences were 
eliminated. This subset was used to check for any possible bias in the original 
Kabat data. It also provided the possibility of doing a parallel analysis, the results 
of which could be compared with the original set.
2.2.1.2 Complete Antibody V Region Sequences
The sequences were again selected from the Kabat database after entries with 
ambiguous or unknown residues had been discarded. The selection was also re­
stricted to all the sequences which started within 5 residues of the start and ended 
within 5 residues of the end of the standard Kabat alignment. Sequences contain­
ing an identical V segment to other selected sequences were also eliminated.
2.2.1.3 TCR V Region Sequences
The paper describing the IUIS classification scheme for TCR V segment sequences 
contains information on which clone names belong to each class in the scheme. 
These clone names were initially used to identify the sequences to be retrieved 
from the database. The Kabat entry number for each of these clones in the data­
base was identified. The corresponding sequence was retrieved from Kabat and 
was then used as the basis of a further search for similar sequences. Sequences 
which matched in either residues 1-50, 50-93 or 30-70 (Kabat residue numbering)
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were identified.
V segment sequences which had been extracted directly from the published 
classification scheme were then aligned in the same way as those extracted from 
Kabat. These also were then used as probes for further searches of the Kabat 
database (again using the same three sequence ranges).
It was possible that there were further matching entries in Kabat which had not 
been retrieved because they contained sequence errors, inconsistent clone names 
or were only partial sequences. In an attempt to retrieve these sequences, a se­
lection was made of all sequences containing 30 residues or more, but excluding 
the ones already retrieved. These were examined manually and an exact class or, 
failing this, the closest matching class, was determined for each.
Any sequences in the classification table which had still not been found by 
this procedure and also where the Kabat sequence identified was very short, were 
searched for in the Genbank database. The SR program was used to translate the 
Genbank Nucleotide sequence into a protein sequence using the feature entries 
present in the Genbank file. These translated regions for each sequence were 
stored on file in case the process needed to be repeated.
Retrieved sequences from all sources were then compared to the classification 
scheme to look for errors. Inconsistencies or obvious errors were noted and the 
sequence was discarded. For each class, excluding non functioning or pseudogene 
classes, the best sequence was identified. In most cases this was the longest, 
but sequences which had known TCR a and /3 pairings were favoured, whereas 
pseudogene sequences in a non pseudogene class were considered unsuitable.
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The chosen sequences were then extracted from the various sources into a 
NBRF format file. All comments in the original format files were retained. Any 
Genbank sequences thus selected were aligned manually according to the Kabat 
alignment.
The complete list of sequences is shown in tables B.2 to B.7 in appendix B.
2.2.1.4 Obtaining Pairs
Paired sequences were then obtained from all the selected sequences. They were 
identified by the ’AAName’ field from the Kabat database. In paired sequences 
this has the same value in both the a  and the /? sequence entries for the TCR, or 
in the light and heavy chain sequence entries, for antibodies
2.2.2 Sequence alignments
Various programs exist which attempt to automatically align sequences (AMPS 
[132], CLUSTALW [133], PILEUP [134]). It was initially attempted to use these 
programs to align the TCR and antibody sequences against one another. However, 
these programs failed to produce sensible alignments, probably due to the large 
number of sequences, the low homology between antibodies and TCRs and the 
high variability in length of the CDR 3 regions. It was therefore decided to use 
a more manual approach to align the sequences, based on structural comparisons 
between the antibody light and heavy chains.
For the T cell receptor groups the first step in the alignment process was to 
manually align the sequences extracted from the Genbank database to fit the Kabat
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alignment.
The Kabat database contains inserted residue fields for some of its sequences. 
These are sequences which do not fit the Kabat alignment because they have extra 
residues between the standardised Kabat positions. To incorporate these residues 
in the data, extra positions were added to the antibody and TCR alignments (au­
tomatically in the program SR).
For the CDR3 region of the heavy chains the length of the alignment expanded 
to approximately 70 residue positions although the longest sequence was only 32 
residues. This was because similar regions of sequence were inserted at several 
different positions. The alignment was edited in this region to consolidate the 
gaps. The heavy and light chain structures of 50 antibodies were all superimposed 
onto one another using conserved residues in the B and C /? strands. From this it 
was possible to determine the positions where the light and heavy chains differed 
structurally. The alignments were altered at these positions to create a structural 
alignment. This was achieved by inserting or moving gaps as required.
The next step was to match the TCR alignments to this structural alignment 
for antibodies. This was achieved by aligning the conserved residue motifs which 
define the limits of the CDRs for antibodies and TCRs.
2.2.3 Sequence variability
Sequence variability was calculated for each chain type for sequences which con­
tained V, D and J segments using the method of Wu and Kabat [135]. The vari­
ability at each alignment position is calculated as the number of residue types
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occurring at the position divided by the frequency of the most commonly occur­
ring residue at the position.
Tr . . ,  number of  di f ferent  amino acids that occur at siteVariability = —  ---- J-— ------------------  :- --- (2.1)
frequency of most common ammo acid at site
2.2.4 Sequence Similarity
Comparisons were made between TCR a  and (3 chains and human light and heavy 
chains using a similarity score comparing one set of sequences to two other sets of 
sequences. The score at each position is defined as the difference in frequencies 
of occurrence of each amino acid at each position compared to each set. The 
score ranges from -2  to 2  with 0  indicating equal similarity to each chain type. 
Positive values indicate greater similarity of the comparison set to one of the sets 
and negative values greater similarity to the other set.
20
SimScore =  Y .  (Freqlres -  Freq2res) (2.2)
r e s = 1
A dissimilarity score was also calculated for each set of frequencies which 
was the sum rather than the difference of the two frequency sets. The two scores 
together indicate which positions are useful in distinguishing which chain type the 
comparison set is more similar to.
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Table 2.1: Kabat residue numbering [129] ranges used in CDR length calculations. Using the 
residue numbering in figure 2.2 the ranges are 24-41 (CDR 1), 57-74 (CDR 2) and 105-137 
(CDR 3).
2.2.5 CDR Ranges
The residue ranges used to delimit the CDRs in the length calculations are shown 
in table 2.1. TCR a-(3 sequence pairs used in the combined CDR 3 length cal­
culation were generated by linking sequences with the same clone name. Highly 
conserved sequence motifs are present at each of these limits, ensuring that the 
length of the equivalent piece of structure is being compared. The structure of 
regions around the three CDRs in the antibodies with solved X-ray structures, as 
well as CD4 and CD8 , were examined (see section 4.5).
2.2.6 Sequence Environments
The similarity of the structural environment of TCRs and antibodies was examined 
by calculating a normalised similarity score for each position which included all 
residues within 5 A of each aligned position in an antibody and aligned TCRs. The 
residues within 5 A of each residue were determined using the average distance 
between the centres of gravities of all residues.
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Table 2.2 shows the average sequence identity between TCR a  and (3 chains and 
the sequences of antibodies of known structure. The overall level of identity is 
low at 15-22 %. The identity to light chains is higher than to heavy chains for 
both TCR a  and (3 chains.
Such low identities between the sequences would often indicate that they had 
different structures. However, other immunoglobulin superfamily members such 
as CD4 and CD8  show high structural homology to antibodies but low sequence 
homology (< 2 0 %).
An analysis of the frequencies of occurrence of residues at positions thought 
to be vital for maintaining the structure of antibodies was carried out to further 
quantify the light and heavy chain character of the two types of TCR sequences 
(table 2.3). The positions chosen were those which are distinct to either antibody 
light or heavy chains. Positions 145 and 147 (residue numbering as in figure 
2.2) are involved in VH - Qj contacts. They are also very conserved positions 
in light chains. TCR (3 chains were most similar to A light chains at these two 
positions, while the TCR a  chains showed greater variation at these positions
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Antibody Sequence TCR a TCR (3
gloop2  light 2 1 .6 20.3
D1.3 light 2 2 .2 2 0 .6
Hyhel 5 light 21.7 2 0 .6
Hy hellO light 2 2 .0 20.7
J539 light 20.3 19.5
Kol light 20.3 2 1 .6
MCPC603 light 22.7 20.5
New light 22.9 22.9
Rei light 2 2 .8 20.9
Rhe light 2 2 .0 22.7
R19.9 light 21.4 2 0 .2
gloop2  heavy 16.1 14.7
D1.3 heavy 14.4 14.0
Hyhel 5 heavy 17.1 15.8
Hyhel 10 heavy 16.8 16.9
J539 heavy 17.1 17.8
Kol heavy 17.5 18.2
MCPC603 heavy 17.0 17.5
New heavy 18.8 16.3
Table 2.2: The average sequence identities between a  and /3 chains and antibodies of known 
structure. The identity score is calculated across the whole V domain sequence including the CDR 
regions.
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Res. Num. Frequency Interface
TCR a TCR/? Ab Heavy Ab k AbA
43 Y 0.77 
F 0.22









L 0.99 P 0.87 P 1.00




W 0.93 L 0.75 L 0.78
138 F 0.96 F 1.00 W 0.99 F 0.99 F 0.98






T 0.98 E 0.98 T 0.97 Vh- Q
147 K 0.24 
I 0.16 
S 0.16
L 0.86 S 0.99 K 0.96 L 0.96
Table 2.3: Table of residue frequencies at conserved interface residues. The residue numbering is 
as in figure 2.2. All residue frequencies greater than 0.1 are shown at each position. Only positions 
which are present in both light and heavy chains and differ in residue type between the two chain 
types are shown. The list of interface residues was taken from [127].
than the antibody chain types. Positions 43, 51, 53 and 138 are involved in 
- VH contacts. In both a  and /3 these residues show greater homology to light 
chains than heavy chains. At three out of these four positions there is virtually no 
heavy chain character while at position 51 it is interesting to note that both a  and 
/? chains show some light and some heavy chain character.
The lengths of the conserved framework loops A-A’, A’-B and E-F, as noted 
by Chothia et al [127] are similar to the antibodies. Of these regions, only the 
A-A’ loop has a different length in k, light (3 residues) and heavy (2 residues) 
chains. In both a  and /? chains the majority of sequences (94% murine TCR a, 
93% murine TCR j3) show the same length as the k light chains.
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Figure 2.1: The V domain of the antibody 4-4-20 [51] showing the structurally important interface 
residues.
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2.3.2 Alignments
A sample of twenty sequences from the alignments of TCR a  and TCR chains 
are shown in figures 2.2 and 2.3 compared to samples of twenty sequences from 
the antibody k, A and 7  chain alignments.
Figure 2.4 shows the RMS at each residue position along the chain for anti­
body k, A and heavy chains. The plots highlight the high structural homology 
between the ^-strand framework regions of the antibody structures. The plot in­
cluding all light and heavy chain structures shows that the strands are structurally 











































































Figure 2.2: An extract of the Ig k , Ig A, Ig 7  and TCR a  chain alignment. Twenty sequences from each group are shown with k chains at the top 
and a  chains at the bottom. The residues are coloured according to type. The all numeric identification codes are Kabat database entry IDs, while 
the others are Genbank database entry IDs. g j
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Figure 2.3: An extract of the Ig k, Ig A, Ig 7  and TCR (3 chain alignment. Twenty sequences from each group are shown with k chains at the top 
and (3 chains at the bottom. The residues are coloured according to type. The all numeric identification codes are Kabat database entry IDs, while 
the others are Genbank database entry IDs. os
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Variability analyses using the Wu and Kabat variability index, for the a  and (3 
chains as well as for the antibody light and heavy chains, were performed. The 
results, for mouse and human, are shown in figure 2.5 and figure 2.6 respectively.
These two sets of results were first compared and it was noted that the vari­
ability of the A chain is much less in mouse than in human. This can be explained 
by the smaller repertoire of mouse A chains. There is also some difference in the 
D-E loop - E strand region (sometimes referred to as the 4th hypervariable region) 
of the TCR (3 chain. In all other respects the mouse and human plots showed a 
similar variability pattern.
Overall, the plots show higher variability in the TCR sequences than in the 
antibody sequences. In the a chain there are discernible peaks in all three CDR 
equivalent regions. Although the j3 chain has peaks in the CDR2 and CDR3 equiv­
alent regions, it has no discernible peak in CDR1. This may indicate that it is not 
involved in binding to the MHC molecule or peptide or that it interacts with a 
highly conserved MHC region.
The following observations on the variability in the (3 strands can be made. In 
the a  chain there is a small peak in variability in the region between the A and A’ 
loops. In the antibody chains only the /c chain shows such a peak although it has a 
much smaller variability. The pattern of variability in the C - C’ region is similar 
in both the TCR a and (3 chains and both antibody light chain types, although 
again the TCR shows a higher variability. In both human and mouse the j3 chain
CHAPTER 2. SEQUENCE ANALYSIS OF IMMUNOGLOBULINS. 48












0 10 20 30 40 50 60 70  80 90  100 110 120 130 140
~ ! CDBT1 I------------- 1 C D H 5 I
H I S  E  E  E l  0  E  E  CD GD
0
0  10 20  30 40 50 60 70  80 90 100 110 120 130 140
P o s itio n
0 10 20 30 40  50 60 70  80 90 100 110 120 130 140








0  10 20 30 40  50 60 70 80 90 100 110 120 130 140
P o s itio n
Figure 2.4: RMS plots for antibody k chains(top left), A chains (top right), heavy chains(middle 
left), k and heavy chains (middle right) and all antibody chains (bottom left) are shown. The CDR 
equivalent regions of the sequence are marked in black above the plot. The conserved (5 strand 
positions are indicated by white boxes above the plot. The numbering is as in figure 2.2. The 
structures used were those in table 1.2. They were multiply fitted on conserved residues in strands 
B and C using MULFIT [136],
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D strand shows fairly low variability, whereas the D loop and E strand show much 
more variability than any antibody chain type. Also, in the a  chain, the D strand 
shows more variability than the E strand whereas in all other chain types it appears 
to be reversed. In the F strand region the variability is similar for all chain types. 
In both species there is a large amount of variability in the G strand of the a chain. 
This is not seen in any of the antibody chain types.
2.3.4 Lengths of CDRs
Plots showing the CDR lengths for antibody k, A and heavy chains and TCR a  
and /? chains are shown in figures 2.7-2.14.
2.3.4.1 CDR1
In both human and mouse the distribution of TCR /? chains is limited to lengths 
10 and 11, with the majority ( 90%) being of length 10. Also in both species the 
most common TCR a  chain length is 11 (90% of TCR a  chains). There is a slight 
difference in the range, however. In humans it is 10 - 12, whereas in mouse there 
are also some chains with length 13. In both species the k chains have two peaks, 
one at 11 and one at 16. The lower length group shows the greatest similarity 
of the antibody chain types to the TCR a  chain apart from the 13 residue chains 
present in mouse. This length is very rarely seen in k chains. The higher length 
group of k chains represents a set of sequences which have a bulge in the side of 
the loop (see figure 4.3).
In both mouse and human the TCR /? chain peak at 10 residues represents a
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Figure 2.5: Variability plots for Mouse TCR a  (top left) and (3 chains (top right), and antibody k 
(middle left), A (middle right) and 7  (bottom left) chains are shown. The CDR equivalent regions 
of the sequence are marked in black above the plot. The conserved (3 strand positions are indicated 
by white boxes above the plot. The numbering is as in figure 2.2.
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Figure 2.6: Variability plots for Human TCR a  (top left) and /3 chains (top right), and antibody k 
(middle left), A (middle right) and 7  (bottom left) chains are shown. The CDR equivalent regions 
of the sequence are marked in black above the plot. The conserved /3 strand positions are indicated 
by white boxes above the plot. The numbering is as in figure 2.2.
CHAPTER 2. SEQUENCE ANALYSIS OF IMMUNOGLOBULINS. 52
similar percentage to the antibody heavy chain peak at 13 residues.
2.3.4.2 CDR2
The length distribution for the TCR /? chain is very similar in both mouse and 
human having a range of 13 -16 and a modal value of 14 residues. The distribution 
of a  chains is also similar in mouse and human, apart from some shorter (7 and 
8  residue) chains in human. The distribution in both a  and /? is very different 
to the antibody light chains where virtually all the sequences are the same length 
(1 1  residues) and belong to the same canonical class (having the same backbone 
conformation).
In a  chains the modal value (11 residues) is the same length as in k. However 
the broader range of the a  chain distribution indicates that it may have a different 
structure. The modal value for the (5 chains is different (14 residues) to either the 
k and A (11) or heavy chains (16) but the shape of the distribution shows some 
similarities to the heavy chain.
2.3.4.3 CDR3
The distribution of both antibody heavy and TCR chains is broader in human 
than in mouse. A possible explanation for this is that the majority of sequences 
for mouse come from inbred strains, whereas the human sequences come from 
the general, outbred population. In both species the minimum TCR (5 length is 
8  residues, but in mouse the range extends to 15 residues whereas in humans it 
extends to 18. Again for the TCR a  lengths, both species show the same minimum
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length of 4 residues but with the maximum for mouse being 15 and that for human 
18 ( although this is quite rare). The modal value for mouse is 12 and for human 
is 1 0 .
The k chains have a modal value of 9 residues in both mouse and humans, 
most chains being of this length although the range is 4 - 11 in human and 6 -1 2  
in mouse. The human A chain distribution shows more similarity to the TCR chain 
than any of the other chain types, although the range is more restricted (from 9-13 
with one outlier of 6  residues). The distribution of TCRs is more restricted than 
the antibody heavy chain distribution (5 - 22 mouse, 5-33 human). The CDR3 
length plots for the eliminated set confirmed these results, with just slight changes 
to some of the frequencies.
The combined length of TCR a  and (3 chain CDR3s in the known pairs is 
shown in table 2.4 and in figure 2.15. In all cases at least one of the chains always 
has a CDR 3 of nine or more residues. This may indicate that this is the minimum 
length required to reach the peptide in the MHC groove. There is a narrower 
distribution of total length than in /t/heavy antibody pairs and the same range is in 
A/heavy pairs (18-34 a/(3,13-39 /c/heavy, 18-34 A/heavy).
2.3.5 Sequence Similarity Plots
The similarity plots for mouse and human showed very similar results except for 
the A chain which has a small repertoire in the mouse. The results are shown in 
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Figure 2.7: Length frequencies of the CDR 1 regions of human TCR a  and /3 chains, and human
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Figure 2.8: Length frequencies of the CDR 1 regions of mouse TCR a  and /? chains, and mouse
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Figure 2.9: Length frequencies of the CDR 2 regions of human TCR o: and f3 chains, and human
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Figure 2.10: Length frequencies of the CDR 2 regions of mouse TCR a  and /? chains, and mouse
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Figure 2.11: Length frequencies of the CDR 3 regions of human TCR a  and (3 chains, and human
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Figure 2.12: Length frequencies of the CDR 3 regions of mouse TCR a  and chains, and mouse
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Figure 2.13: Length frequencies of the CDR 3 regions of human TCR a  and (3 chains, and human
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Figure 2.14: Length frequencies of the CDR 3 regions of mouse TCR a  and (3 chains, and mouse
antibody k,, A and heavy chains, after elimination of identical sequences, are shown.






Lengths of loops (a 3 first)
18 6  1 2 (1) 9 9(2 1 0  8  (8 )
19 5 14(1) 7 12(1 8 11 (2 ) 9 10 (3) 109(1) 118(1)
2 0 9 11 (2) 10 10(9 119(5)
2 1 9 12(1) 10  11 (11 11 10(4) 12 9(17)
2 2 9 13 (7) 10  1 2 ( 8 11 11 (29) 12  1 0  (2 ) 13 9(12)
23 8  15(1) 9 14(1 10 13 (8 ) 11 12(23) 12  1 1 (2 0 ) 13 10(5)
24 9 15 (3) 10 14 (6 11 13(15) 12 12(19) 13 11(13)
25 10 15(1) 11 14(7 12 13(21) 13 12(9) 14 11 (6 )
26 11 15(1) 12 14 (5 13 13(11) 14 12 (5) 15 11 (3)
27 10 17(1) 11 16(4 13 14(4) 14 13 (4) 15 12(1) 1611 (1)
28 12  16(1) 13 15(2 14 14(1) 15 13(1)
29 13 16(1) 14 15(1 15 14 (2)
30 13 17(1)
34 18 16(1)
Table 2.4: The combined length of CDR a 3  and CDR (33 for the sequences of mouse and human 
clones containing the CDR 3 regions of both a  and (3 chains in the Kabat database (a total o f 336 
entries). The numbers in parentheses are the number of occurrences of the combination of lengths.
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Figure 2.15: Frequencies of the CDR regions of human TCR o: and (3 chains CDR, and human 
antibody k , A and heavy chains are shown.
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2.3.5.1 TCR a  chain
In the A and the A’ strands the a  chains shows a pattern of residue types more 
similar to that of the k chains than either the A or the heavy chains. They are least 
similar to the heavy chains.
In the B strand the differences are not large but the a  chain again appears to 
be more like k than A or heavy.
In the C strand, where the a  chains contain the conserved tyrosine (92% of 
sequences) at position 43, there is a large single residue peak favouring the light 
chains (this position is valine (75%) or isoleucine (22%) in heavy chains). Other 
than that there is very little discrimination in this strand.
In the C’ strand there is a definite discernible peak in favour of both light 
chain types. It is not possible to determine which is the most similar as the «/A 
plot shows little discrimination in this strand.
In the D strand the a  chain looks more like the heavy chain whereas in the E 
strand the residue pattern is again more similar to that of the light chains.
There is high conservation of every second residue in all chain types in the 
regions either side of the CDR3 (the F strand and the region before the G strand), 
consistent with the known strand interactions in antibodies. At residue 138 light 
chains almost always have a phenylalanine whereas the heavy chains have a tryp­
tophan. In the a  chain a phenylalaline also occurs at this position. This can be 
seen on the plots as a single residue, light chain favouring, peak at 138.
The G strand shows some heavy chain and also some A chain character.
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2.3.5.2 TCR [3 chains
Overall the ($ chain plots show fewer discernible peaks in all regions. This indi­
cates that the (3 chains show more equal similarity or dissimilarity to both light 
and heavy chains.
In the A strand the f3 chains are again more like k chains than heavy or A. 
However in the A’ strand the (3 chains show more similarity to the heavy chains, 
although it is quite different to any antibody chain type. This region is close to the 
G strand which also shows some heavy chain character.
In the loop between A’ and B the /? chain definitely appears to have most 
similarity to A but also shows some similarity to k. In the B strand itself it is not 
possible to see any obvious preference although the differences are small.
In the C strand, where the /? chain sequences contain the same tyrosine as the 
a  and light chain, the same single residue peak occurs at position 43. The overall 
residue pattern has greater heavy chain character. However the dissimilarity plots 
show that this region has one of the lowest difference values, showing greater 
conservation between the different chain types.
In the C’ strand the (3 chain similarity plots are more similar to light chains 
although it is not possible to determine between A and k.
In the D and E strands it is difficult to determine any discrimination. The E 
strand is close to the B, the D, E, B and A together forming a /? sheet, so they 
would be expected to have similar properties.
As in the a  chain the regions either side of the CDR3 are conserved.
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Table 2.5: The summed similarity score across the alignment to each of the comparison antibody 
chain types.
Finally in the G strand the /3 chain is very similar to the A chain and shows 
some similarity to the heavy but none, or very little to the k, chain.
Table 2.5 summarises the similarity scores across the entire framework regions 
of the alignment. It shows that both the TCR a  and (3 chains appear to have 
significantly more similarity to the light chain types than to the heavy.
2.3.6 Environment scores
Environment score schematics for mouse TCR a  and (3 chains are shown in figures 
2.30 and 2.31 respectively. The pattern of homology is similar to that seen for the 
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Figure 2.16: Similarity plots for mouse a  chains against antibody heavy and k  chains. Negative
values indicate greater similarity to antibody k chains than heavy chains and positive values greater
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Figure 2.17: Similarity plots for mouse a  chains against antibody heavy and A chains. Negative
values indicate greater similarity to antibody A chains than heavy chains and positive values greater










































Figure 2.18: Similarity plots for mouse a  chains against antibody k  and A chains. Negative values
indicate greater similarity to antibody k chains than A chains and positive values greater similarity
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Figure 2.19: Similarity plots for mouse (3 chains against antibody heavy and k, chains. Negative
values indicate greater similarity to antibody k chains than heavy chains and positive values greater
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Figure 2.20: Similarity plots for mouse /3 chains against antibody heavy and A chains. Negative
values indicate greater similarity to antibody A chains than heavy chains and positive values greater
similarity to antibody heavy chains.
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Figure 2.21: Similarity plots for mouse 0  chains against antibody k  and A chains. Negative values
indicate greater similarity to antibody /c chains than A chains and positive values greater similarity
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Figure 2.22: Similarity plots for human a  chains against antibody heavy and k  chains. Negative
values indicate greater similarity to antibody k chains than heavy chains and positive values greater


































Figure 2.23: Similarity plots for human a  chains against antibody heavy and A chains. Negative
values indicate greater similarity to antibody A chains than heavy chains and positive values greater


















Figure 2.24: Similarity plots for human a  chains against antibody k and A chains. Negative values
indicate greater similarity to antibody k chains than A chains and positive values greater similarity
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Figure 2.25: Similarity plots for human chains against antibody heavy and n  chains. Negative
values indicate greater similarity to antibody k chains than heavy chains and positive values greater
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Figure 2.26: Similarity plots for human 0  chains against antibody heavy and A chains. Negative
values indicate greater similarity to antibody A chains than heavy chains and positive values greater
similarity to antibody heavy chains.
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Figure 2.27: Similarity plots for human /3 chains against antibody k and A chains. Negative values
indicate greater similarity to antibody /c chains than A chains and positive values greater similarity
to antibody A chains.
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Figure 2.28: The similarity index values for TCR a  chain V regions against antibody chain types 
are plotted onto a schematic of the k light chain V region of HYHEL-5. The top left plot compares 
TCR a  against Ab k and Ab 7  chains, the top right plot is against Ab A and Ab 7  chains, and the 
bottom plot against Ab k and Ab A chains. Where the value of the difference in frequencies to 
each chain type was less than 1.0 the residue is coloured green (similar to both). Where the first 
mentioned antibody sequence type has a difference value less than the other and this value is less 
than 1.0 the residue is coloured bright red. Where the value is less than 1.5 the residue is coloured 
dark red. If the second chain type has the lower difference score the residue is coloured bright 
blue if the value is less than 1.0 and dark blue if the value is less than 1.5. Diagram created with a 
modified version of molscript [26].
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Figure 2.29: The similarity index values for TCR a  chain V regions against antibody chain types 
are plotted onto a schematic of the k light chain V region of HYHEL-5. The top left plot compares 
TCR a  against Ab k and Ab 7  chains, the top right plot is against Ab A and Ab 7  chains, and the 
bottom plot against Ab k and Ab A chains. Where the value of the difference in frequencies to 
each chain type was less than 1.0 the residue is coloured green (similar to both). Where the first 
mentioned antibody sequence type has a difference value less than the other and this value is less 
than 1.0 the residue is coloured bright red. Where the value is less than 1.5 the residue is coloured 
dark red. If the second chain type has the lower difference score the residue is coloured bright 
blue if the value is less than 1.0 and dark blue if the value is less than 1.5. Diagram created with a 
modified version of molscript [26].
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nature of the (3-sheet which forms the V domain interface is apparent. The large 
difference in environment for the D strand of the a  chain is highlighted.
2.3.7 Conclusions
In homology modelling the choice of the framework structure is crucial to the 
structure of the final model [137]. Previous studies on TCR modelling have 
tended to concentrate on the general similarity of TCR a  and (3 chains to a general 
immunoglobulin fold. In this chapter the light and heavy chain character of a  and 
(3 chains have examined.
The results show that both chain types have features characteristic of both 
light and heavy chains. Heavy chain characteristics include the lengths of the 
third CDRs of both a  and (3 chains and the conserved alanine at the start of this 
loop. Also the length of the D-E loop in the a  chain and the conservation around 
this region is heavy chain like. The length of the (3 chain loop is unlike light or 
heavy chains. Light chain features include the length of the CDR 1 of both a  and 
(3 and the CDR 2 of the a  chain. The length of the A-A’ loop in both a  and (3 
is also characteristic of k, light chains and both chain types show conservation of 
a proline important for the conformation of this loop in k, light chains. Possibly 
the most persuasive evidence of light chain character is the identity of residues 
at positions involved in interdomain contacts in light and heavy chains. These 
positions in both a  and /? show much higher homology to light chain sequences 
than to heavy chain sequences.
From these results it is suggested that a light chain dimer may be a better model
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Figure 2.30: Mouse TCR a  chains environment comparison to Ab k (top left), Ab 7  (top right) 
and Ab A (bottom). The colours indicate the score at each residue position: blue 0 to 0.5 (most 
similar), green 0.5 to 1.0 , yellow 1.0 to 1.5 and red 1.5 to 2.0 (least similar). Diagram created 
with a modified version of molscript [26].
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Figure 2.31: Mouse TCR j3 chains environment comparison to Ab k (top left), Ab 7  (top right) 
and Ab A (bottom). The colours indicate the score at each residue position: blue 0 to 0.5 (most 
similar), green 0.5 to 1.0 , yellow 1.0 to 1.5 and red 1.5 to 2.0 (least similar). Diagram created 
with a modified version of molscript [26].
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of the structure of a TCR than a VL - VH dimer. The use of such a framework 
has been suggested previously [138] though on the basis of very little detailed 
analysis. The structures of light chain dimers have been compared to antibodies 
by Novotny and Haber [117]. They tend to associate in a similar manner to 
the VL - VH module, creating a similar domain interface, although the area buried 
on domain association is less in \^  - \^  by about 3.5 nm2. The combining site 
arrangement resembles the VL - VH structure.
Chapter 3
Modelling of Antibodies
The high structural homology of all the antibody structures so far determined (see 
figure 3.2), the large number of sequences that are known and the possible uses 
to which antibodies could be put [139-141], has led to substantial interest in 
modelling antibody variable domains.
3.1 Homology Modelling
Evolutionary related proteins with homologous sequences have been shown to 
have similar structures. Homology modelling uses this fact to generate models 
of unknown structures. In homology modelling the first step is alignment of se­
quences [142] of proteins with homologous sequences and superimposition [143] 
of their structures. This leads to the identification of the structurally conserved 
regions (SCRs) and the variable regions (VRs). SCRs are often the buried hy­
drophobic core residues which are conserved in sequence and structure. The VRs
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are often the loop regions on the surface of the molecule and are those regions 
which vary in structure most between homologous proteins.
Modelling the SCRs is often just a case of taking the backbone of the most 
homologous structure to the desired sequence and replacing the sidechains. The 
more difficult part of homology modelling is the construction of the VRs. Several 
methods have been developed. They mainly fall into two categories; database 
search methods and ab initio methods.
3.1.1 Database Searching
Distance constraints are generated from homologous proteins for residues on ei­
ther side of the loop region. Protein fragments which match the constraints and 
have the correct number of intervening (loop) residues are selected from a data­
base of protein structures. The fragments selected are fitted onto the anchor re­
gions, sometimes with some minor changes permitted to the conformation of the 
end residues to produce the best superposition. These conformations are then 
screened using an energy function to select a final conformation. For short loops 
the geometric constraints are often sufficient to produce reasonably accurate mod­
els, whereas for longer loops it is necessary to include sequence information when 
searching for fragments.
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3.1.2 A b  i n i t i o  M e t h o d s
With these methods the generation of all possible loops is achieved by confor­
mational search methods. One such method is used in CONGEN [144]. In this 
program the conformation of three central residues in a loop are determined by 
an analytical chain closure algorithm [144-146]. The backbone torsions of the 
preceding and succeeding residues in the loop are rotated in discrete search steps 
to search all available conformational space. CONGEN also implements an en­
ergy minimisation step for each generated conformation, which allows the search 
of conformational space between the torsion steps. The problem with the confor­
mational search approach is that the combinatorial explosion which accompanies 
increasing loop length means that it is only suitable for short loops. Conforma­
tional searching has two advantages over random methods such as Monte Carlo 
simulated annealing [147] or molecular dynamics [148]. First, it is carried out on 
a regular grid with discrete search steps, unlike dynamics or Monte Carlo methods 
that sequentially perturb one conformation into another by small increments and 
hence may sample the same space many times. Secondly, conformational search­
ing does not entail the cost of determining energy derivatives, which are required 
in molecular dynamics.
3.1.3 Screening Conformations
Both conformational search and database screening normally produce many dif­
ferent possible conformations for the region to be modelled. To determine which
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one is to be incorporated in the final model it is necessary to have a screening 
method. Often the energy of each conformation is evaluated using an approriate 
potential energy fuction. The potential generally includes terms for the bonds, an­
gles, torsions and out of plane angles, as well as the non-bond interactions. Usu­
ally, there are also terms for the interactions between the above primary terms, 
known as cross terms. The equation below is that used in the CVFF [149] force- 
field. The first four terms describe the energy required to distort the bonds, valence 
angles, torsion angles, and out of plane angles. Terms five to nine represent re­
lationships between the first four terms. These are the cross terms. The last two 
terms describe the van der Waals and electrostatic interactions between atoms. 
The terms are represented graphically in figure 3.1.
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where & is bond length, 9 is valence angle, 0 is torsion angle and x is out 
of plane angle. The variable r is the distance between atoms, q is partial atomic 
charge and e is the energy of interaction at the most favourable interaction distance 
r*. H, F and D are force constants (equation taken from [150]).




Figure 3.1: A graphical representation of the eleven terms in the CVFF potential described by 
equation 3.1. The numbers refer to the lines in the equation. Adapted from [150].
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3.1.4 Sidechain Building
The two main approaches to sidechain modelling are similar to the two approaches 
to loop modelling, that is database (or knowledge based) methods and ab initio 
conformational search.
3.1.4.1 Database Methods
Certain conformational preferences have been shown for the sidechains of residues 
in particular types of secondary structure [151-153]. These preferences are sig­
nificant in a  helices and p  sheets, but less conservation of conformation is seen in 
loop segments. Some preferences have been noted for loop regions [153]. How­
ever the information available is for all types of loops and turns collectively, thus 
giving low confidence when modelling a specific type of loop such as an antibody 
CDR, which is made up of several different classes of secondary structure.
Ponder and Richards [154,155] have shown that only a limited set of rotamers 
are used for each type of sidechain in the core of proteins, and have constructed 
a library of these conformations. However these rules do not apply to surface 
residues and do not accurately specify all core sidechains.
In the case of canonical CDR loops database methods usually have a higher 
confidence than ab initio methods [120], but for other CDRs database methods 
are not suitable. One of the main problems with the above methods is that they 
do not give much consideration to the local environment of the particular residue, 
which will be especially important in loop residues.
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3.1.4.2 Ab initio Methods
Ab initio generation of side chains involves generating conformations and then 
evaluating them using an objective function. In CONGEN [144] several different 
methods for generating sidechain conformations are implemented:
• All. Generates all possible conformations, using a series of nested loops, 
one for each sidechain torsion. This method is impractical for large numbers 
of sidechains.
• Independent. Each sidechain is build independently of the others. This 
method produces conformations with many van der Waals clashes.
• Combination. Generates a small number of low energy conformations for 
each sidechain and then evaluate the energy of all the combinations of these. 
Again this method is impractical for large numbers of sidechains.
• First. Uses the algorithm described for All, but stops once the first low 
energy conformation is found.
• Iterative. Cycles through the sidechains in a specified order. For each 
sidechain finds the lowest energy conformation. Continues modifying each 
sidechain until the energy converges.
The main problem in sidechain generation is the combinatorial explosion as 
the number of sidechains to be built increases. Monte Carlo/Metropolis methods 
[156,157] have been used to model core sidechains. These methods were adapted
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for use with surface residues such as those in antibody CDRs by Pedersen [136] 
in which a solvation term was included to account for the surface exposure of 
the residues. Sidechain generation by this method is computer intensive and not 
suitable for generation of sidechains for a large number of loop conformations.
3.2 Homology Modelling of Antibodies
For an antibody Fv domain the SCRs consist of the /2-strands, and also all the 
loops except the six CDRs. Figure 3.2 shows twelve antibody structures super­
imposed on their most structurally conserved residues. This figure illustrates the 
high homology of these structures. The CDRs equate to VRs of the antibodies for 
the purposes of homology modelling.
Modelling of the framework (the /2-sheets and non hypervariable loops) is rela­
tively straight forward using the known antibody structures for the backbone struc­
ture and a ’maximum overlap’ [137,158] approach to replace residue sidechains 
differing in the aligned model and structure sequences. The more difficult part 
in the modelling procedure is building the hypervariable loops. Two approaches 
have proved successful in modelling these loops, firstly the canonical loop mod­
elling approach [1 2 0 ] and secondly the combined algorithm for modelling anti­
body loops (CAMAL).
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Figure 3.2: Twelve antibody structures superimposed on their conserved (3 strands. The conserved 
strands are coloured red, the framework blue and the CDRs green.
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3.2.1 Canonical Modelling Method
The canonical loop modelling approach [120] involves identification of simi­
larities between the backbone conformations of the hypervariable regions in the 
antibodies of known structure. For all of the CDRs except H3, groups of antibody 
structures with similarly shaped loops have been identified. These “canonical” 
loops have their structure determined by “key” residues at defined positions in 
the sequence. These residues are involved in packing, have conserved hydrogen 
bonds or have unusual torsion angles. The presence of these residues in an anti­
body sequence to be modelled indicates membership of the canonical class and 
allows prediction of loop conformation, by substitution of the loop from a known 
structure in the class.
3.2.2 CAMAL Modelling Method
The other approach is the Combined Algorithm for Modelling Antibody Loops 
(CAMAL) [5,6 ]. The algorithm is termed a ’’combined” algorithm because a 
combination of database search methodology and conformational searching are 
employed to generate conformers for each antibody CDR. The final conformation 
is chosen from the conformers using energy screening and torsion angle filtering.
The database search utilises distance constraints calculated for the six CDRs in 
the antibody combining site. These are calculated from the known crystal struc­
tures of antibodies. For each CDR in each structure the length from the Ca at 
either end of the loop to the Co: of each residue within the loop is calculated.
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The mean distance and standard deviation are calculated for distances between 
equivalent positions in all of the structures. The constraints use a range of 3.5 
standard deviations either side of the mean distance. A Ca distance database of 
all the proteins in the Brookhaven protein databank is then searched for fragments 
of the required length which satisfy the constraints for each loop and these con­
formations are extracted. Each conformation is fitted onto the antibody structure 
by translating the N terminus to the position of the framework antibody terminus, 
rotating the loop to position the C terminus at the C terminus of the framework 
antibody, and then rotating the loop until its centre of geometry matches that of 
the structure used as the framework.
The central five residue section from each selected database fragment is then 
constructed ab initio using the conformational search program CONGEN [144]. 
The algorithm involves rotation of the two end residues of the five residue segment 
about their torsions. For each conformation of these two residues an analytical 
chain closure algorithm positions the other three residues [145,146]. For loops of 
six and seven residues no backbone conformational search is performed because 
the database saturates the backbone conformational space. Sidechains are still 
constructed using CONGEN. For loops of five residues the database search pro­
duces too many possible conformations and conformational search of the entire 
loop is carried out.
The selection of the final conformation occurs in two stages. First each confor­
mation is evaluated using a solvent modified potential excluding the electrostatic 
and Lennard - Jones attractive potentials. Two different potentials have been used.
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Initially the GROMOS potential [159] was used. Since 1992 the EUREKA po­
tential [160] has been used. The final conformation is then picked from the five 
lowest energy conformations using a torsion angle filter based on the initial data­
base loops.
3.3 AbM: An Algorithm to Model a Complete V Do­
main
The CAMAL algorithm has been incorporated into a commercial antibody mod­
elling program, AbM (Oxford Molecular Group, pic, UK). The program also 
implements antibody framework building and canonical loop construction algo­
rithms enabling the user to generate a complete model of an antibody variable 
domain just by entering the light and heavy chain sequences. The program auto­
matically sets default options for the modelling procedure, although these can be 
changed. The method is described in the following sections.
3.3.1 Sequence Selection
Sequence selection is the process of choosing sequences from the antibodies of 
known structure to be used as the basis for modelling the framework regions of 
the modelled antibody. In AbM the sequence of the light and heavy chain of the 
unknown are manually aligned against the respective sequences of the antibodies 
of known structure.
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Figure 3.3: Flowchart of the procedures implemented in the AbM program.
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3.3.2 Framework Building
The antibody framework strands and conserved loops are built in AbM by the 
program FRAMEBUILD written by Pedersen [136]. The framework building 
involves first resequencing the structures chosen for the light and heavy chain V 
domains to the required sequence for the model, and then fitting the two chains to 
generate the complete Fv framework model.
Sidechain replacement is performed using a maximum overlap protocol. Where 
the structure and the model differ in sequence, a sidechain template is fitted onto 
the backbone atoms with the sidechain torsions adjusted to match those of equiv­
alent torsions in the parent sidechain.
The most structurally conserved strands in the light and heavy chains have 
previously been identified by Pedersen [136]. These residues were used to gener­
ate a mean set of coordinates. By fitting onto these coordinates the two chains are 
positioned relative to each other.
3.3.3 Use of Canonicals
The program CHOTH, written by the author, implements the canonical loop mod­
elling method. The program takes as its input the sequence of the antibody to 
be modelled, the names of the structures to be used as the frameworks for the two 
chains (referred to as the framework structures), and a control file indicating which 
loops canonical loop modelling is to be attempted for. It also reads the configu­
ration file which indicates which loops have canonical classes defined. For each
CHAPTER 3. MODELLING OF ANTIBODIES 100
loop with canonical classes a data file containing sequence patterns for the various 
classes, in a format similar to the Prosite format, is read in (the format is described 
in Appendix A). For each class this file also contains the residue range to be re­
placed (the loop), the length of the loop and two residue ranges which are used 
for fitting. These pattern files contain the classes described in Chothia’s original 
paper on canonicals [120] as well as the additions made in later papers [121,122].
Pattern matching code identifies any canonical loops in the sequence to be 
modelled. Once this has been done it remains to replace the coordinates for each 
canonical loop in the framework PDB file with those of a loop from a structure 
which is a member of the same class. The database of antibody structures created 
for the framework building program described above is used. A sequence file con­
taining the sequences of all the structures in this database is read in, and searched 
for members of the correct canonical class. The most similar structure in terms 
of sequence identity is chosen. The loop region and framework fitting regions are 
extracted from the chosen structure and fitted onto the framework structure. The 
fitted loop residues are then inserted into the framework structure and a new PDB 
file written out containing the canonical loops.
Initially the fitting was performed using a similar algorithm to that used in the 
CAMAL algorithm for fitting database loops onto the framework structure, using 
the centre of geometry of the framework loop. However this method produced 
poor RMS values for some modelled loops because the loop from the framework 
structure had a different take-off angle (angle between the loop and the framework 
strands on either side) to the canonical loop. Also for CDR HI the end points of
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Structure CDR Length Global RMS Local RMS
Ca Backbone Backbone All
gloop2 11 1.103 1.161 0.801 2.898
2hfl 10 1.140 1.150 0.479 0.812
2mcp 17 0.720 0.784 0.546 1.303
2fbj 10 1.681 1.733 0.615 1.052
6fab 11 0.848 0.788 0.631 2.429
ldfb 10 0.871 0.834 0.508 3.256
3hfm 11 0.801 0.775 0.508 2.880
Imam 11 1.251 1.302 0.742 2.812
2fb4 13 0.755 0.780 0.235 2.088
lfdl 11 0.799 0.799 0.267 3.107
lhil 17 1.148 1.151 0.546 1.467
lfl9 11 1.161 1.226 0.801 2.885
Table 3.1: RMS deviations for the CDR LI loops modelled using the canonical modelling method 
implemented in the program CHOTH. The global RMS values are calculated after fitting the struc­
ture and the model on the structurally conserved residues in the interface (3 strands. The local RMS 
values are calculated after fitting CDR LI loop residues of the model with those of the structure. 
The backbone RMS is for the C, Ca and N atoms of each residue.
the loop and the centre of geometry were almost collinear resulting in inaccu­
racy of loop placement. The fitting algorithm was therefore changed, using the 
least squares fitting of structurally conserved regions on either side of the loop to 
position the canonical loop on the framework structure.
CHOTH does not change the sequence of the canonical loops in the PDB file 
because this is done in the FRAMEBUILD step. The sidechains are modelled 
using CONGEN.
Results for modelling of each of the five loops which have canonical classes 
are shown in tables 3.1, 3.2, 3.3, 3.4 and 3.5.
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Structure CDR Length Global RMS Local RMS
Ca Backbone Backbone All
gloop2 7 0.631 0.647 0.228 0.654
2hfl 7 0.709 0.712 0.320 1.237
2mcp 7 0.613 0.538 0.436 0.955
4fab 7 0.768 0.792 0.279 1.144
2fbj 7 0.893 0.867 0.320 2.812
6fab 7 0.293 0.304 0.252 1.031
ldfb 7 0.738 0.750 0.228 1.166
3hfm 7 0.978 1.021 0.437 2.064
Imam 7 1.361 1.362 0.252 0.966
ligf 7 0.749 0.763 0.279 1.144
2fb4 7 1.172 1.247 0.966 2.308
lfdl 7 0.944 0.928 0.502 1.611
lhil 7 0.917 0.922 0.436 1.634
If 19 7 0.915 0.966 0.502 1.725
Table 3.2: RMS deviations for the CDR L2 loops modelled using the canonical modelling method 
implemented in the program CHOTH. The global RMS values are calculated after fitting the struc­
ture and the model on the structurally conserved residues in the interface ft strands. The local RMS 
values are calculated after fitting CDR L2 loop residues of the model with those of the structure. 
The backbone RMS is for the C, Ca and N atoms of each residue.
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Structure CDR Length Global RMS Local RMS
Ca Backbone Backbone All
gloop2 9 1.003 1.031 0.297 1.104
2mcp 9 0.718 0.739 0.242 1.052
4fab 9 1.231 1.255 0.625 1.900
6fab 9 1.160 1.131 0.930 2.047
3hfm 9 0.426 0.394 0.234 1.463
Imam 9 1.270 1.289 0.260 0.704
ligf 9 0.888 0.877 0.416 1.081
lfdl 9 1.126 1.138 0.652 2.243
lhil 9 1.278 1.288 0.242 1.035
If 19 9 1.382 1.389 0.931 2.055
Table 3.3: RMS deviations for the CDR L3 loops modelled using the canonical modelling method 
implemented in the program CHOTH. The global RMS values are calculated after fitting the struc­
ture and the model on the structurally conserved residues in the interface /3 strands. The local RMS 
values are calculated after fitting CDR L3 loop residues of the model with those of the structure. 
The backbone RMS is for the C, Cat and N atoms of each residue.
3.4 Adaptations to CAMAL
The greater reproducibility, ease of use and flexibility of AbM compared to the 
initial implementation of CAMAL, together with the increased number of pub­
lished antibody structures enabled more thorough testing of the algorithm to be 
performed. The first column of RMS values in table 3.6 shows the modelling 
results for eight structures using the standard CAMAL algorithm.
The following sections discuss several adaptations to the basic algorithm. The 
results for modelling after incorporating all of these changes are shown in the 
second column of RMS values in table 3.6 and will be discussed later.
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Structure CDR Length Global RMS Local RMS
Ca Backbone Backbone All
gloop2 5 1.884 1.785 0.204 1.664
2hfl 5 1.176 1.261 0.696 2.301
2mcp 5 0.968 1.004 0.275 1.492
4fab 5 0.672 0.721 0.378 1.867
2fbj 5 0.502 0.515 0.142 1.520
6fab 5 1.358 1.341 0.434 2.002
ldfb 5 0.736 0.736 0.206 0.935
3hfm 5 2.037 2.012 0.937 2.098
Imam 5 1.849 1.845 0.275 1.218
ligf 5 1.335 1.310 0.266 1.664
2fb4 5 0.626 0.621 0.096 0.352
lfdl 5 0.869 0.846 0.448 0.794
8fab 5 1.103 1.106 0.096 0.330
lhil 5 0.565 0.563 0.266 1.083
If 19 5 4.444 4.601 0.696 1.280
Table 3.4: RMS deviations for the CDR HI loops modelled using the canonical modelling method 
implemented in the program CHOTH. The global RMS values are calculated after fitting the struc­
ture and the model on the structurally conserved residues in the interface j3 strands. The local RMS 
values are calculated after fitting CDR HI loop residues of the model with those of the structure. 
The backbone RMS is for the C, Co: and N atoms of each residue.
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Structure CDR Length Global RMS Local RMS
Ca Backbone Backbone All
gloop2 10 1.543 1.609 0.624 2.997
2hfl 10 2.202 2.155 0.624 2.455
2mcp 12 2.022 2.014 0.787 1.623
4fab 12 1.922 2.028 0.787 3.455
2fbj 10 0.767 0.779 0.455 3.076
ldfb 10 1.180 1.202 0.455 2.980
3hfm 9 0.914 0.942 0.561 1.406
ligf 10 1.185 1.202 0.284 2.695
2fb4 10 0.708 0.726 0.200 3.352
lfdl 9 1.369 1.413 0.634 3.336
8fab 10 1.183 1.195 0.200 2.848
lhil 10 0.845 0.829 0.284 2.711
Table 3.5: RMS deviations for the GDR H2 loops modelled using the canonical modelling method 
implemented in the program CHOTH. The global RMS values are calculated after fitting the struc­
ture and the model on the structurally conserved residues in the interface /3 strands. The local RMS 
values are calculated after fitting CDR H2 loop residues of the model with those of the structure. 
The backbone RMS is for the C, Co: and N atoms of each residue.
Structure Loop Length Runtime 1 
(Hr)
RMS 1 Runtime 2 
(Hr)
RMS 2
Gloop2 H2 10 4.75 2.02 Canonical 1.61
H3 4 0.81 1.38 0.15 1.27
2hfl H3 7 0.15 8.01 0.15 2.31
2mcp H3 11 22.4 2.47 18 2.30
4fab H3 7 0.2 2.47 0.14 2.13
3hfm H3 5 0.23 3.98 0.10 1.68
2fb4 LI 13 0.63 4.75 Canonical 0.78
L3 11 13.25 1.74 20.1 1.73
H3 17 24.10 8.52 18.99 4.22
lfdl H3 8 1.17 3.87 39.5 2.18
2fbj H3 9 23.8 3.12 81.2 4.17
Table 3.6: A table of RMS values for the CAMAL modelled CDR loops of eight antibodies 
modelled in AbM before and after modifications to the method. For the H2 loop of Gloop-2 and 
LI loop of 2fb4 the changes to the definition of the canonical loops resulted in their inclusion in 
canonical classes, and therefore the time required for their generation was minimal.
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3.4.1 Database search changes
3.4.1.1 Creation of a Non-redundant Ca  Database
The Co; database in the original implementation of CAMAL contained entries 
for all the structures deposited in Brookhaven database at the time. There are 
many duplicate structures in the Brookhaven database with differing resolution, 
as well as entries missing or dubious coordinates. The original algorithm used a 
program, ELIMINATE, to screen the loops selected in the database search for a 
loop, from the Co; database, for duplicate entries. However this screen was based 
on the names of the entries, and often failed to eliminate all duplicate entries. The 
presence of multiple identical or very similar conformations in the ensemble of 
conformations chosen in the database search can cause bias in the later filtering 
stages. To solve this problem, two changes were made.
The Brookhaven entries contained within the Ca distance database were lim­
ited, as far as possible, to one of each structure. The annotated PDB file list created 
by L.L. Walsh [161] was consulted to identify the highest resolution structure with 
the fewest obvious errors for each protein.
Some proteins are repeated in the non-redundant database, for example if they 
are in complexes, and some protein families contain highly structurally homolo­
gous members. To eliminate duplicates Pedersen clustered the hits from the data­
base search on backbone torsion angles, with one conformation taken from each 
cluster [136].
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3.4.1.2 H3 Constraint Groups
The number of database search constraints that can be generated for a particular 
CDR is limited by the minimum length of loop found in the antibody structure 
database. For CDR H3 this is only four residues. Therefore there were only four 
constraints for H3 using all the structures in the database. It was thought that this 
small number of distance constraints might not provide a sufficient restriction on 
the conformational space to be searched for long CDR H3’s ( > 10 residues).
To test this hypothesis, a set of constraints were created from structures which 
had long CDR H3 loops (more than ten residues). The H3 loop of the antibody 
HIL was modelled using two Ca distance databases, one containing HIL coordi­
nates and one without them. The databases were screened using the constraints 
for long H3’s. In the first case the HIL CDR H3 was chosen from the database as 
the final loop conformation. The middle section, however, which had been con­
structed with CONGEN was not correct. Without HIL in the database the confor­
mation chosen was again better than using constraints for all antibodies (see table 
3.7). Also the run time was reduced from 72 hr to 20 hr on a Hewlett Packard 720 
because of the reduction in the number of database conformations extracted with 
the tighter constraints.
3.4.2 Inclusion of other CDRs while modelling
In the basic CAMAL algorithm each CDR is modelled without any other CDRs 
present. In the original study the presence of the previously modelled loops was
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Figure 3.4: RMS versus length plot for modelling H3 CDR.
shown to reduce the accuracy of the later modelled loops.
However in the current study it was found that serious clashes between atoms 
in two modelled loops often occurred.
Figure 3.4 shows a plot of RMS versus length for CDR H3. There is some 
correlation between loop length and RMS. For CDR H3s of up to ten residues the 
loop conformation can be predicted with RMS values equivalent to that of medium 
resolution X-ray structures. For loops above this length the RMS values for CDR 
H3 are high. The reasons for this could be that no other CDRs are present when 
CDR H3 is modelled. The conformational space available to a long loop is large. 
Without the restrictions defined by the presence of the other loops the H3 loop can 
sample space not normally available to it giving rise to an inaccurate model.
To investigate this possibility the H3 loop of the antibody HIL [61] was mod­
elled with the backbone atoms of the other loops in place (see table 3.7). In one 
experiment only the canonical loops were retained ( L2, L3, HI and H2 ). The
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METHOD CDR H3 Global 
Backbone RMS (A)
CDR modelled without any other loops 
present. Constraints generated using all 
structures.
5.97
CDR modelled with all other loops present. 
Constraints generated using all structures.
4.42
CDR modelled with all other loops present. 
Ca constraints generated for structures with 
CDR H3s longer than 10 residues. HIL 
present in Ca database.
2.87
CDR modelled with all other loop backbones 
present. Ca constraints generated for struc­
tures with CDR H3s longer than 10 residues. 
HIL not in Ca database.
2.68
Table 3.7: The change in RMS deviation for HIL CDR H3 loop as the method has been improved.
loop was modelled better than with all loops absent. However on examination of 
the model it was noted that the CDR H3 loop had been positioned where CDR 
LI would usually be. CDR LI had been poorly modelled initially but its mod­
elled conformation was included in a second experiment. In this case the RMS 
of the H3 loop reduced substantially. The region of LI which contacts H3 is the 
structurally conserved region at the end of the loop (residues 32-34 (Kabat residue 
numbering [129])). Therefore although the loop was not modelled well its con­
formation could be relied on in the region of interest.
3.4.3 Framework take-off angles and H3
CDR H3 occupies a central position in the combining site and therefore has a crit­
ical effect on the combining site topology. H3 is defined as a hairpin loop because
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it inter-connects two j3 strands. It is very variable in length and therefore there are 
a large number of possible backbone conformations. There are no assigned canon­
ical structures to CDR H3 because of this high variability. The take-off angle for 
CDR H3 (see table 3.8) varies by up to 90°. An analysis of take-off angles of all 
CDRs [162] was performed. The results of the analysis suggested two structural 
classes of H3 based just on these take-off angles alone. By incorporating addi­
tional observations it was possible to define seven classes of CDR H3 (see figure 
3.5). The longer CDRs pose more problems for modelling. Therefore for CDR H3 
of 13 residues or longer they are all grouped into one class. Most of H3 are less 
than 12 residues and therefore can be modelled with reasonable accuracy by AbM 
(see figures 2.12 and 2.11). Canonical structures are assigned to CDRs by finding 
the most homologous candidate in each class according to the Dayhoff mutation 
matrix. [163]. However for H3 the approach is to identify the most similar loop 
within its class of take-off angle (see table 3.8).
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Figure 3.5: (A) A cartoon to illustrate the fact that the differences in CDR
take off angle can greatly affect the RMS of the modelled conformation. (B)
The seven proposed CDR3 length classes. The definitions for the classes are:-
H3a loops shorter than 7 residues.
H3b loops of 7 residues.
H3c-f loops in which there is an Arg or Lys at position 106 and an Asp, Ala or Gly at position
136 in 8, 9 and 10, 11 or 12 residue loops respectively.
H3g loops with the motif seen in c-f but of 13 or more residues.
Each class contains structures which differ in their take off angles by less than 35°. The angular
difference is calculated as the angle between the planes defined by the N terminal C-a, centre of 
geometry, and C terminal C -a of the H3 loops for each pair of structures after least squares fitting 
of the structures on conserved /3 strands. For class (a) the mean angular difference is 13.6°(5), for 
class (b) 25.1°(3), for class (c) 7.8°(2), for class (d) 5.9°(6), for class (e) 17.4°(5), for class (f) 
12.1°(3), and for class (g) 13.5°(3). The figures in parentheses are the number of structures in 
each class.
glb2 3hfm lbaf 2hfl 4fab dl3 Imam 2fbj 3fab bl3i2 2mcp lhil 8fab 3671 lfl9 3d6 2fb4
glb2 0.00 4.60 14.28 85.62 45.32 26.54 27.66 17.02 38.71 30.06 46.06 40.36 27.92 32.89 75.41 44.72 20.32
3hfm 4.60 0.00 10.98 83.86 41.09 22.85 23.18 13.66 35.52 25.80 43.40 36.76 23.88 29.14 72.28 41.76 16.59
lbaf 14.28 10.98 0.00 73.30 31.72 12.33 15.94 2.74 24.57 16.84 32.46 26.08 14.15 18.67 61.33 30.78 6.25
2hfl 85.63 83.86 73.30 0.00 56.29 63.90 70.70 70.94 50.77 65.80 41.55 52.03 65.11 59.13 22.71 44.17 69.25
4fab 45.32 41.09 31.72 56.29 0.00 19.88 18.65 29.18 15.90 15.29 21.80 11.09 17.57 14.21 36.51 18.27 25.47
dl3 26.54 22.85 12.33 63.90 19.88 0.00 10.00 9.63 13.31 7.08 22.35 13.92 3.62 6.35 49.69 19.91 6.26
Imam 27.66 23.18 15.94 70.70 18.65 10.00 0.00 14.24 20.45 4.92 29.91 18.68 6.80 11.93 53.70 26.80 10.91
2fbj 17.02 13.66 2.74 70.94 29.18 9.63 14.24 0.00 21.86 14.55 29.90 23.34 11.65 15.96 58.63 28.12 3.76
3fab 38.71 35.52 24.57 50.77 15.90 13.31 20.45 21.86 0.00 15.58 9.47 4.81 14.37 8.53 36.77 6.62 19.23
bl3i2 30.06 25.80 16.84 65.80 15.29 7.08 4.92 14.55 15.58 0.00 25.03 13.80 3.49 7.11 49.15 21.89 10.81
2mcp 46.06 43.40 32.46 41.55 21.80 22.35 29.91 29.90 9.47 25.03 0.00 12.31 23.78 18.00 29.84 3.61 27.82
lhil 40.36 36.76 26.08 52.03 11.09 13.92 18.68 23.34 4.81 13.80 12.31 0.00 13.71 7.77 35.95 8.77 20.17
8fab 27.92 23.88 14.15 65.11 17.57 3.62 6.80 11.65 14.37 3.49 23.78 13.71 0.00 6.05 49.62 20.94 7.92
3671 32.89 29.14 18.67 59.13 14.21 6.35 11.93 15.96 8.53 7.11 18.00 7.77 6.05 0.00 43.72 15.00 12.57
lfl9 75.41 72.28 61.33 22.71 36.51 49.69 53.70 58.63 36.77 49.15 29.84 35.95 49.62 43.72 0.00 30.72 55.85
3d6 44.72 41.76 30.78 44.17 18.27 19.91 26.80 28.12 6.62 21.89 3.61 8.77 20.94 15.00 30.72 0.00 25.70
2fb4 20.32 16.59 6.25 69.25 25.47 6.26 10.91 3.76 19.23 10.81 27.82 20.17 7.92 12.57 55.85 25.70 0.00
Table 3.8: The differences in take-off angle between each pair of structures. The angle calculated is between the centre of geometry of 
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3.4.4 The Problem of Modelling Long H3s: Unsolved or Un- 
solvable?
The algorithm does not model long CDR H3 loops well. This may be because 
of problems with the algorithm but to the author’s knowledge, no other algorithm 
can accurately predict long surface loop conformations. This is probably a reflec­
tion of the inherent flexibility of these long often highly exposed surface loops. 
In X-ray crystallographic structures of antibodies the CDR H3 region often has 
some of the highest B factors, or may even be absent from the density map al­
together. It may therefore not be sensible to try to assign a single conformation 
to such loops, but to define an ensemble of conformations representing the most 
frequently adopted conformations.
Structure Length of CDR RMS before changes RMS after changes to
H3 to method method
ldfb 17 6.10 5.44
2fl9 15 9.09 7.6
Table 3.9: The RMS deviations of the H3 loops of 2 fl9  and ldfb modelled using different versions 
of AbM.
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3.5 Conclusions
Accurate modelling of TCR CDRs will not be possible if antibody CDRs cannot 
be predicted accurately. To test the ability of the algorithm developed previously 
in the laboratory to model antibody CDR conformations several antibodies have 
been modelled. The initial results of this modelling study showed several prob­
lems in predicting CDR conformation. CDR H3 presents the greatest problem 
being most variable in length, sequence and structure. The data show that long 
loops are not predicted well for CDR H3. The conformational space available to 
these loops is large. The method did not impose enough restrictions on this space 
because all the other CDRs are ignored when CDR H3 is constructed. As shown 
by the results for HIL the predictive accuracy of a relatively long CDR H3 (12 
residues) can be substantially improved by including the backbone structures of 
these loops as alanine residues while modelling H3.
In addition the division of CDR H3 into take off angle and constraint groups 
based on length has been shown to improve accuracy.
For the other CDRs the use of canonical loops where possible improved the 
accuracy of their prediction. As the backbone atoms of these loops are included 
while modelling CDR H3 it is important that they are as accurately modelled as 
possible.
TCR CDR 3s in both a  and (3 chains show greater sequence homology to CDR 
H3 than to CDR L3. The lengths of TCR CDR 3 s are more conserved in length 
than H3 with a mean length of about 12 residues. The grouping defined for CDR
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H3 conformations determined in this work may help improve accuracy of CDR 3 
prediction in TCRs.
Chapter 4
Modelling of T Cell Receptors
In this chapter a molecular modelling study on the TCR is described. In chapter 2 
the sequences of TCRs were compared to both immunoglobulin chain types (light 
and heavy) and evidence was presented that both a  and (3 chains show greater 
similarity to light chains. Chapter 3 describes some changes made to a program for 
antibody modelling. These changes were made in parallel with the TCR modelling 
experiments and were incorporated in the TCR modelling method when they were 
identified. In this chapter the modelling of several TCRs will be described using 
a light chain dimer as the structural framework and an algorithm based on the 
CAMAL algorithm of Martin et. al [6].
A model of CD4 was also produced to confirm that the CAMAL algorithm 
could be extended from use with antibodies to other immunoglobulins. The mod­
elled TCR sequences for which there were sequence function data were taken 
from Jorgensen et al. [164]. This enabled a validation of the models.
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The following introductory sections describe some of the previous experimen­
tal structural studies on the TCRs.
4.1 The Sequencing of TCRs
The DNA sequence of a TCR variable region was first isolated in 1984 by Yanagi 
et al [165]. Since then over 500 different TCR mRNAs have been sequenced 
from a variety of organisms. Since the first sequence was isolated many different 
TCR a  and /? chain sequences have been determined using molecular cloning 
techniques. Anchor polymerase chain reaction has been used and this allows very 
rapid isolation of an a  or ft chain gene product using a constant region primer 
[166].
Also analysis has been performed of the resting levels of different TCR V re­
gions in individuals and the changes in concentrations which occur during disease.
4.2 Mutation studies on TCRs
Patten et al [167] attempted to transfer peptide MHC specificity between different 
TCRs by transfer of putative CDRs. Initially they attempted to transfer CDR3 
regions in an attempt to show that these were important for binding to peptide 
and later they transferred all six putative CDRs on to the TCR framework. Even 
with all six CDRs plus some of the framework strand regions these experiments 
failed to transfer specificity, even when the transfer was between TCRs restricted
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to the same MHC using the same VQ gene segment, and were against similar pep­
tides. The explanation offered drew a parallel with antibody humanisation using 
CDR transfer where loss of affinity frequently occurs and often requires specific 
framework mutations back to the original antibody sequence. Therefore, if the 
transferred CDRs did confer a reduced affinity, since the TCRs in general have 
low affinities (10-6) compared to antibodies, any further reduction was likely to 
have made binding undetectable.
Nalefski et al [168] mutated two residues in the TCR a  chain CDR1 region. 
The mutated TCR had substantially decreased recognition of the analytic peptide 
MHC complex. This is most likely to indicate that this region of the molecule is 
part of the antigen combining site.
Site-directed mutagenesis of a conserved amino acid in the CDR (33 loop, 
whose presence correlated with a particular cytochrome C specificity, has been 
shown to affect the fine specificity of that TCR for the antigen [169,170].
The creation of antibody C region/TCR V region and TCR C region/antibody 
V region chimeras has provided some information on the characteristics of the 
Va-Vp interface. VHCQ+ V^ Cg complexes have been produced [171] and it was 
suggested that the formation of this complex indicated that Va and VH domains 
were similar, with the (3 being similar to the light chain (because either a  or H 
could act as a partner for /?). However this combination is also consistent with a 
light chain dimer ( i.e. both the a  and the (3 being similar to the light chain).
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4.3 Structural studies on TCRs
4.3.1 Outline Structure
In 1988 Chothia et al produced a paper comparing the sequences of TCRs and 
antibodies which identified equivalent regions in the sequences of the two types 
of proteins [127]. They defined forty residues of structural importance in antibody 
light and heavy chains which are involved in :
• Inter-domain packing between VL and VH.
• Inter-domain packing between VH and Qj.
• Intradomain packing and hydrogen bonding residues maintaining the (3- 
sheet structure.
• Residues with unusual conformations.
The conservation of these residues in T-cell receptor a  and (3 chains was exam­
ined. There is high conservation of these residues in T-cell receptors. Further, (3 
sheet framework regions were suggested and a possible arrangement for the anti­
gen binding loops which are like those of antibodies with the third hypervariable 
loop of each domain sandwiched between the first and second hypervariable loop 
pairs (see figure 4.1) was proposed.
Novotny et al. [172] carried out sequence analysis and predicted secondary 
structure for the TCR based on antibody structures.








Figure 4.1: This figure is taken from Chothia e ta l [127] and shows the arrangement of combining 
site loops suggested by them for the T-cell receptor combining site. The receptor is suggested to 
bind to the MHC with the central loops over the peptide.
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4.3.2 Transgenic mice
Jorgensen et al [164] used mice transgenic for either TCR a  or (3 chains to map 
TCR-antigenic peptide contact residues. In their experiments the mice were trans­
genic for TCR 5C.C7 a  or f} chain with the chain being expressed on 90% or 98% 
of the peripheral T lymphocytes. They made substitutions in the peptide which 
5C.C7 bound to (MCC 88-103) and injected mice with the changed peptide. They 
sequenced TCRs produced against the new antigen to characterise the al(3 chain 
which had paired with the transgenic chain. For some changes to the peptide 
only a  chain transgenics responded, indicating the (3 chain was important for in­
teraction with that peptide residue (because that was the only chain which could 
change) and vice versa. The peptides they used had charge changes and these 
could be mapped to reciprocal charge changes in the CDR 3 region of the TCR 
chain. Some of the TCRs produced were cross-reactive with the original peptide 
and these in general had neutral residues at the position where the charge change 
occurred. They identified residues in both a  and (3 CDR3s involved in binding the 
peptide. The interacting residues are shown schematically in figure 4.2.
4.3.3 Cross-reactivity of Antibodies to TCRs and Antibodies
Kaymaz et al [173] have shown that there is immunogenic cross-reactivity be­
tween human TCR /5-chains and human or murine antibody light chains. The best 
response was to the CDR 1 equivalent region and the third framework region. This 
is evidence for the structural similarity of TCR chains and antibody chains.
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Figure 4.2: Schematic diagram showing mapped TCR-peptide contacts determined using trans­
genic mice (after Jorgensen et al. [164]).
4.3.4 The affinity of the TCR-MHC-peptide Interaction
The affinities of TCRs have proved more difficult to determine than those of an­
tibodies. This has been partly because of the difficulties in producing soluble 
TCRs.
The first published affinities (K^), by Matsui et al [174], were 4 — 5 x 105M -1 . 
This procedure involved inhibiting the binding of T cells to soluble MHC-peptide 
complexes using anti-Vg antibodies. Weber used inhibition of T cell activation 
under antigen limiting conditions by soluble TCR with anti-MHC antibodies. This 
gave an affinity range of 105 — 5 x 106M _1.
Other studies have used the BIAcore (Pharmacia, Sweden) instrument, in 
which soluble TCR was bound to a sensor chip and the MHC-peptide complex
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passed over it [175]. These experiments obtained similar affinities to those de­
scribed previously. These affinity values were similar to non-somatically mutated 
IgM antibodies and, as T cell receptors do not undergo somatic mutation, this was 
considered reasonable.
However, in more recent studies [176,177], affinities of 1 — 2 x 107M -1 have 
been found. Also different responses to different affinity ligands are involved 
in the selection process in the thymus [178]. High affinity interactions lead to 
negative selection, while lower affinity ones lead to positive selection. The lowest 
affinity TCRs (in which no complexes were detectable) underwent no selection. It 
has been noted that TCRs to allogeneic MHC molecules can have higher affinities 
than those to syngeneic MHC molecules. This can be explained by the lack of 
allogeneic molecules in the thymus, thus avoiding the negative selection process 
[176].
Even these higher TCR affinities are still lower than the affinities of many 
antibodies which can be as high as 1012M -1. As a result it has been difficult to 
reconcile the high sensitivity of TCRs with their low affinity. One explanation 
invokes serial engagement of multiple TCRs by a single MHC peptide molecule 
[179], while multimerization of TCRs and MHCs has also been shown to trigger 
T cells.
4.3.5 Other TCR Molecular Modelling Studies
Novotny et al. [180] modelled a single chain TCR V region constructed using an 
antibody Fv. The CDRs were modelled by conformational search. The model
CHAPTER 4. MODELLING OFT CELL RECEPTORS 124
was used successfully to predict which surface hydrophobic sidechains should be 
mutated to increase solubility.
Buchwalder et al. [181] created a model of a fluorescein binding TCR. First, 
structurally conserved regions were identified in a set of eight antibody structures 
with peptide or hapten antigen specificities. For each of these the most homol­
ogous to the equivalent region in the TCR was identified and used to generate a 
hybrid framework. A database search method was used to assign coordinates for 
the CDR regions. The PDB was searched for loops of the correct length which 
had the best RMS match in the flanking residues. The amino acid sequence was 
changed to that of the TCR. The final stage was a conformational search on the 
CDR regions using molecular dynamics. From the model residues were identified 
which were predicted to be involved in fluorescein binding. Mutation of some of 
these residues showed that they were involved.
4.4 Modelling Strategy
AbM (CAMAL) was designed for modelling antibodies. As TCRs are members 
of the immunoglobulin superfamily it was considered valid to attempt to use AbM 
for modelling TCRs.
As a transitional preliminary step it was decided to model another immunoglob­
ulin superfamily member for which a structure had been determined by X-ray 
crystallography. The protein selected was CD4 which is generally more similar 
to an antibody light chain than an antibody heavy chain, as with both TCR chain
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types.
The CDR2 region of the TCR /? is a very different length to the antibody light 
chain CDR2 and is in fact more similar to antibody heavy chains. If a loop of the 
length of a /? chain CDR2 is positioned using the take off angles from the light 
chain bad clashes occur. So this segment of the light chain was replaced with 
the CDR2 region from the heavy chain carrying with it the heavy chain take-off 
angles. This was first tested in the CD4 modelling which also has a CDR2 loop 
which is different to the light chain.
In choosing the T-cell receptor to model there were two requirements imposed. 
Firstly, the sequences of both the a  and /? chains of a single clone should be 
known. Secondly, the peptide antigen sequence and MHC specificity should be 
known. Ideally the MHC restriction should be to an MHC molecule with a solved 
structure. Choosing TCRs for which some sequence-function data are available 
would allow comparison of the models with experimental data. A set of sequences 
with these features was the group sequenced by Jorgensen et al against MCC 
[164]. Once reasonable results had been obtained with these sequences, a second 
TCR was modelled in order to suggest mutations which would affect binding. 
This allowed testing of the ability of the modelling procedure to produce models 
which had predictive value.
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4.5 Structural Analysis of Immunoglobulins
When modelling loops in proteins two factors which greatly affect accuracy are 
the fidelity of placement of the end points and the angle of the loop compared 
to the framework strands on either side of it. As the antibody modelling studies 
show, the take-off angle for the CDRs is important for their accurate prediction. 
Individual TCR CDR loops show different degrees of homology to the antibody 
heavy and light chains. The take-off angles should therefore be selected from its 
most appropriate donor. To allow this, CDR segments from the most homologous 
antibody region were superimposed in the modelling procedure to give the highest 
probability of a correct take-off angle. The antibody heavy and light chains also 
have different structural definitions of the start and ends of the CDR regions. For 
modelling TCRs the end points should be conserved between the two chain types. 
To determine which regions to superimpose when modelling and the regions to 
define as the loops, the CDR regions of antibody heavy and light chains and CD4 
and CD8 were overlapped using regions on either side of the loop. The overlap 
ranges were changed until the RMS between the fitting regions and CDR regions 
reached a minimum. The fitting ranges are shown in table 4.1.
The three figures 4.3, 4.4 and 4.5 show superimpositions of the strands on 
either side of each of the CDRs and the CDRs in between. CDR 1 is defined 
differently in light and heavy chains. The regions of conservation between chain 
types are in the B and C strands. The end point for CDR2 is different in antibody 
heavy chains and light chains. The nearest conserved piece of structure is the D
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Loop Fitting Range 1 Fitting Range 2
LI 19-23 35-39
L2 46-50 61-65
L3 84-88 98 - 103
HI 18-22 36-40
H2 46-50 66-70
H3 91-95 103 - 107
Table 4.1: Fitting ranges for superimposing CDR loops. These ranges define the first structurally 
conserved regions on either side of the CDR regions that are conserved between chain types (Kabat 
residue numbering [129]).
strand. CDR H2 is variable in structure up to this point whereas the light chain 
has a structurally conserved C”-D loop. There is conservation of an RF sequence 
motif after CDR L2 (95%) and CDR H2 (42%) at the base of the D strand (posi­
tions 75 and 76 (residue numbering as in figure 2.2)). The residues contacting this 
motif are conserved. The high conservation of the motif in TCRs (24% TCR a, 
55% TCR (3) suggests that it is likely to arrange these regions in a similar way to 
antibodies. Interestingly mutations in the RF motif from R to G occur in some of 
the (3 chain sequences. The arginine interacts with an aspartate at position 98 in 
the F strand. In some of the (3 chain sequences the conserved arginine is replaced 
by a glycine. In these sequences a different motif exists in the contacting residues. 
The aspartate at 98 is replaced by a glutamine and the residue after the arginine, 
which is usually phenylalanine, is replaced by a tyrosine. This set of compen­
satory changes should allow a hydrogen bond to form between the tyrosine and 
the glutamine, maintaining the structure (see table 4.2).
CD4 and CD8 are also structurally conserved compared to antibodies at the 
termini of the three CDR regions, indicating that this may be a conserved feature
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Position Frequency
75 76 98
R F D 0.55
G Y Q 0.18
K F D 0.10
G Y P 0.04
N F D 0.03
E S H 0.02
Q F D 0.02
N L D 0.02
R I D 0.01
R F N 0.01
Q S D 0.01
Table 4.2: The frequencies of occurrence of the triplets of residues at positions 75, 76 and 98 in 
the TCR /3 chain are shown (residue numbering as in figure 2.2).
of the immunoglobulin superfamily. The same difficulty in defining the end of 
CDR 2 is found and the structurally conserved region is again the start of the D 
strand (see figure 4.4). The CDR 3 regions are superimposed on the F and G 
strands, the end points for light and heavy chains being similar.
4.6 Modelling CD4: A non Ab Immunoglobulin
4.6.1 Introduction
CD4 was used as a test case to see whether it was possible to model a non antibody 
immunoglobulin using the CAMAL algorithm. The aim was to identify which 
regions might be most difficult to model in T cell receptors and to test the use of 
a hybrid H/L(heavy/light) framework for modelling.
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Figure 4.3: Overlapped CDR 1 regions of the structures from the Brookhaven full release and 
pre-release databases. Light chain framework residues are coloured green, heavy chain framework 
magenta, light chain CDR region yellow and heavy chain CDR region cyan. CD4 and CD8  chains 
are coloured white. The chains have been overlapped using five residues either side of the CDR.
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Figure 4.4: Overlapped CDR 2 regions of the structures from the Brookhaven full release and 
pre-release databases. Light chain framework residues are coloured green, heavy chain framework 
magenta, light chain CDR region yellow and heavy chain CDR region cyan. CD4 and CD8  chains 
are coloured white. The chains have been overlapped using five residues either side of the CDR.
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Figure 4.5: Overlapped CDR 3 regions of the structures from the Brookhaven full release and 
pre-release databases. Light chain framework residues are coloured green, heavy chain framework 
magenta, light chain CDR region yellow and heavy chain CDR region cyan. CD4 and CD8  are 
coloured white. The chains have been overlapped using five residues either side of the CDR.
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4.6.2 Method for Modelling CD4
One chain of the light chain dimer Rei was used as a framework. The sequence 
was changed to that of CD4 in the framework regions, using a maximum overlap 
approach in INSIGHT (Biosym), and this framework energy minimised in DIS­
COVER (Biosym) to a derivative of 0.1. The loop between the B and C strands 
was modelled using the loop builder in INSIGHT (Biosym). The CDR2 region of 
Rei was replaced with that of the most identical heavy chain sequence in this re­
gion (R19.9 [59]) by superimposing the C and D strands. The CAMAL algorithm 
was then applied to the CDR equivalent loops. CDR 1 and CDR 2 equivalent 
loops were modelled using a combination of database and ab intio searching. The 
constraints used in the database search were those derived from antibody struc­
tures. The CDR 3 loop was five residues long and was modelled with CONGEN 
alone. The D-E equivalent loop of CD4 was modelled using CONGEN in accor­
dance with the original CAMAL algorithm. The sequence alignment of Rei and 
CD4 is shown in figure 4.6 which also indicates the CDR ranges.
4.6.3 CD4 Modelling: Results
The RMS deviations for the different regions for the model of CD4 are shown 
in table 4.3. A comparison of the model and the structure is shown in figure 4.7. 
There are two structures for CD4 domain 1 [43,44]. These agree in the positioning 
of the CDR 2 and CDR 3 equivalent regions but differ in the position of the CDR 
1 equivalent region. The deviation along the chain for the model versus structure
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CDR 1
10 20 30 40
REI DIQMTQS P-S SLSASVGDRVTITC QASQDIIKTLN WYQQTPGK
CD4  KKWLGKKGDTVELTC TASQKKSIQFH WKNS---
CDR 2 D-E
50 60 70 80
REI APKLLIY E-A--SNLQAG- VPSRFSGSG SG  TDYTFTIS
CD4 NQIKILG NQGSFLTKGPSK LNDRADSRR SLWDQ GNFPLIIK
CDR 3
90 100 110
REI SLQPEDIATYYC QQYQSLPYT FGQGTKLQIT
CD4 NLKIEDSDTYIC EVE DQ KE-EVQLLVF
Figure 4.6: Structural alignment of CD4 and REI showing the regions which were modelled as 
CDR loops.
Icd4.brk is shown in figure 4.9. The CDR 1 and CDR3 regions of the model 
have low global backbone RMS values of 1.62 A  and 1.31 A .  CDR 2 has an RMS 
of 2.4 A  which is comparable to that of many of the antibody loops modelled 
using CAMAL. The conformations of the model CDR equivalent loop regions 
compared to the structures are shown in figure 4.8. The largest deviations from the 
crystal structures are in the D-E loop region. This has a different conformation to 
either light or heavy chains which was not modelled well using CONGEN (RMS 
of 3.5 A ) .  In the case of CDR 2 the model was built on a heavy chain CDR 2 
which had been spliced into the framework. This shows that reasonable models 
can be generated using a hybrid H/L framework. The model also indicates how 
structurally conserved short (10-11 residues) CDR 1 loops are. These regions 
could be modelled first and included in all further loop modelling.
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Figure 4.7: The molecular model of CD4 N-terminal domain superimposed on the two structures 
with Brookhaven accession numbers 1CD4 and 2CD4. The model is coloured yellow, 1CD4 is 
coloured magenta and 2CD4 is coloured orange.
Loop Global Backbone Local Backbone 
RMS (A) RMS (A)
CDR 1 (25 - 35) 
CDR 2 (51 - 62) 




Table 4.3: The global and local backbone RMS deviations for the CDR equivalent loops in CD4 
(Brookhaven accession number 1CD4). The residue numbering is as in figure 4.6.
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CDR 1 CDR 2
CDR 3
Figure 4.8: A backbone plot of the loop conformations in the model (white) and the two crystal 
structures of CD4 (Brookhaven accession numbers 1CD4 (dark grey) and 2CD4 (light grey)).
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Figure 4.9: A plot of the backbone RMS deviation along the chain for the CD4 model compared to 
the CD4 structure with the Brookhaven accession number 1CD4. The CDR regions are sectioned 
off. The high peak after the CDR 2 region shows the poor modelling of the D-E loop. The residue 
numbering is the same as in 1CD4.
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4.6.4 CD4 Modelling: Conclusions
The modelling of CD4 showed that it is possible to model a member of the im­
munoglobulin superfamily using an antibody V domain, when the sequence align­
ment is known. Previous modelling of CD4 failed because the alignment was 
incorrect [44]. In the case of TCRs the alignment against antibodies is easier be­
cause of the high conservation of certain key residues such as the cysteines at the 
start of CDR 1 and CDR 3, the LLIY (residues 53-56 (see figure 2.2 for residue 
numbering)) motif at the start of CDR 2, an RF (residues 75-76) motif at the end 
of CDR 2, a WY (residues 42-43) motif at the end of CDR 1 and an FG (residues 
138-139) motif after CDR 3. The modelling of CD4 CDR-equivalent regions was 
quite accurate, CDR 1 being well modelled. CDR 3 was short and modelled well 
using conformational search. A problem arose with CDR 2. This region has a dif­
ferent conformation to either light or heavy chains. It is more similar to a heavy 
chain CDR than a light chain CDR and was modelled using a heavy chain CDR 
spliced into the framework. The general positioning of the loop was accurate. 
However the precise conformation was not because of contacts with the non CDR 
D-E loop which was poorly modelled. The rest of the framework was accurately 
predicted. In TCRs the D-E loop is more variable than antibody D-E loops and 
CDR2 is more variable in length than the antibodies. These facts suggest that this 
CDR would be more difficult to model accurately than the other CDRs.
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4.7 Modelling TCRs from Transgenic Mice
4.7.1 Introduction
The CD4 modelling exercise showed that it is possible to produce a reasonable 
model of a non-antibody Ig domain using CAMAL. The next stage was to ap­
ply this experience to TCRs. The sequences chosen were those for which some 
sequence function relationships were known.
4.7.2 Method for Modelling TCRs
TCR frameworks were modelled using the light chain dimer Rei [182]. Where 
the Rei and TCR sequences differed, the TCR sidechains were inserted using a 
maximum overlap approach and the framework minimised to a derivative of 0.1 
in DISCOVER(Biosym). The CDRs were modelled onto this framework using 
CAMAL [6]. In the a  chain the loop regions modelled were positions 23-33,49- 
55 and 91-105; in the /? chain the regions were 24-33,48-59 and 93-107 (Kabat 
residue numbering [129]).
The sequence alignments of the sequences of 5C.C7 against Rei are shown in 
figure 4.10, as are the three CDR /33 variants of 5C.C7 [164] which have been 
modelled. For loops of five residues or less, CONGEN [144] was used to generate 
conformations. The lowest energy conformation was then chosen. For loops of 
six or seven residues, Co: distance constraints within the loop were used to search 
the Brookhaven database [183] for structural segments which matched within a 
tolerance of 3.5 standard deviations. Sidechains were replaced with those of the
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desired loop sequence in CONGEN and were energy screened using a solvent 
modified EUREKA potential [160]. A torsional screen using the initial database 
loops was then performed to choose the final conformation. For loops greater than 
seven residues a combination of database searching and conformational searching 
for the central five residues of the loop was performed. The energy screen and 
torsional screen were then performed on the generated conformations. In all cases 
each loop was constructed in the absence of the others. Distance constraints for 
antibody CDR loop regions were used to extract database conformations for the 
CDRs. For CDR a \  and CDR (3\ the CDR LI constraints were used. For CDR 
gl2 the CDR L2 constraints were used. For CDR [52 the CDR H2 constraints were 
used. The range modelled for CDR (32 does not include the C”-D loop. This 
is because the loop was defined for H2 modelling, and also because no database 
search hits were produced if the longer range including the C”-D loop was in­
cluded. For both CDR a3 and (33 the CDR L3 constraints were used. A five 
residue segment, predicted to be the D-E loop in both chains, was also modelled 
using CONGEN (residues 67-71 in a  and 70-74 in the (3 chains (Kabat residue 
numbering [129])). This region was also ignored when the CDRs were built. The 
final model was minimised in DISCOVER to a derivative of 0.1.
4.7.3 Results: Comparison to experimental data
Models have been created for four TCR sequences. These are related, having the 
same Vo: and V(3 gene segments and only varying in the joining regions of the a  
chain. These sequences were taken from Jorgensen’s recent TCR MHC mapping
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Figure 4.10: Sequence alignment of the modelled TCR sequences against Rei [57]. The table 
below the alignment shows the four CDR a3  regions for the clones modelled.
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study [164] because of sequence-function data defining the MHC -peptide- TCR 
interacting residues. The models could therefore be tested for their ability to pre­
dict the residue positions important for peptide binding. The TCR models showed 
that the Jorgensen interacting residues were solvent exposed.
The peptide sequence which the TCRs bound (MCC peptide ) was modelled 
onto the sequence of the peptide in one of the MHC antigen structures (lvab.brk) 
[25] and the TCR model has been overlaid onto this peptide. The peptide is proba­
bly correctly oriented because the TCR contacting residues were exposed and the 
MHC antigen contacting residues pointed into the MHC antigen. The residues in 
the TCR a  and 0 chains (residues 93a and 98/? (residue numbering as in figure 
4.10)), considered to be important for MHC binding, could be oriented to both be 
less than 5A away from the peptide contact residues, with the TCR oriented with 
its two CDR 3’s over the peptide and the CDR 1 and 2 regions over the MHC a 
helices. This distance could be reduced if the side chain conformation at residue 
93 was more exposed. In this orientation the CDR 1 and 2 of the a  chain contact 
an MHC helix, as does CDR 2 in the 0 chain. CDR 1 in the 0 chain did not contact 
either peptide or MHC. The D-E loop of the a  chain modelled conformation was 
similar to that of a heavy chain D-E loop. The tip of the D-E loop in the 0 chain 
pointed in towards the CDR 01 region.
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MHC
MHC
Figure 4.11: Two views of the TCR - peptide - MHC antigen model. The TCR is coloured blue. 
Only the MHC antigen N- terminal domain is shown. The MHC a  helices on either side of the 
peptide binding cleft are coloured green. The 3  sheet base of the binding cleft is coloured magenta. 
The peptide is coloured white. The two TCR residues predicted to be important for TCR peptide 
interaction are coloured magenta and yellow. The respective residues in the peptide are coloured 
red and orange. The peptide sequence of the MCC peptide has been modelled onto the peptide 
from lvab.brk. The TCR has been positioned so as to minimise the distances between the two 
contact residues and their peptide partners while avoiding clashes between the TCR and the MHC 
antigen. The right hand view shows the MHC antigen helices side on while the left view shows 
them from one end.
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4.8 Modelling a TCR to Suggest Mutations
4.8.1 Introduction
HA 1.7 is aDRl restricted, influenza hemagglutinin peptide (307-319, PKYVKQNTLK- 
LAT) specific, TCR. Wedderbum et al (ICRF, London) had expressed this TCR 
as a chimera with CD3£ in a rat basophil line and it was therefore amenable to 
site-directed mutagenesis. The aim of this modelling study was to identify one 
or more peptide interacting residues in the TCR. These predictions would then be 
tested by site-directed mutagenesis by Wedderbum et al.
4.8.2 Methods
The modelling method for this TCR was essentially similar to the previous mod­
elling. However there are some differences between the automated procedure 
implemented in AbM and the more manual method described above. Firstly the 
framework regions were modelled using the program FRAMEBUILD [136]. This 
positioned the subunits and performed the maximum overlap sidechain replace­
ments. The splicing of the CDR H2 loop into the Rei light chain framework was 
performed by the canonical loop modelling program CHOTH using the conserved 
C’ and D strands.
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4.8.3 Results: Predictive value
The models of the human TCR HA 1.7 were used to predict a peptide contacting 
residue. The model predicted that a glutamic acid residue in the CDR a3 region 
interacted with lysine 316 of the peptide (see figure 4.13). This residue was 
backmutated by Wedderbum et al [184] and binding was eliminated. This model 
at least appears to have predicted a residue which may be involved in peptide 
contacts. Other explanations are possible, for example the single residue change 
could have altered the conformation of other residues, eliminating their interac­
tions [185].
Wedderbum attempted to make complementary changes in the peptide to re­
store binding but this did not succeed. Recently it has been shown that the con­
formation of the MHC helices can change significantly when binding different 
peptides.
4.9 Conclusions
The models generated were consistent with the mode of binding described by 
Chothia and Lesk [127] and Davis and Bjorkman [186] for the TCR to the MHC 
and peptide. In this arrangement CDR a l  and CDR a2 are supposed to contact 
one MHC helix, and CDR 01 and 02 are supposed to contact the other, with the 
CDR3 regions contacting the peptide. In the models, no contacts were observed 
with the CDR 01 region, which also does not show significantly greater sequence 
variability than the framework. These two pieces of evidence are therefore con-
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a) b)
Figure 4.13: Molecular models showing the predicted interaction between TCR HA1.7 and the 
HA 307-319/DR 1 complex. The Vc* and V# chains are shown in blue and orange, respectively 
and the MHC a  and 13 chains in pink and yellow, respectively. The peptide is shown in white and 
is orientated N terminus (right) to C terminus (left) in the two views a) and b). a) side view of the 
TCR-MHC complex showing the proximity of residue TCR V a 95E (see figure 4.12 for residue 
numbering) (space filled red) to peptide residue 316K; b) end view of the TCR-MHC complex 
obtained by rotation of view a) by 90°. The CDR3 loops of the Vq and V (3 chains can be seen 
to be located above the peptide, while the CDR1 and CDR2 regions are positioned over the MHC 
helices. Figures were generated using MOLSCRIPT [26].
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sistent with one another.
The models also suggest a reason why there is a more restricted length dis­
tribution for the CDR a l  loop compared to the CDR LI loop of the antibody k 
chain. The long CDR Lis have a bulge before the start of the C strand which, in 
the model of the TCR MHC complex would clash with the MHC.
The structure of a monomeric TCR /3 chain [3], a homodimer of TCR a  chains 
[4] and, recently, of a mouse MHC class I and a human MHC class I restricted 
TCR a/? heterodimer [1,2] have been published. Only the coordinates of the TCR 
(3 monomer are at present available from the Brookhaven databank. However, the 
descriptions of the structures provide some information for comparing with the 
models.
There follows a description of certain of the features of these structures and 
comparisons are made to the models of the TCRs.
The crystal structure of the /? chain monomers shows higher structural homol­
ogy to the VL in its framework regions. The Va homodimer structure also shows 
higher similarity, in these regions, to the VL than the VH. The light chain dimer 
framework of the models will reflect this.
The residues involved in the V^ -V^  interface have been identified in the a/? 
heterodimer structures. The residues involved are the same as those in antibodies.
The interface in the mouse a/? heterodimer buries only 1160A2 which is at 
the lower limit of that seen in antibody Fabs. In the human dimer the interface 
buries about 1575A2 which is near the upper limit seen in the Fabs. The models 
of the TCRs bury around 1500A2 which is similar to the human dimer. However
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in several of the light chain dimers for which structures are available, only about 
1100A2 are buried.
In the TCR structures the precise conformation and stabilising interactions in 
the CDR a l  and (3\ loops is different to that seen in antibodies. However the 
general conformation is similar. The models are based on light chain constraints 
for this loop region so the models generated are reasonable.
However a feature unique to the a  domain is a strand switch of the C” strand 
from the inner to the outer sheet. This means that the conformation of the CDR2 
region, i.e. the C’-C” loop, the C” strand and the C”-D loop, is significantly 
different to the light chain CDR2 region. The local conformation of this loop is 
similar to the CDR H2 region in antibodies. The model uses light chain constraints 
for this region and is therefore inaccurate.
The conformation of the CDR j32 region in the structures was more similar 
to the CDR H2 region than the CDR L2 region and the local conformation of 
this loop was also similar to the CDR a2 region. In the models the use of H2 
constraints for this region therefore appears to be valid.
The conformations of the D-E loop in the (3 chain structures have the tip of the 
loop pointing towards the CDR1 loop. This was seen in the models where the re­
gion was modelled using CONGEN. The D-E loop in the a  chain folds away from 
CDR1. The models also display this feature, although the exact conformation is 
different.
The CDR (33 region folds away from the core of the domain in the monomer. 
However in the two a(3 heterodimers the conformation is much more upright.
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Garcia et al [1] suggest that, in the monomer, the absence of the a  chain allows 
the CDR3 to fold away from the domain surface towards the solvent. The light 
chain dimer framework used means that the take-off angle generated for modelling 
the CDR j33 is very different to that of a CDR H3 loop, but much more similar 
to that seen in the heterodimer structures. However, without the coordinates it 
is difficult to make an accurate comparison. The CDR a3 location within the 
combining site is very similar to that of a light chain CDR3 when an antibody 
is superimposed.
In the space between the two CDR3 loops, both Wa-V/3 heterodimer structures 
have a cavity. In the human heterodimer this cavity has been shown to be occupied 
by an antigenic peptide residue. The models also show a cavity between these two 
CDRs.
The orientation of the TCR on the MHC in the structures of the complex is 
very different to that used in the modelling experiments. However the structures 
do show that the majority of contacts with the peptide are to the CDR3 loops of the 
TCR. Therefore, although the orientation was wrong, the interactions predicted 
are probably correct.
Overall, the choice of a light chain dimer probably produced a more accurate 
model than if a VLVH heterodimer had been used.
Chapter 5
Humanisation of Antibodies
5.1 Introduction to humanisation
Antibodies have high specificity and affinity. These properties are just those 
needed for drug targeting agents, and there has been much research into their use 
by pharmaceutical companies. However it is difficult to generate human antibod­
ies. Rodent antibodies are often available with the required specificity but these 
are foreign proteins to the human patient and so produce an immune response 
eliminating the antibody from the system. To try to solve this problem changes 
are made to the antibody sequence to reduce the immune response against it. This 
process is known as humanisation.
The most used form of humanisation is CDR grafting in which the CDR loops 
of the rodent antibody are grafted onto the framework of a homologous human 
antibody. The first attempts at this involved grafting the CDRs from a mouse anti­
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body onto the framework sequence of a known human structure (e.g. REI [57] or 
NEW [50]) [187-190]. However the grafting itself usually failed to produce anti­
bodies which bound antigen. It was often necessary to perform ’’back mutations” 
to the mouse framework sequence to produce functional antibodies. Antibody 
modelling is useful in identifying residues to be backmutated and AbM has been 
used successfully to predict required back mutations.
As part of the development of a general immunoglobulin modelling algorithm, 
the differences between mouse and human antibodies were investigated. The re­
sults obtained indicate that the number of residues required to produce a given 
reshaped antibody is surprisingly small.
Two generally applicable methods for reshaping antibodies are described, the 
first based on CDR grafting using rational rules for generating the sequence, and 
the second on a new approach which was given the name resurfacing. In the 
latter approach many fewer changes to the mouse sequence need to be made as 
only the surface of the antibody is changed to that of a human antibody. The 
methods have been applied to two antibodies, both of which have been expressed 
and characterised.
This work has been described in detail in a series of papers [191-193]. Here a 
brief history of the main parts of the project will be given. A paper is also included 
describing the results to date for two antibodies humanised by both resurfacing 
and CDR grafting.
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5.2 Creation of sequence database
For both approaches a comprehensive database of antibody sequences is required. 
Some V l and V# sequences are known to be expressed together. Choosing a 
known V^-V# pair has two advantages. Firstly the light and heavy chain in the 
pair should associate and secondly they will hopefully not generate epitopes which 
will give rise to a human anti-mouse antibody (HAMA) response.
Aligned human and mouse antibody Ey sequences were extracted from the 
Kabat database [129]. Clone information defining V^-V# pairings was retained.
5.3 Analysis of Fy surface residues
The following protocol was used to identify the surface residues in an antibody. 
The structures of 12 antibody structures from the Brookhaven database [183] were 
superimposed. The relative accessibility of each residue was calculated using the 
DSSP accessibility calculation routine [194]. Using this data for R19.9 [59] a cut­
off was defined to identify accessible residues. A value of 30% was chosen [192]. 
Structurally aligned positions which had an average relative accessibility greater 
than the cut-off were defined as accessible. There was 98% identity between the 
antibodies in the positions which were above the cut-off.
The surface positions were then extracted from an alignment of light and heavy 
chain sequences. The sets of surface residues in mouse and human sequences were 
compared [192]. The main results from this analysis were, firstly that in no case 
was a human surface identical to a mouse surface. Secondly the homology be­
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tween surfaces in the two species was high. Thirdly there were identical surfaces 
within a species.
5.4 Modelling
Both approaches rely on molecular modelling to identify CDR framework interac­
tions. Models were generated using a modification of the CAMAL procedure [6,7] 
implemented in the program AbM [195]. The heavy and light framework regions 
for each model were chosen from the most homologous antibody of known struc­
ture. Where possible, the CDRs were modelled using a canonical loop [120]. For 
CDRs which did not fit any of the canonical classes, a combination of knowledge- 
based and ab initio methods were used to generate possible CDR conformations.
5.5 Method for CDR grafting
The mouse light and heavy chain sequences were aligned against the human se­
quence database. The human light heavy chain sequence pair with the highest 
total identity against the mouse sequence was determined. The CDRs in the hu­
man sequence were then replaced with those of the mouse antibody, and both the 
original mouse and initial CDR grafted sequences were modelled. All framework 
residues within 5 A of the CDRs were examined. Any which might interfere with 
the CDRs were back mutated. The backmutated sequences were modelled to de­
termine whether the CDR conformation was improved.
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5.6 Method for Resurfacing
The mouse light and heavy chain sequences were aligned against the human se­
quence database. The human light heavy chain sequence pair with the highest total 
identity against the mouse sequence was determined. The surface residues in the 
mouse antibody were replaced with the human sequence. Both the original mouse 
and initial CDR grafted sequences were modelled. All framework residues within 
5A of the CDRs were examined. Back mutations were made at those positions 
which might interfere with the CDRs. The backmutated sequence was modelled 
to determine whether the CDR conformation was improved.
5.7 Comparison of Methods
A comparison of the two methods is shown as a flow chart in figure 5.1. CDR 
grafting involves changing most of the framework to the human sequence whereas 
resurfacing only involves changing the surface of the antibody to appear human 
while retaining the mouse core framework (see figure 5.2). Therefore resurfacing 
should have a better chance of retaining binding while CDR grafting may give 
lower immunogenicity.














Figure 5.1: A flowchart comparing the two humanisation methods.
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Murine Fv Human Fv
Murine Fv with 
human surface
Murine Fv with human 
surface and retained CDR 
supporting residues
Figure 5.2: A schematic illustrating the resurfacing method for humanisation. In the first stage, the 
mouse framework (white) is retained and only the surface residues changed from mouse (black cir­
cles) to the closest human pattern (light grey circles). In the second stage, surface residues within 
5A of the CDRs that are predicted by molecular modelling to perturb the CDRs, are replaced with 
the original mouse residues. This ensures retention of antigen binding.
5.8 Paper describing the humanisation of B4 and 
N901
The paper included below describes the application of both CDR grafting and 
resurfacing methods to two antibodies [193]. The theoretical work was done in 
Bath by Andrew Henry, Jan Pedersen and the author. The experimental work was 
carried out by Immunogen Inc.
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The variable domain resurfacing and CDR-grafting 
approaches to antibody humanization were compared 
directly on the two murine monoclonal antibodies N901 
(anti-CD56) and anti-B4 (anti-CD19). Resurfacing replaces 
the set of surface residues of a rodent variable region with 
a human set of surface residues. The method of CDR- 
grafting conceptually consists of transferring the CDRs 
from a rodent antibody onto the Fv framework of a human 
antibody. Computer-aided molecular modeling was used to 
design the initial CDR-grafted and resurfaced versions of 
these two antibodies. The initial versions of resurfaced 
N901 and resurfaced anti-B4 maintained the full binding 
affinity of the original murine parent antibodies and further 
refinements to these versions described herein generated 
five new resurfaced antibodies that contain fewer murine 
residues at surface positions, four of which also have the 
full parental binding affinity. A mutational study of three 
surface positions within 5 A of the CDRs of resurfaced 
anti-B4 revealed a remarkable ability of the resurfaced 
antibodies to maintain binding affinity despite dramatic 
changes of charges near their antigen recognition surfaces, 
suggesting that the resurfacing approach can be used with 
a high degree of confidence to design humanized antibodies 
that maintain the full parental binding affinity. By compar­
ison CDR-grafted anti-B4 antibodies with parental affinity 
were produced only after seventeen versions were attempted 
using two different strategies for selecting the human 
acceptor frameworks. For both the CDR-grafted anti-B4 
and N901 antibodies, full restoration of antigen binding 
affinity was achieved when the most identical human 
acceptor frameworks were selected. The CDR-grafted anti- 
64 antibodies that maintained high affinity binding for 
CD19 had more murine residues at surface positions than 
any of the three versions of the resurfaced anti-B4 antibody. 
This observation suggests that the resurfacing approach 
can be used to produce humanized antibodies with reduced 




The method of immunoglobulin variable domain resurfacing 
(Pedersen et al., 1994; Roguska et al., 1994) attempts to reduce 
the immunogenicity of murine antibodies while maintaining 
their affinity and specificity by humanizing only the surface 
accessible residues located at conserved positions of the Fv 
framework. Differences in the presentation of surface residues 
in a small number of murine and human antibody variable 
regions have been described by Padlan (1991), and a statistical 
analysis of a large database of murine and human immunoglob­
ulin sequences revealed that the variable domains of murine 
and human antibodies have distinct sets of surface residues 
that mirror the V-gene families (Kabat et al., 1991; Pedersen 
et al., 1994). No mouse framework displays the exact pattern 
of surface residues found in any human framework, but 
generally only a small number of changes are required to 
convert the set of surface residues in a murine Fv to that of 
the most identical surface pattern found on a human Fv. Thus, 
a general algorithm for the humanization of murine Fvs by 
variable domain resurfacing was developed and successfully 
applied to two murine monoclonal antibodies, N901 and anti- 
B4 (Pedersen et al., 1994; Roguska et al., 1994).
In its simplest form, the method of CDR-grafting for 
humanizing antibodies consists of grafting the CDRs from a 
rodent antibody onto the Fv frameworks of a human antibody. 
Constructs made in this way have the advantage of containing 
a minimal number of murine residues in the variable region. 
However the successful design of high-affinity CDR-grafted 
antibodies usually requires that key murine residues be substi­
tuted into the human acceptor framework to preserve the CDR 
conformations (reviewed in Winter and Harris, 1993). Although 
progress has been made towards identifying such framework 
residues either experimentally (Foote and Winter, 1992) or by 
computational methods (Queen et al., 1989), this process is 
generally unique for each reshaped antibody and can therefore 
be difficult to predict (Kolbinger et al., 1993). For many CDR- 
grafted antibodies, the percentages of murine residues in the 
human framework may not differ significantly from those 
found for corresponding resurfaced versions.
The resurfacing algorithm as previously described preserved 
murine residues at surface positions if they were located within 
5 A of a CDR in order to maintain CDR conformations. A 
mutational analysis of the surface positions within 5 A of the 
CDRs of the resurfaced antibodies N901 and anti-B4 has now 
led to resurfaced antibodies containing fewer murine surface 
residues. These versions are compared with the corresponding 
CDR-grafted N901 and anti-B4 antibodies and with the pub­
lished sequences of other CDR-grafted antibodies.
Materials and methods
Murine monoclonal antibodies and cell lines
Anti-B4 and N901 are murine monoclonal antibodies specific
for the CD19 antigen found on human B cells (IgGl, k ;  Nadler
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Fig. 1. VL (upper) and VH (lower) amino acid sequence alignments o f the murine (anti-B4, N901), human (LS5, POP, 21/28, KV4B, KV2F, PL0128, and 
G36005) CDR-grafted (GB4v>/.0, GB4v2.0, G N 9Olv/.0) and resurfaced (RB4v/.0, RN9Olv/.0) variable regions. A period indicates identity to the murine 
residue. Sequences are numbered according to the AbM program (Antibody M odeling program, Oxford M olecular Group, UK) and the AbM numbering is 
used in the text. The antibody numbering according to Kabat (Kabat et al., 1991) is included for comparison.
et al., 1983), and the CD56 antigen found on human natural 
killer cells (IgGl, k; Griffin et al., 1983; Nitta et al., 1989), 
respectively. The human cell lines, SW-2, developed by Smith 
et al., (1989), and the human lymphoblastoid line, Namalwa, 
(A.T.C.C. CRL 1432) were used as the CD56-positive and 
CD 19-positive cell lines, respectively.
Molecular modeling
Models of the murine and humanized Fvs were generated as 
described previously (Roguska et al., 1994) using the methods 
of Martin et al. (1989,1991) and recent modifications (Pedersen 
et al., 1992; Rees et al., 1995), which are encoded in the 
program AbM (Oxford Molecular Group, UK). The structures 
of the most identical sequences in the database of crystal 
structures were used to model the light and heavy chain 
variable regions. The VH and VL domains were paired by a 
least-squares fit onto the most structurally conserved strands 
of the Fv ()-barrel, and then the framework side chains 
were introduced using a maximum overlap procedure. CDR 
backbone conformations were constructed using canonical loop 
structures where possible (Chothia and Lesk, 1987; Chothia 
et al., 1989), otherwise they were built using the CAMAL 
algorithm (Martin et al., 1989, 1991; Pedersen et al., 1992), 
which combines a C“ search of the Brookhaven Protein 
Databank with an ab initio conformational search, followed 
by a series of screening steps. Framework residues in the 
murine and humanized anti-B4 and N901 models were then 
examined by a 5 A proximity procedure (Roguska et al., 
1994). This method analyzes framework CDR interactions that 
have the potential to contribute to antigen binding. If a 
framework residue was located within 5 A of a CDR and there 
was a change in size, charge, hydrophobicity, or potential to 
form hydrogen bonds that could disturb a CDR conformation, 
the human residue was considered a candidate for replacement 
by the amino acid from the murine Fv.
Construction o f humanized V-region genes 
The resurfaced and CDR-grafted VH and VL genes were 
constructed by extension and amplification of four overlapping 
oligonucleotides (120-130 nucleotides) comprising alternating
strands of the full-length genes (Daugherty et al., 1991). For 
N901, the assembled VH and VL genes encoded the following 
sequences in order (5'-3'): a Hindlll cloning site, the consensus 
Kozak sequence (5'-GCCGCCACC-3') (Kozak, 1989), an 
immunoglobulin signal sequence (Jones et al., 1986), an intron, 
the humanized VH or VL coding region, a 3' non-coding 
sequence including a splice site, and a BamW\ cloning site. 
For anti-B4, the assembled VH and VL genes differ from the 
above only by the elimination of an intron between the 
immunoglobulin signal sequence and the VH or VL coding 
region. The assembled humanized variable-region genes were 
subcloned into immunoglobulin expression vectors derived 
from HCMV-VLLys-KR (Maeda et al., 1991), containing either 
the human constant K exon or human-yl constant region gene. 
Expression vectors carrying the resurfaced and CDR-grafted 
anti-B4 variable-region genes differ from the N 901 expression 
vectors by the addition of the human DHFR cDNA positioned 
at the 5' end of the cytomegalovirus (CMV) enhancer in 
reverse orientation with respect to the CMV promoter. Mutant 
VH and VL variable-region genes were constructed by PCR 
mutagenesis (Ho et al., 1989) or by site-directed mutagenesis 
according to Kunkel et al. (1987) of the CDR-grafted and 
resurfaced frameworks.
Expression and purification o f  recombinant antibodies 
Three days prior to transfection, COS cells were plated on 15 
cm tissue culture dishes at 2X 106 cells/30 ml/plate in DMEM 
supplemented with 10% bovine calf serum (total o f 12 plates 
per experiment) which were incubated at 37°C in 7% C 0 2. 
After 3 days, each dish was washed twice with 10 ml HBS 
(137 mM NaCl, 5 mM KC1,0.7 mM Na2H P04, 6 mM dextrose, 
20 mM HEPES, pH 7.05), and then treated with 5 ml trypsin 
solution (Gibco) for 5 min at 37°C, followed by vigorous 
pipetting to detach and disaggregate the cells. The cell suspen­
sion was then added to 5 ml SFM (Hybridoma Serum Free 
Medium, Gibco). Cells were pelleted by centrifugation for 5 
min at 300 g and supernatants removed by aspiration. Cell 
pellets (each about 1X107 cells) were washed twice in 10 ml 
HBS, resuspended in 0.8 ml HBS containing 40 |ig each of
896
5 . 8. PAPER DESCRIBING THE HUMANISA  159









Fig. 2. Comparison o f the binding of resurfaced, CDR-grafted, and murine N901 antibodies. Recombinant and murine antibodies were compared as follows: 
(A, B) Binding o f antibodies to SW-2 cells as measured by indirect immunofluorescence. (C) Competition binding assay measuring the ability o f  resurfaced, 
CDR-grafted, and murine N901 to compete with fluorescein-labeled murine N901 for binding to SW-2 cells. The symbols used in the figure are as follows: 
(O) murine N901, ( • )  G N 901v/.0, (A ) G N 901v/.f, (□ )  RN901 vl.O, (■ )  R N 901v/./.
the VH and VL immunoglobulin expression plasmids, and 
then transferred to 0.4 cm electroporation cuvettes. Cuvettes 
containing the mixture of COS cells and expression plasmids 
were chilled on ice for 10 min, and then pulsed at 230 V and 
960 (iF in a Bio-Rad electroporation apparatus, followed by 
incubation on ice for 10 min. Following electroporation, cells 
from individual cuvettes were added to 40 ml of SFM, plated 
in a 13 cm tissue culture dish, and incubated at 37°C in 7% 
C 0 2. The supernatant was harvested from the transfected cells 3 
days after transfection. Pooled cell supernatants (approximately 
450 ml total) were centrifuged for 20 min at 4500 g, filtered 
through a 0.22 pm filter and concentrated to a final volume 
of 30 ml using a stirred cell apparatus fitted with an Amicon 
YM10 membrane. Tris-HCl (pH 7.4) was added to a final 
concentration of 0.1 M and the resulting solution was applied 
to a column of immobilized protein A (Pierce Chemical Co., 
Rockford, IL.). The column was washed with 0.1 M Tris-HCl 
buffer, pH 7.4, containing 0.15 M NaCl. The bound antibody 
was eluted with 100 mM acetic acid containing 150 mM NaCl, 
and then dialyzed against 10 mM sodium phosphate, 150 
mM NaCl, pH 7.4. Protein concentration was determined by 
measuring absorbance at 280 nm and assuming £,|%icm ° f  14.0 
for IgG. Yields of antibodies were typically 1-2 mg from 0.5 
1 of cell culture supernatant. Antibodies produced in this manner 
are free from any contaminating bovine immunoglobulin as 
determined by isoelectric focusing gels (Roguska et al., 1994), 
thus allowing accurate concentration measurements. The purity 
and integrity of the purified products were confirmed by 
polyacrylamide gel electrophoresis under reducing and non­
reducing conditions. To prevent any non-specific losses due to 
adsorption, bovine serum albumin at a final concentration of 
1 mg/ml was added to the purified antibody for storage prior 
to binding studies.
Competition binding assay
Competition binding assays were performed as described 
previously (Lambert et al., 1991). Briefly, Namalwa cells 
(CD19 antigen-positive, 3X 10s cells/well) or SW2 cells (CD56 
antigen-positive, 5X105 cells /well) in AB buffer [2.5% pooled 
human AB serum (Whittaker) in minimal essential medium 
(Whittaker)] were plated at 25 pi per well in 96-well dishes. 
Twenty-five microliters of AB buffer containing fluorescein- 
labeled anti-B4 (4-6  nM) or N901 (1-3 nM) antibody mixed 
with various concentrations of competing murine or recombin­
ant antibody were added to each well. Positive controls lacked 
competing antibody while negative controls lacked fluorescein- 
labeled anti-B4 or N901. Plates were incubated for 30 min at 
4°C. The cells were washed once with AB buffer (175 pi/ 
well) and fixed with 1% formaldehyde in 10 mM potassium
phosphate, 150 mM NaCl, pH 7.2. The labeled cells were 
analyzed on a FACScan flow cytometer (Becton-Dickinson) 
set on linear fluorescence. The binding of fluorescently-labeled 
antibody was expressed as a percentage of the fluorescence of 
the positive control.
Indirect binding assay
Namalwa cells (for anti-B4) or SW2 cells (for N901) were 
mixed with carrier 4.5 pm polystyrene microspheres (Polysci­
ences, Inc.) and washed twice in 10 ml NGS buffer (2.5% 
goat serum, 2 mM HEPES, pH 7.2, in minimal essential 
medium) at 4°C and resuspended in NGS buffer at 2X105 
cells/ml. Cells (2X104/well) and microspheres (1.8X 106/well) 
were plated at 100 pl/well in 96-well dishes. Various concentra­
tions of primary murine or recombinant human IgG, antibodies 
were added to each well in 100 pi of NGS buffer. One hundred 
microlitres of NGS buffer lacking primary antibody were 
added to control wells. The plates were incubated at 4°C for 
2 h, and then washed twice with 200 pi NGS buffer. Fluor­
escein-labeled secondary antibodies (goat anti-human or goat 
anti-mouse) were added in 100 pi NGS buffer per well and 
plates were incubated in the dark for 1 h at 4°C. The cells 
were again washed twice with NGS buffer (200 pi), fixed with 
1% formaldehyde in 10 mM potassium phosphate, 150 mM 
NaCl, pH 7.2, and analyzed on a FACScan flow cytometer 
(Becton-Dickinson). The binding o f antibody to cells is 
expressed as the fraction of maximal fluorescence.
Results
Humanization of murine monoclonal antibody N901 by CDR 
grafting
The human frameworks chosen to accept the N901 CDRs, 
KV2F VL (Klobeck et al., 1985) and G36005 VH (Schroeder 
et al., 1990), were selected based on their highest sequence 
identity to the N901 VL and VH framework sequences 
(Figure 1). The VL amino acids of N901 and KV2F were 
the same at 66 of 80 (84%) framework positions, and the 
VH amino acids o f N901 and G36005 were identical at 80 
of 94 (86%) framework positions. Modeling identified the 
two human Fv residues Val3 and Arg52 as falling within 5 
A of a CDR and having the potential to disturb CDR 
conformation. Val3 is adjacent to Arg24 and could alter the 
structure of CDR LI. Arg52 is located between Glu40 in 
CDR LI and Met228 in CDR H3 and could influence the 
conformation of either CDR. Therefore, both of these 
residues were replaced with Leu, the corresponding residue 
at both positions in the murine N901 VL. A third residue 
in the human VL, Glnl08, had the potential of interfering
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Fig. 3. Comparison o f the binding of CDR-grafted anti-B4 antibodies. Antibodies were compared as follows: (A, B, C) Competition binding assay measuring 
the ability o f CDR-grafted and murine anti-B4 to compete with fluorescein-labeled murine anti-B4 for binding to Namalwa cells. (D, E) Binding o f CDR- 
grafted and murine an(i-B4 antibodies to Namalwa cells as measured by indirect immunofluorescence. The symbols used in the Figure are as follows: (O ) 
murine anti-B4, ( • )  GB4v7.0, (□ )  G B 4 v /./, (A ) GB4v2.0, ( ♦ )  GB4v2.7, (■ )  G B 4v2J.
with the docking of the KV2F VL and G36005 VH> and 
was replaced with the murine Gly. A CDR grafted N901 
antibody incorporating these substitutions (GN9Olv7.0, Table 
1A) was made and its binding to SW-2 cells was assessed 
by an indirect immunofluorescence assay and a competition 
binding assay. In both assays, the binding of the CDR- 
grafted GN9Olv7.0 antibody was indistinguishable from that 
of the parent murine N901 antibody (Figure 2A,C).
In order to minimize the antigenic potential of the CDR 
grafted N901 antibody, we wished to test whether it was 
possible to reduce the overall occurrence of murine residues 
in the human frameworks while maintaining the binding 
affinity of the murine antibody. Although the assumption 
made in our analysis is that there may be interactions 
between residues that are predicted by modeling to be 
within 5 A of one another, the influence o f such interactions 
between CDR and framework residues on antigen binding 
is difficult to predict and must be experimentally determined 
(Glaser et al, 1992; Wilson and Stanfield, 1993). Therefore, 
antibody version GN901v7.7 was constructed, which restored 
the original human residues Val, Arg, and Gin at the three 
framework positions 3, 52, and 108. GN901v7.7 thus 
contained no murine residues in the human frameworks. 
When this antibody was analyzed for binding on SW-2 
cells, it was also found to be indistinguishable from that of 
the parent murine N901 antibody (Figure 2B,C). Thus, N901 
is a rare example of a murine antibody that was humanized 
by simply transferring its CDRs onto the most identical 
human variable-region frameworks while retaining the binding 
affinity of the original murine monoclonal antibody. This is 
likely a consequence of the high sequence identity between 
the murine and human framework sequences.
Humanization o f murine monoclonal antibody anti-B4 by 
CDR grafting
Selection o f most identical native human Fv. In designing the 
CDR-grafted anti-B4 antibody, two methods for selecting the 
human acceptor frameworks were considered. For a design
based on using the most identical human VH and VL frame­
works, the strategy that had been applied successfully for the 
CDR grafting of the N901 antibody, the most identical human 
frameworks found in the database (Figure 1) were the human 
VH 21/28 (Dersimonian et al., 1987) and human VL POP 
(Spatz et al., 1990). For an alternative design based on using 
the most identical clonally derived Vh-V, pair, the strategy 
used successfully for the resurfacing o f anti-B4, the most 
identical human Fv was LS5 (Silberstein et al., 1989). The 
advantage of the latter strategy is that it ensures proper 
association of the VH and V l subunits without the need for 
evaluation by molecular modeling of the quality of Vh-V l  
docking, and that it reduces the risk of generating potentially 
immunogenic neoepitopes that might be presented by the 
pairing of non-native heavy and light chains. While the 
advantage of the former strategy is that VH and VL sequences 
of higher homology to the murine sequences can be selected, 
the overall framework homologies of the two human sequences 
with respect to anti-B4 were quite similar. The LS5 VH and 
21/28 VH were found to be 71% and 77% identical to the anti- 
8 4  VH, and the LS5 VL and POP VL were found to be 70% 
and 73% identical to the anti-B4 VL, respectively (Figure 1). 
Models of the murine and humanized anti-B4 Fvs were 
constructed and analysed by the 5 A proximity procedure as 
described. Six LS5 human framework residues that had the 
potential to alter a CDR conformation were identified and 
replaced with the corresponding murine residue from the parent 
anti-B4 (Table IIA). This version, GB4v7.0, was made and 
analysed for binding to antigen-positive Namalwa cells (Figure 
3A,D). In two different assays, binding affinity was reduced 
by about a factor o f 10 relative to the parent murine anti-B4. 
In an attempt to improve the binding o f GB4v7.0, nine 
subsequent antibodies were derived from GB4v7.0 by substitut­
ing the appropriate murine residues at different LS5 framework 
positions (Table IIA, footnotes). Only one version, GB4v7.7, 
showed a significant improvement in binding (three-fold) 
relative to the GB4v7.0 antibody (Figure 3A,D). GB4v7.7 was
898
5.8. PAPER DESCRIBING THE HUMANISATION OF B4 AND N901 161




Fig. 4. Comparison of binding of resurfaced and murine antibodies. (A) Binding of resurfaced and murine anti-B4 antibodies to Namalwa cells as measured 
by indirect immunofluorescence. (B) Competition binding assay measuring the ability o f resurfaced and murine anti-B4 to compete with fluorescein-labeled 
murine anti-B4 for binding to Namalwa cells. The symbols used in the figure are as follows: (O) murine anti-B4, ( • )  R B 4 v /./, (□ )  RB4W .2, (■ )  R B 4v/.J , 
(A ) RB4v/.4.
Table I. Humanized versions o f  N901*






vH CDR-grafted version 
Murine N901
KV2F VL + G36005 V„ 
GN901 vl.O  
GN901v7.7
V R Q 
L L  G 1.0
1.0





vH Resurfaced version 
M urine N901






“The human sequences are identified in italics. The various versions of 
GN901 or RN901 have human amino acids in all framework positions 
except where a murine residue is indicated by non-italicized type. A blank 
space for the various versions indicates identity to the human residue. An 
asterisk (*) identifies residues located at surface positions according to the 
criteria o f Pedersen et al. (1994).
bRatio o f the concentration o f humanized N901 required for 50% inhibition 
o f binding o f fluorescein-labeled murine N901 to that required by unlabeled 
murine N901.
constructed by introducing murine residues at VH positions 
182, 184, and 185. These residues are included in CDR H2 
according to Kabat et al. (1991), although in our approach 
they are modeled as framework residues (Pedersen et al., 
1994; Roguska et al., 1994). While little evidence exists for 
the direct interaction of residues in this region with antigens, 
the amino acids positions 182, 184, and 185 are highly 
conserved, which suggested that they might serve a CDR- 
scaffold function. However, even though the binding affinity 
of GB4v/.7 was increased relative to GB4v7.0, it was still less 
than that of the murine anti-B4. Further attempts to improve 
the affinity of the CDR-grafted anti-B4 by further substitutions 
of murine residues in the LS5 frameworks were unsuccessful 
(Table IIA).
Selection of most identical human VH and VL frameworks. 
In this strategy, the most identical human VH, 21/28, and 
most identical human VL, POP, were selected as frameworks 
to accept the anti-B4 CDRs. An Fv model of the anti-B4
CDRs grafted onto the 21/28 and POP frameworks was 
generated and potential CDR-framework interactions were 
identified using the 5 A proximity procedure. A CDR- 
grafted version GB4v2.0 was produced that contained murine 
residues substituted at nine human framework positions 
(Table IIA). However, the binding of GB4v2.0 was similar 
to that of GB4v/.0, ~10-fold lower than that of murine 
anti-B4 (Figure 3B,D).
In an effort to improve binding affinity, the Fv models 
were re-examined. The 5 A proximity procedure was broad­
ened to 6 A in an effort to identify residues which, if 
mutated to the corresponding murine residue, might improve 
the binding affinity of GB4v2.0. By this criterion, an 
additional six murine residues were substituted into the 
human frameworks (Table IIA). Two other substitutions 
were introduced at positions 112 and 242 based on the 
possible effects of these residues on the variable-constant 
region packing which may influence CDR conformations. 
Finally, Pro 124 found in murine anti-B4 is a very unusual 
residue at this position (except for murine subgroup IIB; 
Kabat et al., 1991), and proline was not found at this 
position in any known human antibody, leading to speculation 
that the unusual placement of a proline here might contribute 
to the binding of anti-B4. A new version was made, 
GB4v2.7 (Table IIA), that now incorporated a total o f 18 
murine framework residues, and when tested in the two 
binding assays it was found to be indistinguishable from 
the parent murine anti-B4 antibody (Figure 3C,E).
To further dissect the contributions of the nine additional 
substitutions to the binding affinity of GB4v2.7 relative to 
GB4v2.0, GB4v2.2 and GB4v2.i were generated by co­
expressing the light chain of GB4v2.0 and the heavy chain 
of GB4v2.7, and by co-expressing the light chain o f GB4v2.7 
with the heavy chain of GB4v2.0, respectively (Table IIA). 
Binding tests revealed that the binding of GB4v2.J, like 
GB4v2.7, was equal to that of murine anti-B4, while the 
binding of the GB4v2.2 version was about one-tenth of that 
for anti-B4 (Figure 3C,E). Thus, only the three additional 
changes in the VL framework of GB4v2.0 described above 
were necessary to produce the ten-fold improvement in 
binding affinity needed to restore the full affinity o f murine 
anti-B4. The additional six substitutions in the 21/28 VH 
framework were neither necessary nor deleterious to antigen 
binding. The rationalization of these results will be discus­
sed later.
Contributions to binding affinity by residues located at 
surface positions. We wished to test whether the design of
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Residue Number 51* 52 53 76* 77 78 112 116 124 141 163 167 182 184 185 186* 189 190 191 193 195* 204 242
LS5 VL +  V„ R L L D F T V R 5 A a M A N L Q V T M T T L L
GB4 vl.O R S Y K V K 0.10
GB4 v l.l R S Y N K F K V K 0.33
dGB4 vl.2 R S Y N F K V K 0.15
dGB4 vl.3 R s Y N K K V K n.d.c
dGB4 vl.4 R s Y K K V K n.d.
'G B 4 vl.5 R s Y T K V K n.d.
'GB4v/.<5 R s Y T N K F K V K 0.22
eG B 4v/.7 R s Y T N F K V K n.d.
rG B4v/.S R s Y K A V K V n.d.
«GB4v/.9 K R W s Y K V K 0.20
Residue Number 51* 52 53 76* 77 78 112 116 124 141 163 167 182 184 185 186* 189 190 191 193 195*204 242
POP VL +  21/28 V„ R L L D F r V G S A R M S K F Q V T I R T L L
GB4 v2.0 R S Y R G N K V K 0.11
GB4 v2.1 R W S Y s L R P T G I N K K L V K S 1.0
GB4 v2.2 R S Y R P T G 1 N K K L V K S 0.12
GB4 v2.3 R W s Y s L R G N K V K 1.0
GB4 v2.4 R W Y s L R G N V K 0.40
GB4 v2.5 R W Y s L R G N K V K 0.43
GB4 v2.6 R w s Y s L R G N V K 0.45
Resurfaced anti-B4: RB4
Residue Number
LSS VL + V„
RB4 vl.O  
RB4 v l . l  
RB4 v l.2  













T h e  human sequences are identified in italics. The various versions of GB4 o r RB4 have human amino acids in all framework positions except where a 
murine residue is indicated by non-italicized type. A blank space for the various versions indicates identity to the human residue. An asterisk (*) identifies 
residues located at surface positions according to the criterion of Pedersen et al. (1994).
bRatio o f the concentration of humanized anti-B4 required for 50% inhibition o f binding o f fluorescein-labeled murine anti-B4 to that required by unlabeled 
murine anti-B4.
cn.d. Humanized anti-B4 showed no detectable binding in the competition binding assay (50% displacement o f labeled anti-B4 at greater than 20-fold higher 
concentration than murine anti-B4). 
dPermutations o f  G B 4v/./.as described in the text.
cAlal41 is located in the N-terminal region bordering CDR H I. It is not considered pan  of HI based on the sequence variability definition (Kabat et al., 
1991), but structurally it forms part of the hypervariable loop and has been shown previously to influence the binding affinity o f two antibodies (Woodle 
et al., 1992; Presta et al., 1993). The murine Thrl41 was introduced into G B 4v/.0, G B 4v/./ and GB4v/.2, creating G B 4v/.5 , GB4v/.<5 and G B 4v/.7  
fSaul and Poljak (1993) found that amino acid sequence variations at VH residues 126 and 189 defined structural framework patterns in the VH region based 
on conformational differences in the main polypeptide chain and side-chains of residues 126, 135, 189, and 204 (AbM numbering) and suggested that these 
structural patterns may directly affect the conformation of some residues o f CDR H2. Retention o f the murine residue at position 189 was essential for 
maintenance of the murine binding activity in 4 variants o f humanized M aE ll (Presta et al., 1993). Introduction of the murine residue at this position also 
contributed to the successful CDR grafting o f a murine anti-IgE antibody (Kolbinger et al., 1993). G B 4v/.S incorporated the murine A la i89 and Val204 into 
GB4v/.0.
T h e  murine Arg52 had been introduced into G B 4v/.0 because o f potential interactions with CDR H3. The sequence o f the murine anti-B4 at positions 
Lys51-Arg52-Tip53 is highly conserved in antibodies o f the Kabat murine subgroup VI (Kabat et al., 1991). Thus, two changes were made to G B 4v/.0  to 
generate GB4W .9 in order to test whether the introduction o f all three murine residues would restore parental binding affinity to G B 4v/.0.
the CDR-grafted anti-B4 version GB4v2.i could be improved 
by applying the principles of resurfacing, which are based 
on the premise that the immunogenicity of a foreign protein 
originates with the surface residues (Pedersen et al., 1994). 
The GB4v2.3 human frameworks contained a total of 12 
murine residues, three of which were located at solvent- 
accessible positions, Ser76, Lysl86, and Lysl95 (Pedersen 
et al., 1994; Roguska et al., 1994). We constructed and 
tested antibodies GB4v2.4, GB4v2.J and GB4v2.6 (see Table
IIA), to examine the contributions of the human Asp76 and 
Gin 186 either singly or in combination to the binding 
affinity GB4v2.5. However, the three new antibodies displayed 
a two- to three-fold decrease in binding relative to GB4v2.5 
and murine anti-B4, indicating that the murine residues at 
these surface positions contribute, albeit in a small way, to 
maintaining the proper conformations of the CDR-grafted 
anti-B4 CDRs. These results are in contrast to those obtained 
with the resurfaced anti-B4 (see below), where the residues
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Variable dom ain  resurfacing  and  CD R -grafting  com parisons
Fig. 5. Comparison o f the optimal resurfaced and CDR-grafted versions of anti-B4. Surface residues are space-filled, core and CDR residues are shown as 
ribbons. For all positions (surface, core CDRs) murine residues are colored blue and human residues are colored yellow.
at these positions could be humanized with no loss of binding. 
Refinement o f resurfaced N901
We have previously described the modeling, construction, 
expression, purification, and binding characteristics of a resur­
faced N901 antibody (Pedersen et al., 1994; Roguska et al., 
1994), herein called RN9O1v/.0 (Figure 1). Ideally, all of the 
surface-exposed amino acid residues in the Fv framework of 
a resurfaced antibody form a human surface pattern. However, 
some framework surface residues of the murine antibody may 
be necessary to preserve the proper conformation of the CDRs 
or may be in direct contact with the antigen. Previously, when 
the RN901 vf.O Fv was modeled and compared with the model 
o f murine Fv N901, the retention of only one murine surface 
amino acid was thought necessary, namely Leu at position 3 
of VL. A second version of resurfaced N901, called RN90lv7.7, 
was constructed to test this prediction by replacing the murine 
Leu3 with the human Val3 (Table I). The apparent binding 
affinity o f R N 901v/./ for cell surface antigen was indistin­
guishable from that of the murine N901 in the two different 
binding assays (Figure 2B,C). Therefore the set o f surface 
residues on the murine N901 Fv could be replaced entirely by 
the most identical set of human Fv surface residues without 
affecting the binding affinity of the antibody.
Refinement o f  resurfaced anti-B4
The modeling analysis of the resurfaced anti-B4 antibody 
described previously (Roguska et al., 1994), herein called 
RB4v7.0 (Figure 1), had identified three residues (Ser76, 
Lysl 86, and Lysl95) at surface framework positions that could 
possibly interfere with CDR conformations according to the 5 
A proximity procedure. To analyze their contributions to 
antigen binding, they were systematically replaced with the 
human residues Asp76, Gin 186, and Thrl95 and the effect of  
these substitutions on binding affinity was determined (Table 
IIB, Figure 4). The introduction of all three human residues 
onto the RB4v/.0 surface (version RB4v7.7) resulted in a 
lower binding affinity relative to RB4v/.0 and murine anti- 
84  (Figure 4A,B). Subsequently, three versions with single
mutations (RB4v7.2, RB4v7.2, and RB4v/.4) were tested, 
(Table IIB). The binding affinity of each of these versions was 
equivalent to that of murine anti-B4 (Figure 4A,B). Thus, the 
full murine binding affinity could be maintained in the resur­
faced anti-B4 by the retention o f a single murine surface 
residue. Paradoxically, it appears that any two of the three 
positions can be substituted. Position 76 is located in a serine 
and threonine rich region of the antibody surface and is 
surrounded by five polar side chains (Ser24, Ser71, Ser73, 
Ser75, Thr78). The mutations Lysl86Gln and Lysl95Thr are 
both charge changes in or near the recognition surface of the 
antibody, and while these are not CDR residues, it is possible 
they may be directly involved in antigen binding.
To evaluate which of the three versions o f resurfaced anti- 
64  may be optimal for clinical development, the Kabat database 
(Kabat et al., 1991) was examined to determine human residue 
preferences at positions 76, 186, and 195. At position 76 of 
VL, no human k Vl  sequences had a Ser at position 76, while 
Asp was seen in 101 out o f 135 human k Vl  sequences. At 
position 186 o f VH in Kabat human subgroup I (the LS5 VH 
is a member of subgroup I), Gin was found in 44 o f 49 
sequences while Lys appeared only once. However, at position 
195 there was no marked preference for either the human Thr 
or the murine Lys in the 49 human sequences, with Thr present 
in 2 1 sequences and Lys in 11 sequences. We concluded that 
the surface pattern of the resurfaced version RB4v/.2 antibody 
was closest to the surface pattern of a human antibody.
Models of the optimal CDR-grafted and resurfaced antibod­
ies were then compared (Figure 5). Both Fv sequences contain 
a similar percentage of total murine framework and CDR 
residues, 39% for RB4v7.2 and 28% for GB4v2.3. However, 
RB4v7.2 and GB4v2.2 contain one and three murine residues 
at framework surface positions, respectively. While such com­
parisons cannot be used to predict the immunogenicity of 
antibodies, they do suggest that the resurfacing strategy can 
be used to design humanized antibodies that arc no more likely 
to be immunogenic than a corresponding CDR-grafted version.
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'fab le  III. Sequence alignments of humanized antibodies showing surface positions and murine framework substitutions*
GB 4 v 2 . 3
GN9 0 1 v l . 1
RB 4 v l . 2
RN9 0 1 v l . 1
1 DlOMjrOSPJpLSASyGDRVTITC
2  Q iy i |{ Q S P K IM S A S p G E fV T IT C
3 D lC jw fiO S P flS L S A S j/G D fiV T IT C
4 DIQMTQSPGSLSAslfGDRVTITC
5 ^IZ2QSPfSLSAS§GDlVT ITC
6 M i H q s p | s l s a s | g d | v t i t c
7 RIQMSQSPJTLSASWGDflvi^rC
8 P IQ L JQ S P S S L S A S V G D R V T IT C
9 D |IQ M TQ SP5 SL SA SV G D R V T IT C  
Q SPSSL SA SV G D B V T IT C  
Q S P |S L S A S V G D |V T IT C  
Q SPG T L SL SPG E R A T L SC
LsSgERATLSC 
Q fA S IS C
WFQQKjPGTSPKl 
WYQQKSgjKA P M L L IY  
W Y Q Q T P G K A P l® IY  
WYCXJljjb K A P K L L IY
h k x K k a  pB l l i y  
WVCGKPGKAPKEBWy 
WYQQKPG K A P K L L IY  
WYQQKPGKA P K L L I  Y 
WYQQKRISKA P K L L I  Y 
HYQQKTCKA P K L L I  Y 
W Y Q Q K P G Q A P R L L lfl 
WYQQKPGQA P P Q Q l Y 
W F Q Q R |B Q S P i(R L IY  (■iy 
I P k L L I  Y
G V P ^R E flG S G S G llpF T L T  IS SL Q PD D FA T Y Y  C 
GV tflR E g G S G S G T S Y S  LTISRM EABDAATYYC 
G V P S R F S G sfljsG T D F T L T  I  SSLQ flED FA TY Y C  
GVP3 R FSG SG 3 G T D Y T F T IS S L Q P E D IA T Y Y C
g v p s r f s g s g S g t d f t f t i s s l q e e d i a t y y c
" "  F T IS S L Q P E D IA T Y Y C  
T L T IS S L Q JfB D F A T Y Y C  
F T IS S L Q E E D IA T Y Y C  
IF T F T IS S L Q R R D IA T Y Y C
f t i s s l q ^ S d i a t y y c
T L T IS S L Q p |X > F A T Y Y C  
T L T I  S R L E p D F A M Y Y  C 




G V I^ R F IG S '
G V PSR FS
GVP3 RFSG
G V PSR FSG S
G V PSR FSG S
G IE ^ R F S G S '
GVPARFS
'PD R FSG S'
N o .  o f  
m u r i n e  
r e s i d u e s
FG Q G TK V EgR  
FG SG TK LELK  
FG Q G T K V E IK  









kr  G GG  I K V t .  IK  
F G G G T K L E I
D
0
FG Q G TK V EIK
FG Q G TK V EIK
FGQGT1CVEIK
FG Q G TK V EIK
F G G G T |Q E l tg
FG Q G TK V EIK
f g g g t | H e i §







1 QVQLVQSGABVKKPGSSVKVSCKASCftrFfl WVRQAPGQGLEV*G YNQKFKSW riTADESTNTAYHELSSLRSEDTAflYflcAfl H gQGTLVTVSS 9
2 QVQLQQSGAELAKPGASVKMSCKASO§ri-fl WVKQRPGQGLEVflG v !iQK;- K l f f l :  : A KSS ■ AYMQLSSUFEDSA VYYCaB  B ^Q G TTLTV SS 7
3 E V flI#E S G C G L V Q P G G S I,R L S C A A S G F N IK  WVRQAPGXGLEWVA Y A tiS V K G R F T IsflcflS K N lftfL Q M N S L JlX E D T A V Y Y C M R  W GQGTLVTVSS 4
4 O V Q L > jj^ G G G y V Q E C R S L R L S C ® S G j(H  W V R Q A PG K G LEV ®  i i :$ Q s F g 'l f lF L Q M D S L R l? E D 5flv Y Y c f lR  W G Q G TPV TV SS 2 0
5 Q V Q L V E S G G G W Q P G R S L R lS C S S S G F IF S  WVRQAPGKGLEWVA FR D SV K G R FT ISR D N SK N T L FL Q M D SL K fE D T G V Y FC A R  W GQGTTVTVSS 0
6  g y f l l i .  ESGGiGLVQ P  GG S t.R  I , S C A A GG r C T I  v |tpO A PG K G L E vflH j Y N K A F IS F rtris flJg S K N T flY flQ M N S L Q W tD T A IY Y C A R  WGQGTLVTVS S 1 2
7  Q V Q L V Q S G A E V K K P G S S V K V S C K A S ^IJF S  W ^JqA PG Q G LEW IG  Y A Q l!F K G ® ltf rA D E S T N T A Y M E L S S L R S E D T /f lB c A fl W C ^ c JJ lV T V S S  1 2
8 Q V Q L Q E S G P G L V R P S Q T L S L T C T V S G F T F S  W VRQPPGRGLEW IG Y A l!iFQ G R V T H L V D T3 K N Q F S L R L SSV T A A D T A V Y U K |H  W GQGTTVTVSS 4
9  8 v g i ^ Q S G ^ I c |f G A S \T R V S C K A S g Y ^ f f l  v flK cflP G Q G L E vflG  Y N E K FK G K A K L lfloT ST N T A Y M E L SSL R SE D T A V Y Y C ^y W GQGTLVTVS S 6
1 0  Q V gLyQ SG A EV K K PG A SV K V SC K A SG Y TFB  W V RQAPGOGLEvflc XXXXXX4 B i'k i B d *ST N T A Y M E L SSL |«8 E d 4,AVYYCAS W GQGTLVTVSS 5
1 1  j ^ a L V E S G T O ^ W G S li lL S C A B s ja F iT S  V ^ R Q A m Ig L E W V A  Y A Q S V X ti^ u T I SRIX$SXNlQYLQMNSIHAJEDTAVY YCA R W GQG TLV TV SS 4
1 2  B v i L 2 Q S G | ^ X ^ t ^ S W S C K A s | Y l F S  W VKQRM §GLEW VG Y N g K F |j M l g l §  B '||n T A Y M E L S S I^ B D T A V Y Y C A R  W GQGTLVTVSS 1 0
G B 4 V 2  . 3 QVQLVQSGAKVKKPCASVKVSCKASGYTFT WVRQAPGCjLEWMG Y g O K lf^ R V T Ilg c g sA S T A Y M E L S S L R S E D T A V Y Y C A R  W GQG TLV TV SS S
GN9 0 1 v l . l  Q V Q lV E S G G G W Q P G R S L R L S C A A S G F T F S  WVRQAPGKGLEWVA Y A D SVKGRFTISRDNSKNTLYLQM NSLRAEDTAVYYCAR W GQG TLV TV SS 0
R B 4 V1 . 2  Q V Q L * H GA® # lf^ ASV^ SCK0 S4 Y? F T  W v g Q A ^ G L E t f l G  Y f l f o B o C B l f l f t f t  j s T A Y M E ^ B u tB P P frA V Y Y C A R  W G Q G lg v T V S S  1 9
RN9 0 1 V1 . 1  EV Q LV ESG G G LV Q f’G G SL R L SC A A SG FT FS WVRQAPGKGLEWVA IIlB D S V K G R F T IS R D H X K t||[flL Q tf |S L R A B D T A flY Y C A R  W GQGTTVTVSS 6
•VL (upp«r panel) and VH (lower panel) framework sequences for 12 published CDR-grafted antibodies aligned with CDR-grafted anti-B4 antibody GB4v2.J, 
CDR-grafted N901 G N 901v/./, resurfaced anti-B4 RB4v7.2, and resurfaced N901 R N 901v/./. Surface accessible residues as determined by Pedersen et al. 
(1994) are shaded. A reverse shaded box indicates a framework position where a murine residue was introduced in the human framework to improve binding 
affinity. References for published CDR-grafted sequences: 1. Co el al. (1992); 2. Queen et al. (1989); 3. Carter et al. (1992); 4. Woodle et al. (1992); 5. 
Gorman et al. (1991); 6. Hakimi et al. (1993): 7. Shearman et al. (1991); 8. Tempest et al. (1991); 9. M aeda et al. (1991); 10. Kettleborough et al. (1991); 
11. Presta et al. (1993); 12. Kolbinger el al. (1993).
Discussion
The goal for the humanization by CDR grafting of murine 
monoclonal antibodies N901 and anti-B4 was to generate 
human IgG| antibodies that would retain the full binding 
affinity and specificity of the parent murine antibodies using 
a minimal number of murine amino acid residues in the Fv 
framework sequences to reduce the probability of an immune 
response in man. For both antibodies this goal was achieved 
by selecting the most identical human VH and VL sequences 
without regard to clonal origin. For N901, we paired the VL 
from KV2F and VH from G36005 and for anti-B4, the VL 
from POP and VH from 21/28. The human frameworks selected 
for N901 had identity to the murine sequences to such a degree 
(VL 84% and VH 86% ) that the goal of maintaining full 
affinity in the CDR-grafted antibody could be achieved by 
simply transferring the CDRs from the murine N901 to the 
human Fv framework. No further changes in the Fv framework 
were necessary. The successful CDR-grafting of anti-B4 
required, as observed for most other published humanized 
antibodies (reviewed in Adair, 1992), the substitution of critical 
murine residues into the human framework in order to maintain 
the parental binding affinity. The most identical human 
sequences to anti-B4 showed a 73% and 77% identity across 
the VL and VH sequences, respectively. Two versions of CDR-
grafted anti-B4 were generated which retained the full binding 
affinity of the murine antibody, with GB4v2.5 having a total 
of 12 murine framework substitutions.
Humanization of murine monoclonal antibodies through 
variable domain resurfacing is based on the premise that the 
human anti-murine antibody (HAMA) response to the variable 
region is directed to surface residues only. This assumption 
has not been tested yet for immunoglobulins but is generally 
accepted for the immunogenicity of proteins (Tainer et al., 
1984; Westhof et al., 1984; Novotny et al., 1986; Thornton 
et al., 1986; reviewed in Benjamin et al., 1984). We and others 
(Hurle and Gross, 1994) have speculated that few framework 
surface residues are involved in maintaining CDR conforma­
tions or interact directly with antigen. Therefore few, if any, 
potentially immunogenic murine Fv surface residues will need 
to be retained in a resurfaced antibody to maintain the parental 
binding affinity. The original resurfaced versions of the N901 
(RN901 v/.O) and anti-B4 (RB4v7.0) antibodies (Pedersen 
et al., 1994; Roguska et al., 1994) retained one and three 
murine Fv surface residues, respectively. The residues at these 
positions were considered, from computer models, to be 
candidates for CDR interactions. Experiments were performed 
in which the murine surface residues were systematically 
replaced by the human residues. The single murine surface
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residue in N901 could be replaced without affecting the 
binding affinity, thereby creating a resurfaced N901 Fv with 
a completely human framework surface. For anti-B4, fully 
humanizing the surface resulted in a lower binding affinity 
relative to the murine antibody. However, full binding could 
be restored by the reintroduction of a single murine residue. 
Interestingly, with respect to affinity, it was irrelevant which 
of the three sequence positions was occupied by a murine 
residue. We propose that in such instances selection should be 
made according to the residue preference for the human 
antibodies listed in the Kabat database. Of the constructions 
made, RB4v7.2 had a surface pattern most closely resembling 
that of the human antibody. These results lend support to the 
notion that few Fv surface residues are important for main­
taining binding affinity.
In seeking further supportive evidence for this idea, we also 
analyzed the sequence positions of murine residues that were 
retained for the purpose of maintaining binding affinity in Fv 
sequences of published CDR-grafted antibodies. Table III lists 
twelve published examples of VH and VL framework sequences 
of CDR-grafted antibodies known to us, together with the 
resurfaced and CDR-grafted anti-B4 and N901 sequences. The 
surface residue positions and the murine amino acid residues 
are highlighted. While the published framework sequences of 
CDR-grafted antibodies contain between 0 and 22 murine 
residues (Table m), five Fv sequences contain no murine 
residues on the surface and four sequences have only one 
murine surface residue. This analysis suggests again that 
few surface residues contribute to binding and indicates that 
humanization by variable domain resurfacing has a high 
probability of maintaining the original affinity of the murine 
antibody.
Variable domain resurfacing maintains the core murine 
residues of the Fv sequences, and it could be argued that these 
foreign sequences, despite being internal, could elicit an 
immune response. As noted above, CDR-grafted antibodies 
also generally contain some murine framework amino acid 
residues and rather few are located at surface positions. Indeed, 
in the framework sequences of the CDR-grafted antibodies 
listed in Table m , between 0 and 16 murine residues are part 
of the Fv core. The two resurfaced antibodies shown here, 
RB4v7.2 and RN901 v7.7, have 36 and 22 murine core residues, 
respectively. While these numbers are about two- to three-fold 
larger than for CDR-grafted antibodies, this difference may not 
be significant for the human immune system (see discussion, 
Pedersen et al., 1994). Furthermore, considering that eight of 
the 12 published CDR-grafted sequences listed in Table III 
did not maintain the full binding of their parent antibodies, 
the number of murine residues quoted for these CDR-grafted 
versions would be expected to increase with additional attempts 
at improving affinity, thereby further diminishing the differ­
ences between CDR-grafted and resurfaced antibodies.
CDR-grafted and resurfaced versions of N901 were gener­
ated (GN901v7.7 and RN901v7.7) that had no murine residues 
at surface framework positions. Because the CDR-grafted 
version contains no murine core framework residues as well, 
a conservative approach would be to choose this antibody over 
the resurfaced version for a therapeutic application. For anti- 
64, however, the CDR-grafted and resurfaced versions differed 
in the degree to which their surfaces could be humanized with 
retention of full binding affinity. The best CDR-grafted version, 
GB4v2.J, required three murine residues at surface positions 
to maintain binding, while the best resurfaced versions needed
Variable domain resurfacing and CDR-grafting comparisons
only one surface murine residue. Thus, even though the 
resurfaced version of anti-B4 RB4v7.2 has 36 murine residues 
in the Fv core, it is conceivable that it would be less 
immunogenic than the CDR-grafted version with nine murine 
residues in the Fv core because it has a pattern of surface 
residues that is more identical to a human surface pattern. This 
argument ignores, of course, the possibiltiy of immunogenic T- 
cell epitopes, the importance of which in antibody immuno- 
genicity is unknown. While this hypothesis can only be proven 
by clinical trials, this analysis would predict that similarly low 
immunogenicity might be expected for Fv resurfaced antibodies 
as has been observed for CDR-grafted antibodies (see unpub­
lished proceedings of the Fifth Annual IBC Conference on 
Antibody Engineering, 7-9 December, 1994, San Diego, USA, 
and the unpublished proceedings of the Tenth International 
Conference on Monoclonal Antibody Immunoconjugates for  
Cancer, 9-11 March, 1995, San Diego, USA; Anasetti et al., 
1994; Caron et al., 1994).
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The two reshaping methods described represent two different strategies to solve 
the same problem. Essentially a resurfaced antibody is murine with human surface 
residues while a CDR grafted antibody is human with a murine combining site.
The methods have both been successful in generating reshaped antibodies 
which bind antigen with the same affinity as the original antibody. The resurfac­
ing method is less prone to affinity loss since the initial murine framework-CDR 
combination is retained. However the immunogenicity of the antibodies is not yet 
known.
These data may also indicate why some murine antibody subgroups are more 
immunogenic than others. Within some subgroups few mutations (2-3 residues) 
are required to generate a human surface and within others there is a more distant 
relation between the V^/V# surfaces (8 - 1 0  residues).
5.10 The TCR Epitope Problem
One problem which antibody resurfacing does not address is the removal of TCR 
epitopes, that is the processed peptides presented to T cells by MHC, from the 
antibody sequences. There are a very large number of possible peptide sequences 
and mouse antibody sequences are likely to have unique epitopes which will mark 
them as foreign proteins.
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5.10.1 An Approach to TCR Epitope Removal
The body is tolerant to all the antibodies it produces. Many of these antibodies 
are similar in sequence to mouse antibodies. However any differences will result 
in foreign peptides which could act as antigenic peptides, which when associated 
with MHC would activate the T Cell response. To limit this response modifica­
tions could be made to the mouse antibody to make it contain only linear combina­
tions of residues which also occur in human sequences, thus removing the foreign 
peptides. It is still necessary to retain binding and reduce B cell immunogenicity 
as well.
For a resurfacing approach the two aims would be to maintain the human sur­
face residues, and to substitute the fewest possible residues to remove peptide 
epitopes, so that the mouse core structure and CDR loop topology were main­
tained.
Each chain in an antibody Fy domain is over 100 residues in length. The 
length of an antigenic peptide is 10-15 residues for an MHC class II restricted T 
cell. The number of possible combinations of residues is therefore very large, and 
searching through all the possible combinations would not be practical. However 
a Monte Carlo/Metropolis method would be able to sample some of the sequence 
phase space. In such an approach individual random changes would be made 
to the sequence. After each change, a score would be generated, which would 
include terms for similarity to the mouse sequence and number of peptides which 
matched human fragments. If the score was improved after a particular change
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it would be retained. If the score was worse, the change could still be retained. 
The probability of retaining a worse score would depend on a temperature factor. 
A fixed number of steps would be performed at each temperature, after which 
it would be reduced. The whole process would then be repeated at a series of 
decreasing temperatures. In theory, the high temperature steps would allow the 
exploration of a large amount of sequence space, and the gradual reduction in 
temperature would trap the sequence at a maximum score.
A program has been written which attempts to remove T cell epitopes using 
the above ideas. The residues at the surface positions and in the CDRs are fixed. A 
database of human fragments of a specified length at each position is created. The 
number of steps at each temperature, the staring temperature, the final temperature 
and the temperature step size are input. The sequence is scored using the following 
equation:
The equation used to calculate the probability of retaining a worse score is:
E  = NMatchFrag +  (I dent Score x LenFrag) (5.1)
P(E) — exp(dE/Temp) (5.2)
The residue patterns required for binding to some MHC class I molecules 
are known [23]. However the MHC class II molecules do not have the same 
restrictive binding pockets as the MHC class I molecules. Molecular dynamics
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has been used to attempt to predict potential T cell epitopes [196]. If it is reliable 
this information could be used to reduce the number of peptide sequences which 
need to be examined. Work on this project is ongoing.
Chapter 6
General Discussion
6.1 Reasons for Modelling TCRs
The sequences of proteins are more easily and more rapidly determinable (using 
the techniques of molecular biology) than are their structures (using X-ray crys­
tallography). In the case of TCRs the first sequence was elucidated in 1984. Since 
that time many hundreds of different TCR sequences have been determined. How­
ever it is only in the last two years that the structure of a TCR was first solved. 
Many groups around the world had been trying to accomplish this, but the TCR 
proved difficult to solubilise and crystallise. The initial structure determined was 
only of a /3 chain [3], which had to be mutated to remove oligosacharide binding 
sites. Later an a  chain dimer and very recently a TCR/MHC complex have been 
solved.
Although modelling is never completely accurate, the immunoglobulin super­
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family is probably one of the most amenable to it. The large number of sequences 
and the increasing number of structures of antibodies and other immunoglobulins 
such as CD4 and CD8 , provides a useful database of information to start mod­
elling other members of the family with reasonable accuracy. Techniques already 
exist, and modelling has been used successfully to predict mutations in humani­
sation, and in other antibody modification experiments.
6.2 TCR Modelling
In Chapter 2, both TCR a  and chains were shown to be more similar to k 
light chains than to antibody heavy chains. In Chapter 4 the similarities found 
between the predicted models and the X-ray structures showed that the use of a 
light chain dimer framework was reasonable. The models also correlated well 
with the two structures in the existence of a cavity between the two CDR3 regions 
of the TCR. This was shown to be involved in peptide binding in the structure of 
the TCR MHC peptide complex. However CDR a.2 was poorly modelled. The 
conformation of the region is unique to this TCR chain type. It is therefore not 
surprising that it was inaccurately modelled. However it was encouraging that 
the sequence analyses through the sequence similarity and environment scores, as 
well as the CD4 modelling study, indicated that the region would be difficult to 
model.
The orientation of the TCR in the model complex was not correct. With hind­
sight the diagonal orientation shown in both structures so far determined does
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produce a much closer interaction between the TCR and the MHC. No previous 
modelling study on the TCR correctly predicted the orientation.
6.3 Future of TCR Modelling
In the future, modelling studies on TCRs will obviously be able to use a TCR 
framework. Also it is possible that canonical loop conformations will exist for at 
least the CDR1 and CDR2 loops of both TCR chains. It has been suggested that 
the larger overall variability between TCR sequences will mean that the canonical 
classes will probably be restricted to particular sub families. Canonical classes 
exist for CDR L3 in antibodies. Given the greater light chain character of both 
TCR chain types, it may be that there are canonical classes for both CDR o:3 and 
CDR (33. However more structures will need to be determined before this can be 
known. The greater possibility for variability in this region in TCRs compared to 
antibodies may argue against the existence of canonicals for either CDR3 region.
6.4 Antibody Modelling
The TCR modelling algorithm is based on antibody modelling and, during the 
development of the algorithm, many antibody models were created. It became 
apparent that the CAMAL algorithm did not always produce accurate results. 
Modifications to the algorithm, described in Chapter 3, increased the accuracy 
of modelling. One change which improved accuracy of CDR L1-L3 and H1-H2
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was the use of canonical loops where possible. This produced more consistent 
results than the CAMAL algorithm. CDR H3 is the most variable in structure and 
gave the most variability in accuracy of modelling. Two modifications; firstly in­
clusion of the backbone (including carbon) for the previously modelled loops 
and, secondly, use of broad structure classes for CDR H3 to restrict the choice 
of take-off angle, have improved accuracy for H3. The exclusion of other CDRs 
while modelling each loop was based on evidence that the inclusion of all atoms 
of previously modelled loops could produce a cumulative error. The original an­
tibody used to develop CAMAL, Gloop 2, has a very short CDR3 loop. It may be 
that inclusion of CDRs is not necessary in the case of short loops, but, for mod­
elling longer CDR loops, their presence is required to restrict the conformational 
space available to the loop. The broad classes defined for CDR H3 are only de­
signed to restrict the take-off angle. The conformations of the loops within a class 
are not necessarily similar. It is still not possible to model CDR H3 loops of more 
than 12  residues with any accuracy.
6.5 Humanisation
The resurfacing method for humanising antibodies requires fewer changes to the 
sequence than the CDR grafting. In the two antibodies for which this method has 
been used, N901 and B4, full binding affinity was retained, with the backmutation 
of only 0 and 1 residues respectively required. It seems likely that the chances of 
success will be greater using this method rather than CDR grafting. However it
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still remains to be determined whether resurfaced antibodies will be non immuno­
genic in humans. These studies are being undertaken at present by ImmunoGen 
Inc. (USA).
6.6 Evolutionary Relationships
Immunoglobulins are present in all extant (still surviving) jawed vertebrates but 
are absent from invertebrates. This indicates that they evolved more than 500 
million years ago. The two largest protein groups in the Ig superfamily are the 
TCRs and the antibodies. The evolutionary relationships among these rearranging 
receptors is still uncertain. It has been suggested that the rearranging receptors 
may evolve at a faster rate than other proteins because they have to adapt to match 
the contra-evolving (evolving to try to evade the immune response) bacterial and 
viral antigens. This may make it more difficult to determine relationships between 
them.
The previous chapters contain a presentation of sequence and structural analy­
sis of the TCR and possible structural relationship of the TCR to antibodies. One 
puzzling feature of this work was the discovery that both a  and (I TCR chains 
were more similar to the antibody light chain. It would be interesting as future 
work to try to incorporate this into the scheme of immunoglobulin evolution.
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Appendix A
Programs Used and Written
A.l ALSCRIPT
Produces colour sequence alignment postscript files. It was written by Geoff Bar­
ton (gjb@bioch.ox.ac.uk) and is available from him.
A.2 AMPS
Geoff Barton’s multiple sequence alignment program. It is available from him 
(gjb@bioch.ox.ac.uk).
A.3 AbM
The commercial version of the CAMAL antibody modelling program suite orig­
inally written by Andrew C.R. Martin [6], and modified by Jan Pedersen and the
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author. It is maintained by, and available from, Oxford Molecular Ltd.
AbM has a curses menu interface in which the sequences are entered and mod­
elling options set. The interface program writes a command file for the builder 
program. This program does some of the processing steps itself, while others are 
performed by separate programs, which are run by the builder. These programs 
are:-
• FRAMEBUILD. Builds the framework regions.
• CHOTH. Models the canonical loops and replaces the CDR H3 loop with 
one from the same H3 takeoff angle class.
• CONGEN. Generates loop conformations and adds sidechains to the CDR 
residues.
• EUREKA. Perform the energy screen of the generated loop conformations.
A.4 TCRM
A version of AbM modified by the author for use in some of the modelling de­
scribed in this thesis. This had greater flexibility than AbM in areas such as loop 
range definition, choice of framework and selection of modelling method. Many 
of the flexibility enhancements in TCRM have since been added to AbM.
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A.5 INSIGHT
A commercial molecular display program published by Biosym Ltd.
A.6 DISCOVER
A commercial molecular dynamics/minimisation program published by Biosym 
Ltd.
A.7 MASE
A multiple alignment sequence editor written by Don Faulkner. The program is 
available from mbcrr.harvard.edu. This program has been modified by the author 
to allow NBRF format file reading and writing, and some bugs have been fixed.
A.8 MULFIT
This is a multiple structure fitting program written by Jan Pedersen (jan@iris8.carb.nist.gov).
A.9 McSIDE
A protein structural analysis and sidechain generation program (using Monte Carlo 
techniques) written by Jan Pedersen which also includes code for producing postscript 
ball and stick plots.
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A.10 MOLSCRIPT
This program written by Per Kraulis produces protein schematic pictures. It is 
available from him (pjk@ciclid.csb.ki.se). Modifications were made by the author 
to molscript (vl.4) to allow individual secondary structure elements to have more 
than one colour, with the colour being specified by the atom colour of the Ca atom 
of each residue.
A.11 RASTER3D and IMAGEMAGICK
These programs were used to create and display rendered versions of the MOLSCRIPT 
plots. RASTER3D was originally written by David J. Bacon and Wayne F. An­
derson with modifications by Mark Israel, Stephen Samuel, Michael Murphy, 
Albert Berghuis and Ethan A Merritt (merritt@u.washington.edu). It is avail­
able from ftp.bmsc.washington.edu. IMAGEMAGICK is written by John Cristy 
(cristy@dupont.com) and available as:
ftp://ftp.x.org/contrib/applications/ImageMagick/ImageMagick-3.6.1 .tar.gz.
A.12 GRASP
GRASP generates pictures of molecular surfaces. It is available from Anthony 
Nicholls (grasp @ cumbih .bioc .columbia.edu).
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A.13 MOL
MOL is a program written by the author of this thesis to analyse sequence struc­
ture, and structure structure relationships in proteins. It includes code to perform:
• Environmental analysis.
•  Kabat fixlen format reading. The program performs the following checks 
on the data:
-  Format of references.
-  Inserted residues are in correct place and have valid three letter code.
-  Line lengths are correct for SEQTPA entries.
-  Looks for missing AAIN (inserted residue) entries by scanning the 
comments for certain phrases.
• Kabat database search for strings. This can be used to pull out the various 
domains e.g. T cell receptor beta chain V regions, or to do more specific 
searches of the Kabat database.
• Protein energy calculations (using vff potential).
• Protein accessibility calculations.
• Alignment of two protein sequence groups.
• Theoretical Removal of TCR Epitopes.
• Basic molecular display .
• Atom selection.
• Structure RMS calculations.
• Structural fitting of proteins.
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A.14 SR(QUALIS)
SR (which has also been called QUALIS in publications) is a sequence analysis 
program written by the author of this thesis to overcome some of the problems 
experienced with the available sequence analysis programs:
• It uses dynamic memory allocation to allow handling of the large numbers 
of sequences that immunoglobulin sequence analysis entails.
• It allows multiple chains from a single clone to be associated with one an­
other, which enables the analysis of a  / 0 chain pairs.
• Sequence searches, alignments, translations and variability, frequency and 
homology calculations can all be performed in a single program.
• Command files allow a degree of automation of repetitive tasks. Searches 
on properties such as specific sequence patterns, title, journal etc. can be 
performed to create subsets. A prosite pattern search routine can identify 
sequence motifs in the sequences.
The program can read NBRF, PIR, GCG, EMBL, Kabat FixLen and AMPS 
block file formats. It can write AMPS input, NBRF and PIR formats.
Sequence patterns, specified in the prosite format are used to search for spe­
cific sequences. Files containing prosite motifs can also be read. Sets of sequences 
can be scanned against these motif databases to identify any motifs they contain.
Sequence pairs can be identified in SR. The program compares clone name 
entries and creates links between entries with matching names. New comments
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are added to the entries indicating the entry ID of the paired sequence, and the 
pair can be written out in a modified NBRF format in which multiple sequences 
may be specified for each entry.
If the sequence data originated from the Kabat database and contains residues 
which do not fit in the standard alignment, SR can expand the alignment to in­
clude all the inserted residues by determining the maximum number of inserted 
residues at each position and then adding gaps to maintain alignment of the other 
sequences.
The DNA translation function reads GCG format translation table. If the se­
quences were read from a GCG or EMBL format file, features from the entries 
in the file can be used to identify the regions to translate. If a CDS feature exists 
for an entry, this feature is selected by default for translation. If no features ex­
ist for an entry or if the user prefers, s/he can specify the regions to translate as 
sequence positions. A logfile is maintained indicating which features or ranges 
were translated for each sequence in the list.
A.15 Conversion Utilities 
A.15.1 RENAT and RENUMPDB
These were used to renumber PDB files. RENAT was written by the author and 
RENUMPDB by Jan T. Pederson.
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A.15.2 TOUDB
This program was used to renumber the final model PDB file from AbM or TCRM 
to the standardised numbering scheme used in those programs. It was written by 
the author.
A.15.3 RDDUMP
This was used to convert from Kabat dump format to NBRF sequence format. It 
was written by the author.
A.15.4 READSEQ
This was used to convert between various sequence formats. This program was 
written by D. G. Gilbert (gilbert@bio.indiana.edu) and is available from ftp.bio.indiana.edu.
A.16 CHOTH Canonical Definition File Format
An example of a Canonical Definition File is shown in figure A. 1. Comment lines 
begin with a #. The first non comment line identifies which loop the classes refer 
to. This has the keyword LOOP followed by the loop identifier. Following this 
line are multi-line records, one for each class. Each record begins with a line 
starting with the keyword CLASS and end with a line starting with the keyword 
ENDCLASS. Each class contains the following fields:
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LENGTH <int> The length of the loop in the range defined by the RANGE 
field.
RANGE 2x <int> The range of residues to calculate length over.
POS <int> The position in the sequence to start pattern matching.
PAT <string> The prosite pattern to match.
FRAME 4x <int> The two framework regions to use for fitting
NTER <int> The residue number of the residue before the first residue to
replace
CTER <int> The residue number of the residue after the last residue to
replace
CHAIN <char> The chain identifier for the chain containing the loop
A.17 Machines used
Most of the programs were run on either Silicon Graphics Personal Irises and Indi­
gos under Irix 3.3,4.05 and 5.2, or on Hewlett Packard 720 and 735 workstations 
under HPUX 9. Some of the later work was done on a Pentium Pro PC under 
Linux.
A.18 Thesis Preparation
The thesis was written in MIeX 2e. Many of the schematic diagrams were created 
in CorelDraw! v4 and v7 and Visio 4.0. The colour molecule figures were created 
as screen dumps on an SG. All figures were included as encapsulated Postscript 
files. Dvips was used to convert to a single final Postscript file, which was printed 
using a Hewlett Packard 5M Postscript laser printer, except the colour pages which 
were printed on a Tektronix Phaser 340 (my thanks go to David Osguthorpe for 
allowing me to use this) and an Epson Colour 800. The humanisation paper was 
scanned in using a Microtek E6 page scanner.
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#end of L3 classes (3)
Figure A.l: The canonical definition file used for the CDR L3 loop of antibodies.
Appendix B
Data on Sequences and Structures
B.l Numbering Schemes
Alignment in Thesis Kabat Heavy Kabat Kappa Kabat Lambda Kabat Alpha Kabat Beta
1 1 1 1 0 1
2 2 2 2 1 2
3 3 3 3 2 3
4 4 4 4 3 4
5 5 5 5 4 5
6 6 6 6 5 6
7 7 7 7 6 7
8 8 8 8 7 8
9 9 9 9 8 9
10 - 10 10 9 10
11 10 11 11 10 11
12 11 12 12 11 12
13 12 13 13 12 13
14 13 14 14 13 14
15 14 15 15 14 15
16 15 16 16 15 16
17 16 17 17 16 17
18 17 18 18 17 18
217
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Alignment in Thesis Kabat Heavy Kabat Kappa Kabat Lambda Kabat Alpha Kabat Beta
115 D D D D D
116 D D D D D
117 D D D D D
118 D D D D D
119 D D D D D
120 D D D D D
121 D D D D D
122 D D D D D
123 D D D D D
124 D D D D D
125 D D D D D
126 D D D D D
127 D D D D D
128 D D D D D
129 D D D D D
130 D D D D D
131 D D D D D
132 D D D D D
133 D D D D D
134 D D D 102 D
135 D D D 103 105
136 D 96 96 104 106
137 D 97 97 105 107
138 103 98 98 106 108
139 104 99 99 107 109
140 105 100 100 108 110
141 106 101 101 109 111
142 107 102 102 110 112
143 108 103 103 111 113
144 109 104 104 112 114
145 110 105 105 113 115
146 111 106 106 114 116
147 112 107 D 115 116A
148 113 108 D 116 N
149 N 109 D 116A N
150 N N D N N
Table B .l: The table shows the various Kabat numbering schemes and the scheme used in the 
multiple chain type alignment created in this thesis (see figures 2.2 and 2.3). There are some regions 
which are aligned differently in the alignments, and therefore it is not possible to match position 
numbers between them (these occur in the three CDR regions). These are indicated by a D.
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B.2 IUIS Classification of Kabat Entries
This section contains six multipage tables of TCR sequences (tables B.2-B.7). The sequences are 
divided into their official class designations. The tables identify which sequences in the Kabat 
database are in each of the officially designated classes, and which of these sequences were used 
in the analysis. Inconsistencies between the Kabat sequences and those in the official designation 
papers [125,126] are also noted.
Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
AV1S1 008449 ! T T ll’CL In Paper. Complete Complete X01133 ??????
008450 AlO’CL Complete None ?????? ??????
008451 Ts3-3a Complete Complete ?????? ??????
AV1S2 015626P TA31 In Paper. Complete-1 Joining Errors X02928 ??????
008460! NA5&10’CL In Paper. Complete Complete M27352 ??????
008458 TA84’CL Complete Complete ?????? ??????
008459 TA46’CL Complete Complete ?????? ??????
AVI S3 008452 5H’CL In Paper. 0 aa/1 nuc diff - Explained Complete None X02833 ??????
008453 X ! 5/10-20D’CL In Paper. Complete-1 Complete X05733 009096
008457 M14T Val sterile’CL Partial None ?????? ??????
AV1S4 008445 X ! MOUSE E l’CL In Paper. Complete Complete 009163
AV1S5 008455 X ! C5’CL In Paper. Complete Complete 009145
AV1S6 008454 X ! C l l ’CL In Paper. 1 aa/1 nuc diff - Un­
explained: M26423 has correct se­
quence
Partial Complete M26423 009168
AV1S7 015643 P MOUSE Val - Ja6.19 (J6.19 
in paper)
In Paper. Complete Joining Errors M38104 ??????
AV1S8 008441X ! No. 8 In Paper. Complete Complete X56701 009130
008444 BVI/5.al’C L (B V l/5.al in In Paper. 0 aa/1 nuc diff - Explained Complete Complete M31647 ??????
008442
paper)
B10-4’CL 0 aa/1 nuc diff Complete Partial ?????? ??????
008443 B615-1’CL 0 aa/3 nuc diff Complete Partial ?????? ??????
AVIS? 008479 ! 14.12’CL Closest to AV1S2 (9 aa/15 nuc diff) Partial Partial ?????? ??????
008480 ! 14.16’CL Closest to AV1S2 (9 aa/15 nuc diff) Partial Partial ?????? ??????
008456 ! BDC2.5’CL Closest to AV1S5 (7 aa/12 nuc diff) Complete None ?????? ??????










Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
AV2S1 008430! TA39’CL In Paper. Complete Complete X02929 ??????
AV2S2 008428 ! Va2.2(pFGB)’CL In Paper. Complete None ??????
AV2S3 008421 ! PL23.1’CL In Paper. Complete-2 Complete M21857 ??????
008422 PL51.1.1’CL Identical to 8421 Complete-2 Complete ?????? ??????
008424 PL127.8’CL Identical to 8421 Complete-2 Complete ?????? ??????
008425 PL172.10’CL Identical to 8421 Complete-2 Complete ?????? ??????
008426 PL183.2’CL Identical to 8421 Complete-2 Complete ?????? ??????
008423 PL83.12’CL Identical to 8421 Complete-2 Complete ?????? ??????
AV2S4 025908 ! P14A.2’CL (P14A.1 in pa­
per (P14A.1 is AVI 8S1))
In Paper. Complete Complete X06771 ??????













019355 L-9.w7’CL Complete-2 Partial ?????? ??????
021435 Tcra V2.1’CL Complete-2 None ?????? ??????
AV2S6 008427 X ! 9C127’CL In Paper. Complete-2 Complete 009226
AV2S7 008429 ! KB5 (Va2-JaA10’CL) In Paper. Complete Complete M60999 ??????
DV2S8 010137<5 MOUSE Vd8’CL (41BNT- In Paper. Partial None ??????
019409 !
117 in paper) 
Va2.4’CL Complete None ?????? ??????
AV2S9 ?????? LD3 In Paper. Complete Complete M34196 ??????
008431X ! 101’CL Complete Complete ?????? 009223
021439 V2.5’CL Complete None ?????? ??????
AV2S? 019411 ! Va2.6’CL Closest to AV2S1 (4 aa/7 nuc) Complete-1 None ?????? ??????
021436 Tcra V2.2’CL Closest to AV2S2 (1 aa/1 nuc diff) Complete None ?????? ??????
008439 M14T Va2 sterile’CL Closest to AV2S4 (2 aa/2 nuc diff). Partial None ?????? ??????
021437 Tcra V2.3’CL
Pseudogene?
Closest to AV2S4 (2 aa/2 nuc diff). Complete-2 None ?????? ??????
021440 Tcra V2.6’CL
Pseudogene?








Family Kabat ID Clone name Comments V region J Region GENB ank/EMBL 
accession number
PairCode
019410! Va2.5’CL Closest to DV2S8 (3 aa/5 nuc diff) Complete None ?????? ??????
021438 ! Tcra V2.4’CL Closest to DV2S8 (3 aa/5 nuc diff). 
Similar to 019357
Complete None ?????? ??????
019357 ! L-9.10’CL Closest to DV2S8 (3 aa/6 nuc diff). 
Similar to 021438 (1 nuc del)
Complete Partial ?????? ??????
019359 ! H-10.B5’CL Closest to DV2S8 (3 aa/7 nuc diff) Complete Partial ?????? ??????
019361 ! H-16.B6’CL Closest to DV2S8 (2 aa/5 nuc diff) Complete Partial ?????? ??????
AV3S1 ?????? A2.2 In Paper. Complete None X02857 ??????
008399 ! pHDS58’CL In Paper. Complete Complete ??????
AV3S2 008401X ! MOUSE C9’CL In Paper. Complete Complete X05734 009154
008404 K1-2’CL Partial Complete ?????? ??????
008405 KL’CL Partial Complete ?????? ??????
008403 K1-3’CL Partial Complete ?????? ??????
AV3S3 008400X ! 8/10-2’CL In Paper. Complete Complete X05732 009138
AV3S4 008406 X ! AF.3.G7’CL In Paper. Complete Complete M16678 009153
AV3S5 008397 X ! AR-5’CL In Paper. Complete Complete M21202 009162
008398 Ts3-8a Complete Complete ?????? ??????
AV3S6 ?????? P2111 In Paper. Complete None M33586 ??????
008402 ! M14T Complete None ?????? ??????
AV3S7 ?????? ! L D l’CL In Paper. (025412 matches name but 
is fragment)
Complete Partial M34194 ??????
AV3S8 ?????? PJF1A In Paper. Complete None M76612 ??????
008407 ! Va3.2’CL Complete-1 None ?????? ??????
AV4S1 008409 ! TA65’CL In Paper. Complete Complete X02932 ??????
008411 50.1 ALPHA’CL 0 aa/1 nuc diff - Explained Complete Complete ?????? ??????
008410 PL214.12’CL 1 aa/2 nuc diff (CT to TC swap) Complete Complete ?????? ??????
AV4S2 015630P MD13 In Paper. Complete Joining Errors X02969 ??????
008414 ! TA28’CL In Paper. Partial Complete X02931 ??????










Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
AV4S3 008419 ! 112-2 GENOMIC’CL In Paper. Complete None X05187? ??????
008578 112-2’CL In Paper. Partial Complete X05187? ??????
?????? AP11.2’CL In Paper. ???????? ???????? ??????
AV4S4 008417 Va4.4’CL In Paper. Complete None M38678 ??????
027522 ! Va4.4-Ja24’CL 0 aa/1 nuc diff Complete Complete ?????? ??????
AV4S5 008486 BDFLAII (BDFLII in pa­
per)
In Paper. Pseudogene Complete Joining Errors X03669 ??????
AV4S6 008420 X ! DA.33.C2’CL In Paper. Complete Complete M l6675 009085
AV4S7 008416X ! BB1.D5’CL In Paper. Complete Complete M16676 009160
DV4S8 010146(5 (52.3 In Paper. Partial Complete X13316 ??????
AV4S9 008412 PJR-25’CL In Paper. Complete Partial M21205 ??????
?????? X ! MT1-14 In Paper. Complete Complete M34198 M34199
AV4S10 008418 ! M14T allele l ’CL (A26 in 
paper)
In Paper. 1 extra aa Complete Complete M22660 ??????
AV4S11 008413 X ! F5’CL In Paper. Many aa/many nuc diff 
- Unexplained: X I4387 has correct 
sequence
Complete Complete X14387 009116
AV4S12 ?????? ! HL228 In Paper. Complete Complete M61133 ??????
AV4S? 008485 ! YLA6’CL Closest to AV4S11 (9 aa/25 nuc diff) Complete None ?????? ??????
008415 ! 8.2’CL Closest to AV4S9 (2 aa/4 nuc diff) Partial Complete ?????? ??????
AV5S1 008446 ! TA72’CL In Paper. Complete Complete X02933 ??????
AV5S2 008484 ! MDA’CL In Paper. Complete Complete X02967 ??????
015627P TA80 In Paper. 2 aa/6 nuc diff - Unex­
plained
Partial Joining Errors X02939 ??????
AV5S3 ?????? MA25 In Paper. ???????? ???????? ??????
AV6S1 008494 ! T A l’CL In Paper. Complete-1 Complete X02934 ??????
DV6S2 025902 ! TCRAV6’CL (AV6 in pa­ In Paper. Complete Complete M94080 ??????
010147(5
per)
Z68’CL In Paper. Partial Partial M37279 ??????
ADV7S1 015628 P TA27 In Paper. Complete Joining Errors X02935 ??????
Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
?????? R16.14 In Paper. ???????? ???????? ??????
?????? V(56.3 In Paper. ???????? ???????? ??????
ADV7S2 ?????? A3 8 In Paper. ???????? ???????? ??????
015637P Va7.2 ( V a l .2 in paper) In Paper. Complete None M38679 ??????
008435 ! TCDa3’CL In Paper. Complete Complete M37597 ??????
?????? R16.8 In Paper. ???????? ???????? ??????
015722P M 23’CL In Paper. 0 aa/1 nuc diff - Explained Complete Joining Errors ??????
010135(5 Y93A’CL In Paper. 0 aa/1 nuc diff - Explained Complete Complete M26447 ??????
010133<5 TCDd2’CL Complete Partial ?????? ??????
008436 VCa3’CL Complete Partial ?????? ??????
DV7S3 015718 P 2B4.Exp In Paper. Complete Joining Errors ??????
DV7S4 015725P Z49 In Paper. Complete Joining Errors M37287 ??????
DV7S5 010132(5 Z53’CL In Paper. Complete Partial M37285 ??????
DV7S6 010134(5 TCD(51 In Paper. Complete Partial M37600 ??????
010136(5 T195/BW In Paper. Complete Complete M26448 ??????
AV8S1 008394 ! TA61’CL In Paper. Partial Complete X02936 ??????
AV8S2 008386 ! P71’CL In Paper. Complete Complete X02970 ??????
015393P BVI/5.a2 In Paper. Complete Joining Errors M31649 ??????
008388 Cw3/1.1A’CL 0 aa/1 nuc diff. 1 extra aa Complete Complete ?????? ??????
AV8S3 008381 F3.4’CL In Paper. Complete None X06306 ??????
008379 3F9-ALPHA7 ’ CL (3F9 in In Paper. 0 aa/1 nuc diff. - Ex­ Complete Complete M l5063 ??????
008380 !
paper)
M14T allele 2 ’CL
plained. 1 extra aa 
1 extra aa Complete Complete ?????? ??????
008393 X LB2’CL 1 aa/1 nuc diff (at N terminus) Partial Complete ?????? 009156
AV8S4 008390 ! Va8.4’CL In Paper Complete None M38680 ??????
AV8S5 008383 F3.2’CL In Paper. Complete None X04332 ??????
008382 X ! 5/10-20K’CL Complete Complete ?????? 009150
AV8S6 008387 ! F3.3’CL In Paper. Complete None X06305 ??????
AV8S7 008389 ! F3.5’CL In Paper. Complete None X06307 ??????









Family Kabat ID Clone name Comments V region J Region GENB ank/EMBL 
accession number
PairCode
021351 X ! N15’CL Complete Complete ?????? 021353
AV8S9 008385 X ! ZZ38’CL In Paper. Complete Complete M l6677 009120
AV8S10 ?????? ! p l l4 In Paper. Pseudogene Complete None X17181 ??????
AV8S11 ?????? ! pOll In Paper. Pseudogene Complete None X17173 ??????
AV8S12 ?????? ! MT1-33 In Paper. Complete Complete M34206 ??????












AV8S14 ?????? ! P1F12C4 In Paper. Complete Complete M34210 ??????
AV8S15 015672P GHY-ALPHA-2 (HY-A2 
in paper)
In Paper. Complete Joining Errors X60320 ??????
AV8S? 008384 ! F3-20’CL Closest to AV8S5 (1 aa/1 nuc diff) Complete Complete ?????? ??????
024704 ! CAS 20’CL Closest to AV8S5 (2 aa/4 nuc diff) Complete Complete ?????? ??????
008395 ! M14T-6’CL Closest to AV8S8 (1 aa/2 nuc diff) Partial Complete ?????? ??????
008396 M14T-7’CL Closest to AV8S8 (1 aa/2 nuc diff) Partial Complete ?????? ??????
AV9S1 ?????? BM1037 In Paper. ???????? ???????? ??????
AV9S2 008489 ! GH Y- ALPHA-1 ’ CL(HY- 
A1 in paper)
In Paper. Complete Complete X60319 ??????
AV9S? 019366 ! H-12.C4’CL Closest to AV9S2 (2 aa/3 nuc diff) Complete Partial ?????? ??????
AV10S1 008473 ! ValO-Ja26’CL In Paper. Complete Complete M38102 ??????
008475 FN1-18’CL 1 aa/2 nuc diff (At N terminus) Partial Complete ?????? ??????
AV10S2 008472 X ! D 6’CL In Paper. 1 extra aa Complete Complete M20875 009109
AV10S3 008474 X ! 1F8’CL In Paper. 0 aa/2 nuc diff - Un­
explained: M20876 has correct se­
quence. 1 extra aa
Complete Complete M20876 009110
AV10S4 ?????? P022 In Paper. ???????? ???????? ??????
AV10S5 ?????? ! P102 In Paper. Complete None X17176 ??????
AV10S6 ?????? P109s In Paper. Complete None X17178 ??????
019364 ! H-16.B11’CL Complete Partial ?????? ??????








Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
AV10S8 ?????? ! P1D3A6’CL In Paper. (025411 matches name but 
is fragment)
Complete Complete M34212 ??????
AV10S9 ?????? ! 7/6A H l’CL In Paper. (025415 matches name but 
is fragment)
Partial Complete M34216 ??????
AV10S? 019362 ! L-9.2’CL Closest to AV10S1 (10 aa/15 nuc 
diff)









In Paper. 1 extra aa 
1 extra aa 


















AV11S2 008466 ! MOUSE 2B4’CL In Paper. 1 extra aa Complete Complete X02968 ??????
AV11S3 008468 ! Vall-Ja39’C L (V all.3  in 
paper)
In Paper. 1 extra aa Complete Complete M22603 ??????




l l . l ( a ) ’CL ( V a i l . la  in
paper)
dG8’CL















AV11S6 008470 ! l l . l ( d ) ’CL (V a il .Id  in 
paper)
In Paper. 1 extra aa Complete None M73264 ??????
AV11S7 008469 ! 11.3(a)’CL (V a ll.3 a  in 
paper)







Closest to AVI 1S2 (Half is homolo­
gous, half isn’t)
Closest to AVI 1 S3 (1 aa/7 nuc diff) 














AV12S1 008408 ! BDFLAI’CL (BDFLI in 
paper)
In Paper. Complete Complete X03668 ??????










Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode





















































Closest to AV15S1 (4 aa/9 nuc diff) 









AV16S1P 015641P MOUSE 58a-b-BWaB 
(BW.B in paper)
In Paper. Many aa/0 nuc diff - Dif­
ferently translated
Complete Joining Errors X51643 ??????
AV16S2P 025900P AV16.1 In Paper. Many aa/0 nuc diff - Dif­
ferently translated
Complete Joining Errors M94080 ??????
AV16S? 008440 ! CIO’CL Closest to AV16S1P (2 aa/5 nuc 
diff). Functional
Partial Complete ?????? ??????
AV17S1 008492 ! 42H11’CL In Paper. 1 extra aa Complete Complete M16118 ??????




In Paper. 0 aa/1 nuc diff - Explained: 











AV17S3 ?????? BM.B In Paper. ???????? ???????? ??????






Closest to AV17S2 (9 aa/13 nuc diff) 
Closest to AV17S2 (5 aa/8 nuc diff) 













AV18S1 025906 P P14A.1 In Paper. (See also AV2S4) Partial Joining Errors X06773 ??????








Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
AV18S? 008487 ! 17.2’CL (17.A2) Closest to AV18S2 (17 aa/35 nuc 
diff)
Complete Complete ?????? ??????
008488 ! 23.32’CL (23.A1) Closest to AV18S2 (17 aa/35 nuc 
diff)
Complete Complete ?????? ??????
AV19S1 008461 ! VaAlO-JaAlO’CL In Paper. Complete Complete M22604 ??????
008481 9.4’CL 1 aa/1 nuc missing. Partial Partial ?????? ??????
AV20S1 008483 ! Va5T’CL In Paper. Complete None ??????
DV101S1 010150 717.7D’CL (7-17.1 in pa­ In Paper. Complete Complete M23545 ??????
010148
per)
M21 In Paper. Complete Partial X63934 ??????
010149
010151
d7.1 (<57.1 in paper) 
T245/BW
In Paper.
In Paper. 1 aa/1 nuc diff - Un­











Partial Partial ?????? ??????
DV102S1 025905 TCRDV2’CL (DV2 in pa­ In Paper. Complete None M94080 ??????
015721P
per)
M il In Paper. Complete Joining Errors ??????
DV104S1 010130 Z10 In Paper. Complete Partial M32780 ??????
010131 KN12-D1 In Paper. Complete Partial ??????
010129 DN-4’CL Complete Complete ?????? ??????
DV105S1 010143 Z72 In Paper. Partial Partial M37282 ??????
?????? No name In Paper. Complete None M64239 ??????
010140 MOUSE Vd5 
GERMLINE’CL (glV<55 in
In Paper. 0 aa/1 nuc diff - Explained Complete None M23382 ??????
010139
paper)
MOUSE d7.3’CL (gl(57.3 In Paper. 0 aa/1 nuc diff - Explained Complete Complete M23095 ??????
010144
in paper) 
Z35’CL Partial Partial ?????? ??????









Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
010142 Z44’CL 1 aa/1 nuc diff Partial Partial ?????? ??????
Table B.2: The table shows the Kabat entry IDs of members of the officially designated classes for mouse a  and 6 chains [126]. A group of six question 
marks indicates data which is not known or not available. In the Kabat ID column there are also flags indicating whether the sequence has a known pair 
(X), whether it was used in the analysis (!), and if it is defined as a psuedogene in the Kabat database (P). Where sequences did not match the sequences or 
names of members of any of the existing classes, the closest matching class was identified and a temporary class created with a name ending in a question 









Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
AV1S1 008117 ! HAPIO’CL In Paper Complete Complete X04949/M 13722 ??????
008265 HAP60’CL In Paper Partial None M l 3723 ??????
026043 U8’CL 2 aa/6 nuc diff (Nter) Partial Complete ?????? ??????
AV1S2A1N1T 008107 PY14’CL In Paper Complete Complete M l2423 ??????
008110 HAVT18’CL In Paper Complete Complete M27368 ??????
AV1S2A1N2T ?????? V a l.2 In Paper Complete Complete X02592/M 12959 ??????
008255 AA27’CL In Paper Partial Complete M17666 ??????
008109 AB22’CL In Paper Complete Complete M17646 ??????
AV1S2A1N3T ?????? UB oil 4/4 In Paper Complete Complete X63455 ??????
008111 X ! HA1.7’CL Complete Complete ?????? 008921
AV1S2A2T 008108 ! pJM 3Ell’CL In Paper. 1 aa/1 nuc diff - Unex­
plained: M l2959 has correct seq
Complete Complete M l2959 ??????
AV1S2A3T 008112 WADM31F’CL In Paper. Complete None D 13077 ??????
008113 ! AB18’CL In Paper. 1 aa/2 nuc diff - Explained Complete Complete M17647 ??????
AV1S2A4T 015395P ! AP511 In Paper Partial Joining Error M l7665 ??????
AV1S2A5T 008251 ! pHaT’CL (pHoT3 in pa­
per)
In Paper. 10 extra aa Partial Complete K02777 ??????
AV1S3A1T 008118 ! PY14.2’CL In Paper. Complete None X02850 ??????
?????? A87’CL In Paper. Partial Complete J03597 ??????
008256 AT5B1’CL Partial Partial ?????? ??????
008260 AT5B1’CL Partial Complete ?????? ??????
AV1S3A2T 025946 X ! WM (WM-3’CL in paper) In Paper Complete Complete M86361 025948
008231 WADM07B’CL In Paper Complete None D 13070 ??????
008119 AA17’CL In Paper. 12 aa/3 nuc diffs - 11 aa Complete Complete M l7649 ??????
?????? No name
Explained 
In Paper Complete Complete Z26593 ??????
?????? 40 In Paper Partial Complete M87871 ??????
?????? 28 In Paper Partial Complete M87869 ??????
AV1S4A1N1T 008116! RIO’CL In Paper Complete Complete M35617 ??????









Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
AV1S4A1N2T 008258 A E ll ’CL In Paper Partial Complete M17668 ??????
008230 V al.n l’CL In Paper. 1 aa/4 nuc diff - Explained. 
0 aa/2 nuc diff - Unexplained
Complete None L06885 ??????
AV1S5 008114 ! AE24A’CL In Paper Complete Complete M17650 ??????
AVIS? 008247 ! AB17’CL Closest to AV1S2A1N2T (5 aa/8 
nuc diff (1 del res))
Partial Complete ?????? ??????
008253 ! AB28’CL Closest to AV1S2A1N2T (1 aa/1 
nuc diff)
Partial Complete ?????? ??????
AV2S1A1 008244 ! HAVT06’CL In Paper Partial Complete M27369 ??????
?????? AV2S1*01 In Paper ???????? ???????? ??????
AV2S1A2 ?????? ! X 8B3 In Paper Complete Complete M81774 M81773
008144 IGa09’CL In Paper Complete-2 None X58746 ??????
008142 A FllO ’CL In Paper Partial Complete M17652 ??????
008143 AC112’CL In Paper Partial Complete M17653 ??????
008145 AV2S1’CL (AV2S 1*02/03 
in paper)
In Paper Partial None LI 1159 ??????
AV2S1A3T 008242 HAP26’CL In Paper Partial Complete X04940/M 13724 ??????
008243 ! HAP71’CL In Paper Partial Complete X04946/M13725 ??????
?????? A13ct7 In Paper Partial None S60781 ??????
AV2S2A1T 008128 AG llO ’CL In Paper Complete Complete M17655 ??????
008245 AD17’CL In Paper Partial Complete M17669 ??????
008127 AA13’CL In Paper Complete Complete M l7654 ??????
?????? pV.l In Paper Complete None X06193 ??????
008130 ! p24.1’CL In Paper Complete Complete X06192 ??????
AV2S2A2T 008129 ! AC17’CL In Paper Complete Complete M17656 ??????
AV2S3A1T 008131 ! AA25’CL In Paper Complete Complete M17657 ??????
AV2S3A2T 008204 WADM31J’CL In Paper Complete None D 13078 ??????
008290X ! S14.50’CL Partial Complete ?????? 008889
AV2S? 023270X ! XPZIO’CL Closest to AV2S3A2T (3 aa/3 nuc 
diffs)








Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
AV3S1 008152 HAP05’CL In Paper. Complete Complete X04948/M13726 ??????
008151 HAP44’CL In Paper. Complete Complete X04955/M13727 ??????
027015 X ! 18039 D6’CL Complete Complete ?????? 027023
027016 18039 G14’CL Complete Complete ?????? ??????
AV3S? 026048 ! P9’CL Closest to AV3S1 (1 aa/3 nuc diff) Partial Complete ?????? ??????
008207 3.1’CL Closest to AV3S1 (0 aa/2 nuc diff) Complete Complete ?????? ??????
AV4S1 008181 ! HAP08’CL In Paper. Complete Complete X04937/M 13728 ??????
?????? DD1 In Paper. Complete Complete L26451 ??????
?????? AS1 In Paper. Complete Complete L29035 ??????
AV4S2A1T 008176 ! HAVTOl’CL In Paper. Complete Complete M27372 ??????
008175 HAVT27’CL In Paper. Complete Complete M27371 ??????
AV4S2A2T 008177 ! HAVT33’CL In Paper. Complete Complete M27370 ??????
008179 A-55’CL In Paper. Complete Complete M l 8460 ??????
AV4S2A3T 008178 ! Va4.nl’CL In Paper. Complete None L06886 ??????
AV4S? 008377 ! AV4S1’CL Closest to AV4S1 (2 aa/2 nuc diffs) Partial None ?????? ??????
AV5S1 008153 IGRalO’CL In Paper. Complete None X58747 ??????
008246 ! HAP35’CL In Paper. Partial Complete X04953/M13729 ??????
008226 WADM06D’CL In Paper. Complete None D 13069 ??????
AV5S? 023271 ! XPD25’CL Closest to AV5S1 (2 aa/3 nuc diff) Partial Complete ?????? ??????
ADV6S1A1N1 ?????? ! GERM V In Paper. Complete None M21626 ??????
008238 TCRAV06Sl*0rCL In Paper. 14 aa/1 nuc diff - Unex­
plained (G inserted). Doesn’t match 
class (2 real nuc diffs)
Partial None L09757 ??????
ADV6S1A1N2T 009773 DS6’CL 6 In Paper. Complete Complete M21624 ??????
009966 KT06ACL S In Paper. 22 aa/1 nuc diff - Ex­
plained (C inserted)
Partial Complete ??????
AV6S1A2N1 008239 TCRAV06S1*02’CL In Paper. 14 aa/1 nuc diff - Unex­
plained (G inserted)
Partial None L09758 ??????









Family Kabat ID Clone name Comments V region J Region GENB ank/EMBL 
accession number
PairCode
008237 Vaw33.nl (Vaw31n in pa­ In Paper. Complete None L06884 ??????
008240
per)
TCRAV06S1*03’CL In Paper. 14 aa/1 nuc diff - Unex­ Partial None L10122 ??????
008172 HAPOl’CL
plained (G inserted)
In Paper. Many diffs to paper - Ex­
plained (but 027014 has same seq.
Complete Complete M13730 ??????
?????? VA6.2
Why?) 
In Paper. Complete None S51029 ??????
?????? 17A2 In Paper. Partial Complete M87870 ??????
AV6S? 008238 TCRAV06S1*01’CL In class ADV6S1A1N1 in paper 
but doesn’t match it. Closest to 
AV6S1A2N2 but 1 nuc diff
Partial None L09757 ??????
027014X ! 18030 B31’CL Same as 8172! Complete Complete ?????? 027022
AV7S1A1 ?????? No name In Paper. Complete Complete D21847 ??????
?????? P ASa9 In Paper. Complete Joining Error M l2070 ??????
008139 ! XS9’CL In Paper. Complete Complete M16746 ??????
015394P SUP-T1 In Paper. Complete Joining Error X03751 ??????
?????? AV7S 1*01/03/04 In Paper. ???????? ???????? ??????
026155 TcHST2’CL Complete Complete ?????? ??????
AV7S1A2 008138 ! HAP21’CL In Paper. Complete Complete X04939/M13731 ??????
008213 AV7S1’CL (AV7S 1*02/05 In Paper. Partial None L I1161 ??????
026045
in paper) 
US3’CL Partial Complete ?????? ??????
AV7S2 008257 HAP12’CL In Paper. Partial None X04938/M13732 ??????
008134 ! IG R all’CL In Paper. Complete None X58744 ??????
AV7S? 025436 ! CF8’CL Closest to AV7S2 (2 aa/2 nuc diffs) Complete Complete ?????? ??????
AV8S1A1 008146 ! HAP41’CL In Paper. Complete Complete X04954/M13733 ??????
008147 HAP17’CL In Paper. Complete Complete X04950/M13734 ??????










Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
?????? AV8S 1*01/03/04 In Paper. 1 aa/1 nuc diff - Unex­ Partial None LI 1162 ??????
?????? AV8S1*1
plained 
In Paper. ???????? ???????? ??????
008378 AV8S1’CL 1 aa/1 nuc diff Partial None ?????? ??????
AV8S1A2 008150 WADM35ACL In Paper. Complete None D 13079 ??????
?????? AV8S1*02 In Paper. ???????? ???????? ??????
?????? AV8S1*2 In Paper. Complete None M99570 ??????
008149 X ! S14.4’CL In Paper. 1 aa/1 nuc diff - Unex­
plained. Same as AV8S1A1
Complete Complete M97714 008869
023272 ! XPR04’CL 1 aa/1 nuc diff Complete Complete ?????? ??????
AV8S2A1N1T 008164 ! HAP50’CL In Paper. Complete Complete X04956/M 13736 ??????
008165 HAVT24’CL In Paper. Complete Complete M27373 ??????
008167 8.2’CL Complete Complete ?????? ??????
023273 XPZ10-V8S2J11’CL Complete Complete ?????? ??????
AV8S2A1N2T 008166 AG212’CL In Paper. Complete Complete M17658 ??????
AV9S1 008122 ! HAP36’CL In Paper. Complete Complete X04942/M 13737 ??????
?????? P No name In Paper. Partial Joining Error M90479 ??????
023274 XPF10-V9S1J53’CL Complete Complete ?????? ??????
AV10S1A1 008206 ! TCRAV10S2*01’CL In Paper Complete None L09760 ??????
?????? 22DAG In Paper Partial Complete M87868 ??????
AV10S1A2 008211 ! WADM22B In Paper Complete None D 13075 ??????
008205 TCRAV10S2*02’CL In Paper Complete None L09759 ??????
AV10S1A3T 008154 ! HAP58’CL In Paper Complete Complete X04957/M 13738 ??????
AV11S1A1T 008160 HAP02’CL In Paper Complete Complete X04936/M 13739 ??????
008281P HAP28’CL In Paper. Lot missing res within se­ Fragment Partial X04952/M 13740 ??????
008162 HAP29’CL
quence 
In Paper Complete Complete X04941/M 13741 ??????
008161 HAP32’CL In Paper Complete Complete M l 3742 ??????
023269 X ! XPE15’CL 2 extra aa Complete Complete ?????? 023275









Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
AVIIS? 008196 V a ll.n l’CL N terminus looks wrong (3 nuc re- 
peat+4 aa/7 nuc diff)
Complete None ?????? ??????















?????? 64.8P In Paper Partial Complete M87866 ??????
?????? E4 In Paper Complete Complete Z46641 ??????
008123 X ! HBP-MLT’CL Complete Complete ?????? 008988
AV13S1 008200 X ! S26.2’CL In Paper Complete Complete M97722 008904
008197 HAVT15’CL In Paper Complete Complete M27374 ??????
008198X AL62.24’CL Complete Complete ?????? 008959
008199X S25.13’CL Complete Complete ?????? 008891
ADV14S1 025191 <5 DV8-E6’CL (E6 in paper) In Paper Complete Partial Z46644 ??????
008233 HUMAN HAVT20’CL In Paper (see also 8235) Complete Complete M27375 ??????
008235
(HAVT20 in paper) 
HAVT20’CL In Paper (see also 8233). 10 aa/2 nuc 
diffs - Unexplained (Bad alignment 
for 9 aa diffs)
Complete None M27375 ??????
?????? ! 115E15 In Paper Complete Complete Z29614 ??????
AV14S2A1T 025886 ! Val4.2-AL4.rCL In Paper Complete Complete M64355 ??????
008234 14.1’CL (Val4.1 in paper) In Paper. 11 aa/5 nuc diffs - Partially 
explained
Complete Partial X58157 ??????
AV14S2A2N1T 008241 ! WADM20F’CL In Paper Complete None D13074 ??????
AV14S2A2N2T 008236 V al4 .n l’CL (Val4.n in pa­
per)
In Paper. Complete None L06880 ??????
AV14S2A3T ?????? ! No name In Paper Complete Complete M95394 ??????
AV14S? 008124 ! 14.2’CL Closest to ADV14S1 (1 aa/2 nuc 
diff. 8235 has same aa diff)
Partial None ?????? ??????
026052 U39’CL Ambiguous - matches all AV14S2 
classes








Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
AV15S1 ?????? No name In Paper Complete Complete S60795 ??????
008170 HAVT31’CL In Paper Complete Complete M27376 ??????
008249 Pt’CL (AP13 in paper) In Paper. 1 aa/2 nuc diff - Explained Complete Complete X05771 ??????
?????? 2DLE In Paper Partial Complete M90482 ??????
008295 X DE49’CL In Paper Partial Complete Z22965 009066
008171 AL8’CL 2 extra aa Complete Complete ?????? ??????
026746X ! 37’CL Complete Complete ?????? 026751
026747X 43’CL Complete Complete ?????? 026752
AV16S1A1T 008120! AG21’CL In Paper. Complete Complete M17651 ??????
AV16S1A2PT 015396P HAVT32’CL In Paper Complete Joining Errors M27377 ??????
ADV17S1A1T 008157 ! A B l l ’CL In Paper. Complete-1 Complete M l7660 ??????
?????? K15A In Paper. Partial None M22936 ??????
?????? KT05E In Paper. ???????? ???????? ??????
?????? AV17.1a In Paper. Partial None D13071 ??????
008248 V al31.1’CL Also matches ADV17S1A2N1T Partial None ?????? ??????
AV17S1A2N1T 008220X AL61.102’CL In Paper. Complete Complete M97704 008868
008221X ! S14.6’CL Complete Complete ?????? 008890
008248 V al31.1’CL Also matches ADV17S1A1T Partial None ?????? ??????
AV17S1A2N2T ?????? HTA61 In Paper. Complete None X70309 ??????
008232 X RFL3.8’CL In Paper. Complete Complete M77498 008953
AV18S1 008158 ! AB21’CL In Paper Complete-1 Complete M17661 ??????
AV19S1 008156 AC24’CL In Paper Complete-1 Complete M 17662 ??????
008201X ! S30.10’CL In Paper Complete-1 Complete M97724 008954
AV20S1 008180 ! AE212’CL In Paper. 1 extra aa Complete Complete M17663 ??????
AV21S1A1N1 ?????? Vc*21a In Paper ???????? ???????? ??????
008168 AF211’CL In Paper. 3 aa/6 nuc diff - Partially Complete Complete M 17664 ??????
008227 WADM24B’CL
explained 
In Paper. Complete None D13076 ??????
008300X DE5’CL In Paper. Fragment Complete Z23047 009071









Family Kabat ID Clone name Comments V region J Region GENB ank/EMBL 
accession number
PairCode
008169X ! L17Ti’CL In Paper Complete Complete M15565 008839
009774 S KT08ACL In Paper Complete Complete X14548/Y00793 ??????
AV21S1A2PT ?????? Va21c In Paper ???????? ???????? ??????
AV21S? 026046 U64’CL Closest to ADV21S1A1N2 (0 aa/1 
nuc diff)
Partial Complete ?????? ??????
026050 P26’CL Closest to ADV21S1A1N2 (3 aa/6 
nuc diff (1 del nuc causes 3 aa diff)).
Partial Complete ?????? ??????
AV22S1A1N1T 008121 IGRal2’CL In Paper Complete None X58745 ??????
008252 AC9’CL In Paper. 4 aa/7 nuc diffs - Unex­ Partial Complete M 17671 ??????
008223 X ! AL61.270’CL
plained 
In Paper Complete Complete M97706 008878
008224 X S14.107’CL Complete Complete ?????? 008848
AV22S1A1N2T 008229 Va22.nl’CL In Paper Complete None L06881 ??????
026748 NP-7’CL Complete Complete ?????? ??????
AV22S1A2N1T 008228 ! WADM13D’CL In Paper Complete-1 None D 13072 ??????
AV22S1A2N2T 008225 Va22.n2’CL In Paper Complete-1 None L06882 ??????
AV22S? 023337 ! ICHVIO’CL Closest to AV22S1A1N1T (2 aa/3 
nuc diffs)
Complete Complete ?????? ??????
008222 ! L90’CL Closest to AV22S1A1N1T (1 aa/1 
nuc diff)
Complete Complete ?????? ??????
026041 ! TcPUN’CL Closest to AV22S1A1N1T (3 aa/7 
nuc diff). V similar to 008252
Partial Complete ?????? ??????
AV23S1 008133 ! IGRaOl’CL In Paper Complete None X58736 ??????
008259 AD210’CL In Paper Fragment Complete ??????
AV23S? 008132X ! UA-S2’CL Closest to AV23S1 (1 aa/1 nuc diff) Complete Complete ?????? 008829
008214 J33’CL Closest to AV23S1 (1 aa/1 nuc diff) Complete Complete ?????? ??????
027018 LWF A20,C8-1 ’ CL Closest to AV23S1 (1 aa/1 nuc diff) Complete Complete ?????? ??????
008215 K64’CL Closest to AV23S1 (1 aa/2 nuc diff) Complete Complete ?????? ??????
008216 KSR2’CL Closest to AV23S1 (2 aa/3 nuc diff) Complete Complete ?????? ??????








Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
008218 K42’CL Closest to AV23S1 (3 aa/4 nuc diff) Complete Complete ?????? ??????
008219 L97’CL Closest to AV23S1 (3 aa/3 nuc diff) Complete Complete ?????? ??????
AV24S1 008135 IGRa02’CL In Paper Complete None X58737 ??????
008250 
027019 !










AV25S1 008141 ! IGRa03’CL In Paper Complete None X58738 ??????
AV26S1 008137 IGRa04’CL In Paper. 1 aa/1 nuc diff - Un­
explained: X58739 has correct se­
Complete None X58739 ??????
008136 ! 62.119’CL
quence
Complete Complete ?????? ??????
AV27S1 008155 IGRa05’CL In Paper. 1 aa/1 nuc diff - Unex­ Complete None X58740 ??????
?????? ! H’CL
plained
In Paper. 1 aa/1 nuc diff - Unex­
plained (same seq as 8155)
Partial Complete M23431 ??????
AV28S1A1T 008140 ! IGRa06’CL In Paper. Complete-1 None X58767 ??????
AV28S1A2T ?????? ! IGRal5’CL In Paper. Complete Complete X61070 ??????
DV28S1A3T 025190<5 DV7-E2’CL (E2 in paper) In Paper. Complete-1 Partial Z46643 ??????
AV29S1A1T 008209 ! IGRa07’CL In Paper. Complete None X58768 ??????
AV29S1A2T 008210 ! Vaw29.nl’CL (Vaw29.n in In Paper. Complete?? None L06883 ??????
??????
paper) 
No name In Paper ???????? ???????? ??????
AV29S1A3T ?????? ! MT-ALL In Paper. Complete Complete S63879 ??????
?????? E5 In Paper. Complete Partial Z46642 ??????
AV30S1A1T 008203 VA30’CL In Paper. Complete-1 None X68696/S59345 ??????
?????? A152 In Paper. ???????? ???????? ??????
?????? No name In Paper Complete None D16586 ??????
008202 X ! S 14.11’CL In Paper. Complete-1 Complete M97712 008903
?????? 139DRD In Paper. Partial Complete M87865 ??????
024068 A28-761’CL Complete-1 Complete ?????? ??????










Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
AV30S1A3T ?????? ! HTA129 In Paper. Complete None X70305 ??????
AV31S1 ?????? Afo name In Paper Complete None X73521 ??????
008195 ! VA31’CL In Paper. Partial None X68697/S59347 ??????
?????? No name In Paper Complete-2 None X70306 ??????
?????? A32ct7 In Paper. Complete-2 None S60792/D16585 ??????
AV32S1 025885 ! Va30-KT2’CL In Paper. Complete Complete M64350 ??????
008208 VA32’CL In Paper. Complete None X68698/S59349 ??????
008212 WADM15B’CL In Paper. Complete None D13075 ??????
?????? Vaw32 In Paper. Complete None X70307 ??????
?????? NA20 In Paper. Complete Fragment S50881 ??????
DV101S1 009768 HUMAN V d l’CL (K15A In Paper. Complete None M22198 ??????
009771
in paper) 
KT10E In Paper. Complete Complete X14545 ??????
009772 HUMAN GROUP O’CL 
(0-240/47 in paper)
In Paper. 1 aa/1 nuc diff - Un­
explained: M l8414 has correct se­
Complete Complete M18414 ??????
?????? D105
quence 
In Paper. Partial Complete X15021 ??????
009767 Pr81 In Paper. Complete Complete X06557/Y00289 ??????
009769 HUMAN F6C7’CL Complete Complete ?????? 010528
009769 HUMAN IDP2’CL Complete Complete ?????? ??????
DV102S1A1T 009785 TRDV2’CL (ALY67V52 in In Paper. Complete-1 None X I5207 ??????
009781
paper)
LB117’CL (LB 117<51.7 in In Paper. 1 extra aa Complete Complete X13950 ??????
009783
paper)
LB207’CL (LB2075 in pa­ In Paper. 1 extra aa Complete Complete X13952 ??????
009782
per)
LB210’CL (LB210<5 in pa­ In Paper. 1 extra aa Complete Complete X13951 ??????
009784
per)
KT19E’CL In Paper. 1 extra aa Complete Complete X I4546 ??????








Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
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?????? PT11 In Paper. Complete Partial M21784 ??????
009780 KT14E In Paper. 1 extra aa Complete Complete X14547 ??????
?????? No name In Paper. Complete Complete X72501 ??????
009778 G6’CL 1 extra aa Complete Complete ?????? ??????
009779 AB12’CL 1 extra aa Complete Complete ?????? 010527
009964 VTC’CL 1 extra aa Partial Complete ?????? ??????
DV103S1A1T 009775 Vd2’CL (AP11 in paper) In Paper. Complete None M23326 ??????
009776 WM14’CL In Paper. Complete Complete X13954 ??????
009777 KT041 In Paper. Complete Complete X I4544 ??????
?????? HC<54 In Paper. ???????? ???????? M94081 ??????
DV103S1A2T ?????? GLV<53 In Paper. Complete Fragment X15261 ??????
Table B.3: The table shows the Kabat entry IDs of members of the officially designated classes for human a  and 6 chains [125]. A group of six question 
marks indicates data which is not known or not available. In the Kabat ID column there are also flags indicating whether the sequence has a known pair 
(X), whether it was used in the analysis (!), and if it is defined as a psuedogene in the Kabat database (P). Where sequences did not match the sequences or 
names of members of any of the existing classes, the closest matching class was identified and a temporary class created with a name ending in a question 
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accession number
PairCode
BV1S1A1N1 ?????? H18 In Paper Complete None L36092 ??????
008866 HBVT73’CL In Paper Complete Complete M27381 ??????
008860 PL5.2’CL In Paper Complete Complete M13836 ??????
008861 PL5.6’CL In Paper Complete Complete M13837 ??????
008862 PL6.1’CL In Paper Complete Complete M13838 ??????
008863 PL6.4’CL In Paper Complete Complete M13839 ??????
008864 SUP-Tl’CL In Paper Complete Complete M16834 ??????



















BV1S1A1N2T 008865 HBVT96’CL In Paper Complete Complete M27380 ??????
BV1S1A2 008867 ! VB1 VARIANT’CL (308C 
in paper)
In Paper. 1 aa/1 nuc diff - Un­
explained: M27904 has correct se­
quence
Complete None M27904 ??????
BV2S1A1 008887 PUCM4-4 (C-BETA- 
2)’CL
In Paper. Complete Complete M12886 ??????
008886 PL6.21’CL In Paper. Complete Complete M13842 ??????
008885 PL2.13’CL In Paper. Complete Complete M l 3840 ??????
?????? MT1-1G In Paper. Complete None M l 1955 ??????
008898 ph7’CL In Paper. 2 aa/3 nuc diffs - Unex­
plained. Matches BV2S1A3N2T
Partial Complete M l5222 ??????
008888 HT1.9’CL In Paper. Partial None X57603 ??????
?????? BV2.1a In Paper. Complete None D13082 ??????
?????? B16 In Paper. Complete Partial S50221 ??????













BV2S1A2 008893 WBDP25G’CL In Paper. Complete None D13087 ??????








Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
008891X ! S25.13’CL In Paper. Complete Complete M97721 008199
BV2S1A3N1 008896 HT120’CL In Paper. Complete None X57604 ??????
BV2S1A3N2T 008895 ! ph34’CL In Paper. Complete Complete M 14263 ??????
008898 ph7’CL Classed as BV2S1A1 in paper. 
Matches this class
Partial Complete ?????? ??????
BV2S1A3N3T 008897 W B D M llD ’CL In Paper. Complete None D13088 ??????
BV2S1A4T 008894 ! MT1-1 In Paper. 1 aa/2 nuc diff - Unex­
plained (AC to CA swap): M l 1954 
has correct sequence
Complete Complete M l 1954 ??????
BV2S1A5T ?????? ! 4.49 In Paper. Complete Complete X74852 ??????
BV2S2A10 008968 0RBV2S1*2’CL In Paper. Complete None X72718 ??????
??????
(ORBV2S2*l in paper) 
HVB22.1 In Paper. 3 aa/3 nuc diff - Unex­
plained. Matches BV2S2A20
Complete None L05149 ??????
BV2S2A20 008899 ORBV2S2*l’CL In Paper. 1 aa/1 nuc diff - Unex­ Complete None X72717 ??????
??????
(ORBV2S2*2 in paper) 
HVB22.1
plained
Classed as BV2S2A10 in Paper. 
Matches this class
Complete None L05149 ??????
BV2S2A30T 008900 HT22G’CL In Paper. 2 aa/2 nuc diffs - Un­
explained: X57605 has correct se­
quence
Partial None X57605 ??????
BV3S1 ?????? X I 1 In Paper. Complete None L36092 ??????
008920 HT12’CL In Paper. Complete None X57610 ??????
008919 HBVT22’CL In Paper. Complete Complete M27382 ??????
008918 PL4.4’CL In Paper. Complete Complete M13843 ??????
?????? Vb3.1 In Paper. Complete Complete X74846 ??????
008922 DT259’CL In Paper. 2 aa/3 nuc diff - Explained Complete Complete X04929 ??????
009066X DE49’CL In Paper. Fragment Complete Z22967 008295
008921X ! HA1.7’CL In Paper. Complete Complete X63456 008111
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BV4S1A1T ?????? 111E15 In Paper. Complete Complete Z29580 ??????
008901 PL2.14’CL In Paper. Complete Complete M l 3846 ??????
008907 2G2’CL (2G2/3 in paper) In Paper. Partial Complete M13553 ??????
008902 D T llO ’CL In Paper. Complete Complete X04921 ??????
008906 B1-75’CL In Paper. Complete Complete M18461 ??????
008904X ! S26.2’CL In Paper. Complete Complete M97723 008200
?????? X6A In Paper. Complete None L36092 ??????
008903 X S14.11’CL Complete Complete ?????? 008202
027022 X 18030 B31’CL Complete Complete ?????? 027014
027023 X 18030 D6’CL Complete Complete ?????? 027015
009015 102DRF Ambiguous:
BV4S1A2T
Also matches Partial Complete ?????? ??????
BV4S1A2T 009007 ! HBP48’CL In Paper. Partial Complete X04926 ??????
009015 102DRF Ambiguous:
BV4S1A1T
Also matches Partial Complete ?????? ??????
BV4S1A3T 008905 ! PL5.7’CL In Paper. Complete Complete M13847 ??????
BV4S20 ?????? ! H28.1 In Paper. Complete None L05150 ??????
BV5S1A1T ?????? K56 In Paper. Complete None L36092 ??????
008870 HBP51’CL In Paper. Complete Complete X04927 ??????
008871 PL7.16’CL In Paper. Partial Complete M13849 ??????
008994 PL4.16’CL In Paper. Partial Complete M13848 ??????
008868 X ! AL61.102’CL In Paper. Complete Complete M97705 008220
008869 X SI 4.4’CL In Paper. Complete Complete M97715 008149
BV5S1A2T 008872 ! ph24’CL In Paper. Complete Complete M14271 ??????
BV5S2 ?????? A ll In Paper. Complete None L36092 ??????
008877 IGRb09’CL In Paper. Complete None X58802 ??????
008977 ! PL2.5’CL In Paper. Partial Complete M13850 ??????
020388 BV5S2 Partial None ?????? ??????
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008873 12A1’CL In Paper. 3 aa/9 nuc diff - Unex­ Partial Complete M13551 ??????
?????? 12A1’CL
plained
In Paper. 3 aa/9 nuc diff - Unex­ Partial Complete M 14299 ??????
?????? HBP-/32
plained
In Paper. 3 aa/1 nuc diff (1 nuc in­ Partial Complete X01411/K02780 ??????
025948 X ! WM’CL (WM-3 in paper)
sert) - Unexplained 
In Paper. Complete Complete M86362 025946
BV5S3A2T ?????? A27 In Paper. Complete None L36092 ??????
008875 ! HT415.3’CL In Paper. Complete None X57612 ??????
BV5S3A3T 008876 ! IGRb08’CL In Paper. Complete None X55801 ??????
020389 BV5S3’CL Partial None ?????? ??????
BV5S4A1T 008979 ! IGRb06’CL In Paper. Partial None X58803 ??????
BV5S4A2T 008959 X ! AL62.24’CL In Paper. Complete Complete M97709 008198
?????? A14 In Paper. Complete None L36092 ??????
BV5S5P ?????? 9 In Paper. Complete None X61439 ??????
?????? H18 In Paper. Complete None L36092 ??????
020390 BV5S5’CL Partial None ?????? ??????
BV5S6A1T 008879 ! HT415’CL In Paper. Complete None X57615 ??????
BV5S6A2T 008996 ! IGRb07’CL In Paper. Partial None X58804 ??????
BV5S6A3N1T 008882 R1F3’CL In Paper. Partial None S50547 ??????
008883 R2B6-5’CL Partial None ?????? ??????
020391 BV5S6’CL Ambiguous: Also matches 
BV5S6A3N2T
Partial None ?????? ??????
BV5S6A3N2T ?????? X1A In Paper. Complete None L36092 ??????
008878 X ! AL61.270’CL In Paper. Complete Complete M97707 008223
?????? 8.19 In Paper. Complete Complete X74847 ??????
008965 CH35B’CL (No name in In Paper. Complete None M73465 ??????
??????
paper) 
No name In Paper. Complete Complete X68527 ??????
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020391 BV5S6’CL Ambiguous: Also matches 
BV5S6A3N1T
Partial None ?????? ??????
BV5S7P ?????? A14 In Paper. Complete None L36092 ??????
020392 BV5S7’CL (H I39.1 in pa­
per)
In Paper. 2 aa/6 nuc diffs - Un­
explained: L26226 has correct se­
quence
Partial None L26226 ??????
BV5S? 020387 ! BV5S1 Closest to BV5S1A1T (1 aa/1 nuc 
diff)
Partial None ?????? ??????
BV6S1A1N1 008834! HBP50’CL In Paper. Complete Complete X04934 ??????
?????? 12.1 In Paper. ??????? ???????? ??????
?????? 9 In Paper. Complete None X61440 ??????
?????? H18 In Paper. Complete None L36092 ??????
BV6S1A1N2T ?????? 1.26 In Paper. Complete Complete X74843 ??????
BV6S1A2P 008957 6. IB (3.2 in paper) In Paper. Complete Partial M97943 ??????
BV6S1A3T 015402P 4D1 In Paper. 1 extra aa. Partial Joining Error M13550 ??????
008988 X ! HBP-MLT’CL (4D1 in pa­
per)
In paper. 1 extra aa. 0 aa/1 nuc diff 
- Unexplained: M l2883 has correct
Partial Complete M12883 008123
009010 PL4.14’CL
sequence 
In Paper. Partial Complete M13852 ??????
009022 HBP04’CL In Paper. Partial Complete X04922 ??????
BV6S2A1N1T 008851 ATL12-2 (ATL12-2G in In Paper. Complete Complete M l 1953 ??????
008853 !
paper)
HBVT23’CL In Paper. Complete Complete M27383 ??????
009009 PL5.10’CL In Paper. 1 aa/3 nuc diff - Unex­ Partial Complete M13854 ??????
008852 ph5’CL
plained 
In Paper. Complete Complete M l4260 ??????
?????? W/36.3 a In Paper. ??????? ???????? ??????
?????? A14 In Paper. Complete None L36092 ??????
BV6S2A1N2T 008854 HBVTIO’CL In Paper. Complete Complete M27384 ??????


















In Paper. 2 aa/2 nuc diff - Un­



























In Paper. 1 aa/3 nuc diff - Un­































BV6S4A3T 008839 X ! 
008841 
??????



















BV6S4A4T 008842 ! ph22’CL In Paper. Complete Complete M14261 ??????
BV6S4A5N1T 008836 HBVT116’CL In Paper. 1 aa/3 nuc diff - Un­
explained: M27385 has correct se­
quence
Complete Complete M27385 ??????
BV6S4A5N2T ?????? ! 1.40 In Paper. Complete Complete X74844 ??????
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009013 OT-1 (OT-1/2 in paper) In Paper. Partial Complete ??????
008991 HUMAN OT-2’CL (OT- In Paper. Partial None ??????
008990
1/2 in paper)
PCR-l’CL (PCR-1/2 in pa­ In Paper. Partial Complete ??????
??????
per)
H137 In Paper. Complete None L36092 ??????
BV6S5A1N2T 008832 HVBT45’CL (HBVT45 in 
paper)
In Paper. Complete Complete M27387 ??????
BV6S5A2 ?????? ! HVB15 In Paper. Complete None L36190 ??????
024900 Vb6.7b’CL (GL-PA in pa­
per)
In Paper. Partial Complete X61443 ??????
BV6S6A1T 008859 ! HT147’CL In Paper. Complete None X57607 ??????
BV6S6A2T ?????? ! A212 In Paper. Complete None L36092 ??????
?????? V/36.14b In Paper. Partial None L14483 ??????
BV6S7P 015596P TCRB-V6.10 (11 in paper) In Paper. Complete None X61444 ??????
?????? X21B In Paper. Complete None L36092 ??????
BV6S8A1T ?????? V/36.11a In Paper. ???????? ???????? ??????
BV6S8A2T ?????? ! X1A In Paper. Complete None L36092 ??????
?????? V/36.11c In Paper. Partial None L I4432 ??????
BV6S9P ?????? X1A In Paper. Many diffs - Explained Complete None L36092 ??????
?????? V/36.12a In Paper. Many diffs - Explained Partial None M97503 ??????
BV6S? 024348 P TCRBV6Sl*3p’CL Closest to BV6S1A2P (1 aa/1 nuc 
diff)
Complete None ?????? ??????
BV7S1A1N1T 008880 PL4.9’CL In Paper. 1 aa/1 nuc diff - Un­
explained: M l3855 has correct se­
quence
Partial Complete M13855 ??????
BV7S1A1N2T ?????? K56 In Paper. Complete None L36092 ??????
008963 IGRbl9’CL In Paper. Complete None X58813 ??????
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?????? ! N (31.\ In Paper. 1 aa/2 nuc diff - Unex­
plained
Complete Complete X74842 ??????
BV7S2A1N1T 008981 HT267’CL In Paper. Partial None X57618 ??????
009014 PL4.19’CL In Paper. 5 aa/15 nuc diff - Unex­ Partial Complete M13856 ??????
008955 vb7.nl’CL
plained
In Paper. Many diffs - Explained Complete None L06887 ??????
021892 ! BV7S3’CL Ambiguous: Also matches 
BV7S2A1N4T
Complete None ?????? ??????
BV7S2A1N2T 008980 HT267.1’CL In Paper. 0 aa/1 nuc diff - Unex­
plained
Partial None X57616 ??????
BV7S2A1N3T 008958 vb7.n2’CL In Paper. Complete None L06888 ??????
BV7S2A1N4T ?????? G54 In Paper. Complete None L36092 ??????
021892 BV7S3’CL Ambiguous: Also matches 
BV7S1A2N1T
Complete None ?????? ??????
BV7S2A2T 008881 ! IGRbl8’CL In Paper. Complete None X58812 ??????
BV7S3A1T 008825 ! IGRbl7’CL In Paper. Complete None X58811 ??????
BV7S3A2T ?????? X21B In Paper. Complete None L36092 ??????
008982 ! HT267.2’CL In Paper. Complete None X57617 ??????
?????? BV7.3b In Paper. 1 aa/2 nuc diff - Unex­ Complete None D13083 ??????
021891 BV7S2’CL
plained
Complete None ?????? ??????
BV8S1 008822 VB8.1’CL (M18H7.1B7 in In Paper. Complete None X07192 ??????
008820
paper)
YT35’CL In Paper. Complete Complete K01571/X00437 ??????
008989 JM ’CL (4D8 in paper) In Paper. Partial Complete K02885/X01417 ??????
?????? No name In Paper. Partial Complete X01417 ??????
008821 ! phi 1’CL In Paper. Complete Complete M 14265 ??????
?????? H7.1 In Paper. Complete None U03115 ??????
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008816 BM3-2’CL (M3-2 in pa­ In Paper. Complete None K02546 ??????
008815
per)
VB8.2’CL (p8H7.1B5 in In Paper. Complete None X07222 ??????
008993
paper)
HBP41’CL In Paper. Partial None X04925 ??????
008824 PL3.3’CL In Paper. Partial Complete M13858/M16307 ??????
?????? ! X 8B3 In Paper. Complete Complete M81773 M81774















BV8S2A2N2T 008818 HT242’CL In Paper. 1 aa/1 nuc diff - Unex­
plained (same diff as 8817)
Complete None X57720 ??????
BV8S3 008823 ! VB8.3’CL In Paper. Complete None X07223 ??????
?????? H130.1 In Paper. Complete None U03115 ??????
BV8S4P 015399P VB8.4 (pBH9.1R3 in pa­
per)
In Paper. Complete None X07224 ??????
BV8S5P 015400P VB8.5 (M18VB8.5 in pa­ In Paper. Complete None X06936 ??????
??????
per)
No name In Paper. Many diff - Unexplained Partial Partial M l 3576 ??????
?????? G15 In Paper. Complete None L36092 ??????
BV8S? 009038 ! CHIB’CL Closest to BV8S3 (1 aa/1 nuc diff) Partial None ?????? ??????
BV9S1A1T ?????? K56 In Paper. Complete None L36092 ??????
009071X DE5’CL In Paper. Fragment Complete Z23044 008300
008961 HT307’CL In Paper. Complete None X57614 ??????
008960 IGRb20’CL In Paper. Complete None X58814 ??????
008978 ! PL2.6’CL In Paper. 2 aa/2 nuc diff - Unex­ Partial Complete M13859 ??????
021893 BV9S1’CL
plained
Complete None ?????? ??????
BV9S1A2T 008962 ! V b9.nl’CL (Vb9.n in pa­
per)
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BV9S2A1PT 015518P H307.1(HT307.1 in paper) In Paper. Complete None X57608 ??????
?????? VW114 In Paper. 1 aa/1 nuc diff - Explained Complete None M33240 ??????
BV9S2A2PT ?????? X21B In Paper. Complete None L36092 ??????
BV9S? 021894P BV9S2 Closest to BV9S2A2PT (0 aa/1 nuc 
diff)
Complete None ?????? ??????
BV10S1P ?????? C215 In Paper Complete None L36092 ??????
008850 PL3.9 In Paper. 1 aa/1 nuc diff - Unex­ Complete Complete M13860/M16309 ??????
015401P ATL12-1
plained (Could be functional gene) 
In Paper. Many aa/0 nuc diff - 
Translated differently in Kabat
Complete None M l 1956 ??????
BV10S2O ?????? HVB26.1 In Paper Complete None L05151 ??????
BV10S? 008850 PL3.9 Classed as BV10S1P (1 aa/1 nuc diff 
- Unexplained (Could be functional 
gene)
Complete Complete M13860/M16309 ??????















BV11S1A2T ?????? ! 1.3 In Paper. 11 extra aa (may be 
wrong)
Complete Complete X74845 ??????
BV11S20P ?????? HVB36.1 In Paper. Many aa/0 nuc diff - Dif­
ferently translated
Complete None L05152 ??????
BV12S1A1N1 ?????? Allele 1 In Paper. Genbank code not found ???????? ???????? S47256 ??????
BV12S1A1N2 ?????? H7.1 In Paper Complete None U03115 ??????
015403 P ph27 In Paper Complete Joining Errors M14268 ??????
008984 ! HBP54 In Paper. Partial Complete X04935 ??????
020393 BV12S2’CL Partial None ?????? ??????
BV12S1A1N3 008983 PL4.2’CL In Paper. 5 aa/2 nuc diff (in­
sert/delete pair) - Explained.
Partial Complete M13862 ??????
BV12S1A1N4 ?????? Allele 4 In Paper. ???????? ???????? ??????










Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
008938 IGRbl3’CL In Paper. Complete None X58808 ??????
?????? ! GM2.11 In Paper Complete Complete M64352 ??????
BV12S2A2T 020395 ! BV12S4’CL (H18.1 in pa­
per)
In Paper. Partial None L26230 ??????
BV12S2A3T 008956! WB DM 21C’CL In Paper. Complete None D13084 ??????
BV12S3 ?????? G15 In Paper Complete None L36092 ??????
009006 HT96’CL In Paper. Partial None X57609 ??????
?????? No name In Paper ???????? ???????? ??????
027026 ! LWF A20,C8’CL Complete Complete ?????? ??????
BV12S? 020394 ! BV12S3’CL Closest to BV12S3 (2 aa/2 nuc diffs) Partial None ?????? ??????
BV13S1 ?????? X1A In Paper Complete None L36092 ??????
008930! PL4.24’CL In Paper. Complete Complete M13863 ??????













BV13S2A1T ?????? 5-2’CL In Paper. Complete None X61445 ??????
008999 PL5.3’CL In Paper. Partial Complete M l 3864 ??????
?????? HVB15.2 In Paper Partial None L26229 ??????
008953 X ! RFL3.8 (RFL3.8b in pa­ In Paper Complete Complete M77498 008232
??????
per)
X21B In Paper Complete None L36092 ??????
?????? G54 In Paper Complete None L36092 ??????
020512 BV13S2’CL Partial None ?????? ??????





In Paper. Many aa/0 nuc diff - Dif­
ferently Translated
Complete None M31347 ??????
BV13S2A3PT ?????? pMF /34.3 In Paper. ???????? ???????? ??????
BV13S3 ?????? 11 In Paper Complete None X61446 ??????








Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
008952 V/313.n l’CL In Paper Complete None L06890 ??????
?????? ! V/313.3 In Paper Complete Complete X74850 ??????
?????? K56 In Paper Complete None L36092 ??????
020513 BV13S3’CL Partial None ?????? ??????
BV13S4 ?????? ! 4-1 In Paper. Complete None X61447 ??????
?????? A14 In Paper. Complete None L36092 ??????
020514 BV13S4’CL Partial None ?????? ??????
BV13S5 ?????? 9 In Paper. Complete None X61653 ??????
008941 ! IGRbl5’CL In Paper. Complete None X58810 ??????
008951 V bl3.n2’CL In Paper. 1 aa/2 nuc diff - Unex­
plained (GC to CG swap)
Complete None L06891 ??????
?????? H18 In Paper. Complete None L36092 ??????
020515 BV13S5’CL Partial None ?????? ??????
BV13S6A1N1T 008932 ! HT165’CL In Paper. Complete None X57721 ??????
BV13S6A1N2T 008931 IGRbl6’CL In Paper. Complete None X58815 ??????
009001 17A2’CL Ambiguous: Also matches 
BV13S6A2T
Partial Complete ?????? ??????
BV13S6A2T ?????? X1A In Paper. ???????? ???????? L36092 ??????
008934 HT165.2’CL In Paper. Complete None X57606 ??????
008935 ! A 2’CL (A2/3 in paper) In Paper. Complete Complete S60794 ??????
020516 BV13S6’CL Partial None ?????? ??????
009001 17A2’CL Ambiguous: Also matches 
BV13S6A1N2T
Partial Complete ?????? ??????
BV13S6A3T ?????? ! 3.1 In Paper. Complete Complete X74848 ??????
BV13S6A4T 008933 ! V bl3.n3’CL In Paper. Complete None L06892 ??????
BV13S7 ?????? ! A212 In Paper. Complete None L36092 ??????
020517 BV13S7’CL (HI27 in pa­
per)
In Paper. 1 aa/1 nuc diff - Unex­
plained
Partial None L26228 ??????









Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
020518 BV13S8’CL (HI27 in pa­
per)
In Paper. Partial None L26227 ??????
BV13S? 008998 G36’CL Closest to BV13S3 (0 aa/1 nuc diff) Partial Complete ?????? ??????
025888 V bl3.6-B R 5.irC L Closest to BV13S6A2T (3 aa/5 nuc 
diff)
Partial None ?????? ??????
BV14S1 ?????? C21 In Paper. Complete None L36092 ??????
008924 ! ph21’CL In Paper. Complete Complete M l4267 ??????
008925 PL8.1’CL In Paper. Complete Complete M16314/M13865 ??????
008985 HBP55’CL In Paper. Partial Complete X04928 ??????
?????? 8.9 In Paper. Complete-2 Partial M l7200 ??????
008997 67DRF’CL Partial Complete ?????? ??????
009000 40’CL Partial Complete ?????? ??????
009003 212DRD’CL Partial Complete ?????? ??????
















009002 5A2’CL Partial Complete ?????? ??????
BV15S20P ?????? V11B In Paper. Complete None L05153 ??????
?????? HT-9 In Paper. ???????? ???????? ??????
BV16S1A1N1 008826 VB16’ CL (No Name in p a ­ In Paper. Complete None X06154 ??????
008987 !
per)
HBP42’CL In Paper. Partial Complete X04933 ??????
008828 HT370’CL In Paper. Complete None X57723 ??????
?????? H130.1 In Paper. Complete None U03115 ??????
BV16S1A1N2 008827 HT219’CL In Paper. Complete None X57722 ??????
BV17S1A1T ?????? C215 In Paper. Complete None L36092 ??????
008928 ! HBVT02’CL In Paper. Complete Complete M27388 ??????
023276 X XPZIO’CL Ambiguous: Also matches 
BV17S1A3T








Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
BV17S1A2T 008954X ! S30.10’CL In Paper. Complete Complete M97725 008201
BV17S1A3T ?????? ! No name In Paper. 1 aa/1 nuc diff - Unex­
plained
Complete None L19936 ??????
023276 XPZIO’CL Ambiguous: Also matches 
BV17S1A1T
Partial Complete ?????? ??????
BV17S? 024070! B17-438’CL Closest to BV17S1A1T (1 aa/1 nuc 
diff)
Complete Complete ?????? ??????
BV18S1 ?????? A16 In Paper. Complete None L36092 ??????
008847 HBVT56’CL In Paper. Complete Complete M27389 ??????
008845 p29’CL In Paper. Complete Complete M 14270 ??????
008846 p26’CL In Paper. Complete Complete M l5223 ??????
008848 X ! S14.107’CL In Paper. Complete Complete M97711 008224













BV19S20 020520 B V 19S2(0)’CL In Paper. Partial None L26225 ??????
BV20S1A1N1 008946 ! Vb 18(A)’CL (H29 in pa­
per)
In Paper. 1 extra aa Complete None Z13967 ??????
BV20S1A1N2 008947 V b l8(B)’CL In Paper. Complete None ??????
?????? BV20.1a In Paper. Complete None D13086 ??????
?????? BV20S1 In Paper. Complete None L36092 ??????
008949 WBDM30ACL 1 extra aa Complete None ?????? ??????
BV20S1A1N3T 008948 V b20.nl’CL In Paper. Complete None L06893 ??????
BV20S1A2P 015595P 
??????










BV20S1A3T 008950! HUT’CL (HUT102/3 in pa­
per)
In Paper. Complete Complete M13554 ??????
BV21S1 008844! Vb21.1’CL (BV21.1 or 
H I8.1 in paper)
In Paper. Complete None M33233 ??????











Family Kabat ID Clone name Comments V region J Region GENB ank/EMBL 
accession number
PairCode
BV21S2A1N1 ?????? V/?21.4a In Paper. ???????? ???????? ??????
BV21S2A1N2T 008966 ! IGRb02’CL In Paper. Complete None X58797 ??????
BV21S2A2 ?????? H7.1 In Paper. Complete None U03115 ??????
?????? ! IW6 In Paper. Complete Complete X56665 ??????
?????? H7.1 In Paper. 6 aa/8 nuc diff - Explained Complete None M33234 ??????
?????? H12.18 In Paper. Complete None L36092 ??????
008855 Vb21.2’CL 7 aa/9 nuc diff. Could be M33234 
(H7.1)
Complete None ?????? ??????
BV21S2A3T 008843 ! Vb21’CL In Paper. Partial Complete M62377 ??????
BV21S3A1T 008856 ! Vb21.3’CL (BV21.3 in pa­
per)













BV21S3A2N2T ?????? BV21S3 In Paper. Complete None L36092 ??????
?????? ! DD11 In Paper. (009069 is fragment of this 
seq)
Complete Complete Z23042 ??????
BV22S1A1T 008917 ! Vb23’CL In Paper. Complete None M62379 ??????
BV22S1A2N1T ?????? K26 In Paper. Complete None L36092 ??????
008915 IGRb03’CL In Paper. Complete None X58798 ??????
008916 HT2.10’CL In Paper. Complete None X57727 ??????
BV22S1A2N2T ?????? ! No name In Paper. Complete Complete M64351 ??????
BV22S? 024355 ! newmal87pro’CL Closest to BV22S1A2N1T (3 aa/3 
nuc diff)
Complete None ?????? ??????
BV23S1A1T 008914 ! Vb22’CL In Paper. Complete None M62378 ??????
BV23S1A2T ?????? H7.1 In Paper. Complete None U03115 ??????













BV24S1A1T 008910! Vb24’CL In Paper. Complete None M62376 ??????
BV24S1A2T 008908 IGRb05’CL In Paper. Complete None X58800 ??????
Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
008909 HT77’CL In Paper. Complete None X57725 ??????
008967 CH18B’CL (No name in In Paper. Complete None M73464 ??????
023275 X !
paper)
XPE15’CL Partial Complete ?????? 023269
BV24S1A3T ?????? ! H130.1 In Paper. Complete None U03115 ??????
BV25S1A1T 022634 ! BV25S1’CL (HVB30.A in 
paper)
In Paper. 1 aa/1 nuc diff - Un­
explained: L26231 has correct se­
quence
Complete None L26231 ??????
BV25S1A2PT ?????? H130.1 In Paper. Complete None U03115 ??????
BV25S1A3T ?????? ! HsVB25 In Paper. Complete None L26054 ??????
BV26S1P ?????? H130.1 In Paper. Complete None U03115 ??????
BV27S1P ?????? K26 In Paper. Complete None L36092 ??????
BV28S1P ?????? C68 In Paper. Complete None L36092 ??????
BV29S1P ?????? C215 In Paper. Many aa/0 nuc diff - Dif­
ferently translated
Complete None L36092 ??????
BV30S1A1PT ?????? H137 In Paper. ???????? ???????? L36092 ??????
BV30S1A2PT ?????? HVB15 In Paper. ???????? ???????? L36190 ??????
BV31S1P ?????? H137 In Paper. Many aa/0 nuc diff - Dif­
ferently translated
Complete None L36092 ??????
BV32S1P ?????? H18 In Paper. Many aa/0 nuc diff - Dif­
ferently translated
Complete None L36092 ??????
BV33S1P ?????? C68 In Paper. Many aa/0 nuc diff - Dif­
ferently translated
Complete None L36092 ??????
BV34S1P ?????? C21 In Paper. ???????? ???????? L36092 ??????
Table B.4: The table shows the Kabat entry IDs of members of the officially designated classes for human beta chains [125]. A group of six question 
marks indicates data which is not known or not available. In the Kabat ID column there are also flags indicating whether the sequence has a known pair 
(X), whether it was used in the analysis (!), and if it is defined as a psuedogene in the Kabat database (P). Where sequences did not match the sequences or 
names of members of any of the existing classes, the closest matching class was identified and a temporary class created with a name ending in a question 










Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
BV1S1A1 009111 BW14’CL In Paper. Complete Complete M20177 ??????
009084 1.9.2’CL In Paper. Complete Complete X02778 ??????
015688P Vbl-Db2.1-Jb2.4 
(37.2A10 in paper)
In Paper. Complete Joining Errors M22606 ??????
009083 A20.2.15’CL In Paper. Complete Complete M l 1456 ??????
009087 BW5147’CL In Paper. 1 aa/1 nuc diff - Explained 
(Variant 1)
Complete Complete X02779 ??????
009086! V B l l ’CL In Paper. 1 aa/1 nuc diff - Explained 
(Variant 1)
Complete Partial M13676 ??????
009082 86TTCL In Paper. 0 aa/1 nuc diff - Explained 
(Variant 2)
Complete Complete X00438 ??????
009109X D6’CL In Paper. 0 aa/1 nuc diff - Explained 
(Variant 2)
Complete Complete M20877 008472
009110X ! 1F8’CL In Paper. 0 aa/1 nuc diff - Explained 
(Variant 2)
Complete Complete M20878 008474
009085 X ! DA.33.C2’CL Complete Complete ?????? 008420
BV1S1A2 009112 V B la’CL (SWR-1 in pa­
per)
In Paper. Complete None ??????
BV2S1 009159 A R l’CL In Paper. 0 aa/1 nuc diff - Un­
explained: X02780 has correct se­
quence
Complete Complete X02780 ??????
009165 VB6’CL In Paper. Partial Partial M13671 ??????
009161 BDFLBI (BDFL1 in pa­
per)
In Paper. Complete Complete X03670 ??????
009164 MOUSE V b2-D bl.l- 
Jbl.2’CL (18.2A10 in 
paper)
In Paper. Partial Complete M22605 ??????
009162X ! AR-5’CL In Paper. Complete Complete M21203 008397








Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
009163X ! E l ’CL In Paper. 1 aa/2 nuc diff - Explained 
(Variant)
Complete Complete X01642 008445
009160X BB1.D5’CL Complete Complete ?????? 008416
009287 18N.30’CL Partial Complete ?????? ??????
BV3S1A1 009102 3H.25’CL In Paper. Complete Complete M12415 ??????
009099 2B4#71’CL (B.6(2B4) in In Paper. Complete Complete K02548 ??????
009101X
paper)













009286 A4.A1’CL Ambiguous: Also matches 
BV3S1A2
Partial Complete ?????? ??????
BV3S1A2 009104! V3.1a’CL (SWR-3 in pa­ In Paper. Complete None ??????
009286
per?)
A4.A1’CL Ambiguous: Also matches 
BV3S1A1
Partial Complete ?????? ??????
BV4S1 009089 ! TB3’CL In Paper. Complete Complete X02781 ??????
009088 VB9’CL In Paper. Complete Partial M l 3674 ??????
?????? X MT1-14 In Paper. Complete Partial M34199 M34198
?????? 52H10F11’CL In Paper. (009271 is fragment of this Complete Complete M16121 ??????
?????? 42H11”CL
sequence)
In Paper. (009270 is fragment of this Complete Complete M16122 ??????
009090 BB02”CL
sequence) 
In Paper. Complete-1 Complete X54322 ??????
BV5S1 009092 VB5.1’CL In Paper. Complete None M15613 ??????
009093 ! NB3’CL In Paper. Complete Complete M27349 ??????
009091 VB8’CL In Paper. Complete Partial M l 3673 ??????
015695 P LH8-2 In Paper. Complete Joining Errors M21674 ??????
009094 ! TB21’CL In Paper. 1 aa/1 nuc diff - Explained 
(Variant)










Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
025314 9429A -5-l’CL Partial Complete ?????? ??????
025315 9429A-5-22’CL Partial Complete ?????? ??????
025317 9429B-5-1.24’CL Partial Complete ?????? ??????
025318 9429B-5-25’CL Partial Complete ?????? ??????
025319 9429B-5-26’CL Partial Complete ?????? ??????
025320 B 6-5 -l’CL Partial Complete ?????? ??????
025321 B6-5-2’CL Partial Complete ?????? ??????
025322 B6-5-3’CL Partial Complete ?????? ??????
025323 B6-5-4’CL Partial Complete ?????? ??????
025324 B6-5-5’CL Partial Complete ?????? ??????
025325 B6-5-6’CL Partial Complete ?????? ??????
025326 B6-5-7’CL 1 aa/1 nuc diff Partial Complete ?????? ??????
025327 B6-5-8’CL Partial Complete ?????? ??????
025328 B6-5-9’CL Partial Complete ?????? ??????
025329 B6-5-10’CL Partial Complete ?????? ??????
BV5S2A1 009095 VB5.2’CL In Paper. Complete None M15614 ??????
015694P BW12 In Paper. Complete Joining Errors M20136 ??????
009096 X ! 5/10-20D Class BV5S2A2 in paper but 
matches this class
Complete Complete X05737 008453
009097 LH8-1 Class BV5S2A2 in paper but 
matches this class
Complete Complete M21673 ??????
021353X ! N 15’CL Complete Complete ?????? 021351
BV5S2A2 009098 ! NZW22s’CL In Paper. Complete Complete M30881 ??????
009096 X 5/10-20D’CL In Paper. 1 aa/1 nuc diff - Unex­ Complete Complete X05737 008453
009097 LH8-1’CL
plained (see BV5S2A1)
In Paper. 1 aa/1 nuc diff - Unex­
plained (see BV5S2A1)
Complete Complete M21673 ??????
BV5S3P 015691P VB5.3 (V/35.3P in paper) In Paper. Many aa/0 nuc diff - Dif­
ferently translated
Complete None M15615 ??????








Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
009151 V B l’CL In Paper. Complete Partial M 10093 ??????
009152 M 3’CL In Paper. Complete Complete M l2434 ??????
?????? 5.3.18’CL In Paper. (009272 is fragment of this Complete Complete M16120 ??????
009158 p3F9’CL (3F9 in paper)
sequence) 
In Paper. Partial Complete M29841 ??????
009156 X ! LB2’CL In Paper. 1 aa/1 nuc diff - Explained 
(Variant)













BV6S1A2 009157 V6a’CL (SWR-6 in paper) In Paper. Complete None ??????
BV7S1 009149 ! 2CB [pHDS 11]’ CL In Paper. Complete Complete X00696 ??????
009150X
(pH D Sll in paper) 
5/10-20K’CL In Paper. Partial Complete X05735 008382
BV8S1 009144 VB8.1’CL In Paper. Complete None M15616 ??????
009145X ! C5’CL In Paper. Complete Complete X01641 008455
009143 TB12’CL In Paper. Complete Complete X02783 ??????
025910 P H B .l’CL In Paper. Complete Complete X06772 ??????
009226 X 9C127’CL Text says vb8.1 Fragment Complete ?????? 008427















009137 B6.2.16 In Paper. Complete Partial M 19404 ??????
?????? V2.1 In Paper. Partial Fragment M34205 ??????
009139 3A9’CL In Paper. 1 aa/1 nuc diff - Unex­ Complete Complete M26417 ??????
009141 ! N B l’CL
plained (N terminus)
In Paper. 2 aa/2 nuc diff - Explained 
(Variant)
Complete Complete M27350 ??????
009138 X ! 8/10-2’CL Complete Complete ?????? 008400
BV8S2A2 009140! C127’CL In Paper. Complete None ??????










Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
BV8S3 009147 VB8.3’CL In Paper. 1 aa/1 nuc diff - Unex­ Complete None M15618 ??????
009146 TB23’CL
plained 
In Paper. Complete None X02785 ??????
?????? ! 2B11 In Paper. Complete Complete M34219 ??????
009148 MOUSE MDA ’CL Partial Partial ?????? ??????
009223 X MOUSE 101’CL Text says vb8.3 Fragment Complete ?????? 008431
009227 MOUSE 8F8.10’CL Text says vb8.3 Fragment Complete ?????? ??????
BV8S? 023723 ! 38CH Vb8.2’CL Closest to BV8S2A1 (1 aa/1 nuc 
diff)
Complete Complete ?????? ??????
BV9S1 009133 VB2’CL In Paper. Complete None M13677 ??????
027524 ! Vb9-Dbl.l-Jb2.1’CL Complete Complete ?????? ??????
BV10S1A1 ?????? V/J10-8 In Paper. (some uncertain nu­
cleotides)
Complete None X56725 ??????
009130X ! No. 8 In Paper. Complete Complete X56702 008441
009132 VB3’CL In Paper. 1 aa/3 nuc diff - Unex­ Partial Partial M l 3678 ??????
?????? MT1-27
plained (N terminal) 
In Paper. Partial Complete M34201 ??????
009128 Cw3/1.1’CL Complete Complete ?????? ??????
009127 VIOB’CL Complete None ?????? ??????
BV10S1A2 009131 ! VIOA’CL (SWR-1 in pa­ In Paper. Complete None ??????
019735
per)
BUB/BnJ’CL Partial None ?????? ??????
BVIOS? 009129 ! 50.1 BETA’CL Closest to BV10S1A1 (1 aa/4 nuc 
diff)
Complete Complete ?????? ??????
BV11S1 009114 VAK (LVAK in paper) In Paper. Complete None N00046 ??????
009113 VB5’CL In Paper. Complete Partial M l 3670 ??????
009115 ! F3-42 (cF3-42 in paper) In Paper. Complete Complete X04331 ??????
009117 A K l’CL In Paper. 2 aa/3 nuc diff - Unex­
plained








Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
009116 X ! F5’CL In Paper. 1 aa/2 nuc diff - Unex­
plained (CT to TC swap)
Complete Complete X14388 008413
BV12S1T 009122 NZW8’CL In Paper. 2 extra aa Partial Complete M30880 ??????
015689P VB7 (V/37 in paper) In Paper. 1 aa/5 nuc diff Partial Joining Errors M13672 ??????
009120X ! ZZ38’CL 47 extra aa (complete v region) Complete Complete ?????? 008385
BV13S1 009118 ! B V I/5 .b ll’CL In Paper. Complete Complete M31648 ??????
?????? V/310 In Paper. 3 aa/7 nuc diff - Unex­
plained: Pseudogene in M l3675
???????? ???????? M13675 ??????
009119 Vbl2H6 [V bl3]’CL 
(V/312H6 in paper)
In Paper. Complete Complete M25913 ??????
BV14S1 009167 ! VB14-J6.19’CL (VB14GL 
in paper?)
In Paper. Complete Complete X03277 ??????
009166 SJL33’CL In Paper. Complete Partial M11858 ??????
009168X ! C l l ’CL In Paper. 1 aa/1 nuc diff - Explained 
(Variant)
Complete Complete M26418 008454
BV15S1A1 ?????? ! FN1-18 In Paper. Complete Complete X04047 ??????
BV15S1A2 009121 ! SJL73’CL In Paper. Complete Partial ??????
BV16S1A1 009124X ! 4.C3’CL In Paper. Complete Complete X03865 008465
009123X BIO’CL In Paper. Complete Complete X03864 008464
BV16S1A2 009125 ! BDFLBIFCL (BDFLI in 
paper)
In Paper. Complete Partial X03671 ??????
009126 SJL4 In Paper. 1 aa/2 nuc diff - Un­
explained: M l 1860 has correct se­
quence
Complete Partial M l 1860 ??????
BV17S1A1 009105 ! VB17A’CL In Paper. Complete-2 Complete M l6203 ??????
BV17S1A2P 015692P VB17B In Paper. Complete None M22007 ??????
BV17S1A3 009106 ! VB17A2’CL In Paper. Complete-2 None M61184 ??????
BV18S1 009169 ! V b l8’CL In Paper. Complete None X16695 ??????
?????? pMlpr2 In Paper. 4 aa/10 nuc diff - Unex­
plained (N terminal diffs)









Family Kabat ID Clone name Comments V region J Region GENB ank/EMBL 
accession number
PairCode
BV19S1A1 ?????? V /3l9a In Paper. ???????? ???????? ??????
BV19S1A2P 009108 VbN3(Vbl9)’CL (N3 in 
paper)
In Paper. Complete None X16691 ??????
BV20S1 009107 ! VB20’CL (K9 in paper) In Paper. Partial None X59150 ??????
BV21S1P 015696P MOUSE VbNl (N1 in pa­
per)
In Paper. Many aa/0 nuc diff - Dif­
ferently translated
Complete None X16689 ??????
BV22S1P 015697 P MOUSE VbN2 (N2 in pa­
per)
In Paper. Many aa/0 nuc diff - Dif­
ferently translated
Complete None X I6690 ??????
BV23S1P 015698 P MOUSE VbN5 (N5 in pa­
per)
In Paper. Many aa/0 nuc diff - Dif­
ferently translated
Complete None X I6692 ??????
BV24S1P 015699P MOUSE VbN8 (N8 in pa­
per)
In Paper. Complete None X I6693 ??????
BV25S1P 015700 P MOUSE VbN9 (N9 in pa­
per)
In Paper. Partial None X16694 ??????
Table B.5: The table shows the Kabat entry IDs of members of the officially designated classes for mouse (3 chains [126]. A group of six question marks 
indicates data which is not known or not available. In the Kabat ID column there are also flags indicating whether the sequence has a known pair (X), 
whether it was used in the analysis (!), and if it is defined as a psuedogene in the Kabat database (P). Where sequences did not match the sequences or 
names of members of any of the existing classes, the closest matching class was identified and a temporary class created with a name ending in a question 








Family Kabat ID Clone name Comments V region J Region GENB ank/EMBL 
accession number
PairCode
GV1S1P 015409 P Vl.GL’CL (ASH4 in pa­
per)
In Paper. Complete None M l2949 ??????
GV1S2A1T 010516 V2.GL’CL (ASH4 in pa­ In Paper. Complete-2 None M l3429 ??????
015417P
per)
HGP01 In Paper. Many aa/Many nuc diffs - Complete None M27338 ??????
010518 V2-JP1’CL (No name in 
paper)
Unexplained 
In Paper. Complete Complete S72759 ??????
GV1S2A2T 010517 HGT26 In Paper. Complete-1 Partial M27337 ??????
GV1S3A1N1T 010507 HUMAN V3.GUCL In Paper. Complete Partial? M13430 ??????
010508
(ASH4 in paper) 
MOLT-13 (k in paper) In Paper. Complete Partial Y00790 ??????
010506 LSG12’CL(AS7l2 in pa­ In Paper. Complete Partial M13824/X03437 ??????
015416P
per)
HGP03 In Paper. Complete Joining Errors M27336 ??????
010510 V3-Jlrs’CL (V73 in paper) In Paper. 2 extra aa Complete Partial? S72844 ??????
010723 G3 (V73 in paper) In Paper Partial Partial S60175 ??????
010722 E103’CL Partial Partial ?????? ??????
GV1S3A1N2T 010511 PT7 I/2 In Paper. Complete-4 Partial M13231 ??????
010509 V g l . l ’CL (pgV7 l . l  in pa­
per)
In Paper. Complete Partial X04038 ??????
GV1S4A1N1T 010515 V4.R’CL (AS6 in paper) In Paper. Complete None M13584 ??????
GV1S4A1N2T ?????? 601 In Paper. Complete Partial M36285/X13354 ??????
GV1S5 010512 Vg5’CL (B27 in paper) In Paper. Complete None M36286/X13355 ??????
010513 Vg5’CL (V75 in paper) In Paper. 0 aa/2 nuc - Unexplained: 
Y00482 has correct sequence
Complete Complete Y00482 ??????
010514 GC12-GH3’CL (GH3 in 
paper)
In Paper. Complete Complete X15018/Y00814 ??????
GV1S5P 015410P V5.GUCL (ASH7 in pa­
per)










Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
GV1S6P 015411P V6.GL’CL (ASH7 in pa­
per)
In Paper. Many aa/0 nuc diff - Dif­
ferently translated
Complete None M13432 ??????
GY1S7P 015412P V7.GL’CL (ASH7 in pa­
per)
In Paper. Several aa/0 nuc diff - Dif­
ferently translated
Complete None M13433 ??????
















GV2S1A1 010522 HGP02 In Paper. Partial Complete M27335 ??????
010525 Vg9(A6)’CL (AA6 in pa­ In Paper. Partial None X08086 ??????
010526
per)
PBLC1.15 In Paper. Complete Partial M16768 ??????














010528 F6C7’CL Complete Complete ?????? 009769
GV2S1A2 010523 LKG20’CL (AK72O in pa­ In Paper. Partial Complete X03436 ??????
010524
per)





In Paper. 2 aa/0 nuc diff - Explained 













In Paper. Partial Complete M27343 ??????
019510P TRGV10 (V7 IO in paper) In Paper. Many aa/0 nuc diff - Dif­ Complete NA X74774 ??????
026351P HTCRG-V10
ferently translated
Complete NA ?????? ??????
GV4S1P 015424P HUMAN V I1 (AJM15 in In Paper. Complete-5 None X07207 ??????
??????
paper)








Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
019509 P V7 II In Paper. Many aa/0 nuc diff - Dif­
ferently translated
Complete Joining Errors X74775 ??????
GV5S1P 015425P HUMAN VA (AA6 in pa­
per)
In Paper. Complete None X07208 ??????
GV6S1P 015426P HUMAN VB (AJM15 in 
paper)
In Paper. Many aa/0 nuc diff- Dif­
ferently translated
Complete None X07209 ??????
Table B.6: The table shows the Kabat entry IDs of members of the officially designated classes for human 7 chains [125]. A group of six question marks 
indicates data which is not known or not available. In the Kabat ID column there are also flags indicating whether the sequence has a known pair (X), 
whether it was used in the analysis (!), and if it is defined as a psuedogene in the Kabat database (P). Where sequences did not match the sequences or 
names of members of any of the existing classes, the closest matching class was identified and a temporary class created with a name ending in a question 









Family Kabat ID Clone name Comments V region J Region GENB ank/EMBL 
accession number
PairCode
GV1S1 010791 V 3’CL (TC-13 in paper) In Paper. Complete Partial M13337 ??????
?????? FT6 In Paper. Partial None X04396 ??????
?????? pAA42 In Paper. Partial None X62546 ??????
025688 Vg5 B ’CL (gB-V5 in pa­
per)
In Paper. 3 extra aa Complete Partial? Z48592 ??????
GV2S1A1 010792 MOUSE V 4’CL (TC-11 in In Paper. Complete Partial M13338 ??????
??????
paper)
13 In Paper. Only 2 aa in M l3339! Fragment None M13339 ??????
GV2S1A2 025689 Vg6 B ’CL (gB-V6 in pa­
per)
In Paper. Complete None Z48593 ??????
GV3S1A1 010788 MOUSE V 2’CL (TC-17 in In Paper. Complete Partial M13336 ??????
015839P
paper)




















?????? P FT2 In Paper. 1 aa/1 nuc diff - Explained 
(Variant). Pseudogene























GV3S1A3 025691P Vg4 B ’CL (gB-V4 in pa­
per)
In Paper. Complete None Z48591 ??????
GV4S1A1 ?????? BW3.8.1 In Paper. Complete Joining Errors X05501 ??????
025690 Vg7 B ’CL (gB-V7 in pa­
per)
In Paper. Complete None Z48594 ??????
GV4S1A2 ?????? No name In Paper. Complete None M71214 ??????








Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
025684 Vg7 A’CL (gA-V7 in pa­
per)
In Paper. Complete None Z49051 ??????
GV5S1A1 010786 V108B’CL (V10.8B in pa­
per)
In Paper. Complete None M12832 ??????
?????? 14.0 In Paper. 1 aa/3 nuc diff - Explained 
(Variant) (could be GA to AG swap)
Complete Joining Errors M26763 ??????
GV5S1A2 ?????? 14.9 In Paper. Complete None Z22847 ??????
?????? 5/10-1371.2 In Paper. 2 aa/2 nuc diff - Explained 
(Variant)
Complete Complete X03802 ??????
GV5S1A3 010785 TCRG-Vl’CL (V7 I in pa­
per)
In Paper. 3 extra aa Complete None M77017 ??????
GV5S1A4 025685
??????
V gl B’CL (gB-Vl in pa­















In Paper. Complete Complete X00697 ??????
015835P pHDS34 In Paper. Many aa/0 nuc diff - Dif­
ferently translated
Complete Joining Errors K02899 ??????
010782 DFL12 In Paper. Complete Complete K02900 ??????
?????? FT12 In Paper. Complete Joining Errors X04397 ??????
015836P MOUSE 8/10-2 (8/10- 
271.1 in paper)
In Paper. Complete Joining Errors X03801 ??????
010783 TCRG-V2’CL (V72 in pa­
per)
In Paper. Complete None M77018 ??????
?????? 10.4 In Paper. Complete Partial Z22846 ??????
015837P MOUSE 3F9-GAMMA4 
(3F9-74 in paper)










Family Kabat ID Clone name Comments V region J Region GENBank/EMBL 
accession number
PairCode
015838P MOUSE 3F9-GAMMA7 
(3F9-77 in paper)
In Paper. 0 aa/1 nuc diff - Explained 
(Variant)
Complete Joining Errors X03985 ??????
010784 MNG8 In Paper. 1 aa/3 nuc diff - Explained 
(Variant)
Complete Complete ??????
GV5S2A2 025686 Vg2 B ’CL (gB-V2 in pa­ In Paper. Complete None Z48589 ??????
??????
per)
V72 In Paper. ???????? ???????? ??????
GV5S3A1 ?????? 4.5 In Paper. Complete Joining Errors M26764 ??????
010936 V5.7’CL In Paper. Partial None M12833 ??????
GV5S3A2 025687 Vg3 B ’CL (gB-V3 in pa­ In Paper. Complete None Z48590 ??????
??????
per)
V73 In Paper. ???????? ???????? ??????
GV5S? 010787 5/10-12’CL Closest to GV5S1A1 (1 aa/2 nuc 
diff)
Complete Complete ?????? ??????
010973 MNG9’CL Closest to GV5S2A1 (4 aa/13 nuc 
diff)
Partial Complete ?????? ??????
Table B.7: The table shows the Kabat entry IDs of members of the officially designated classes for mouse 7 chains [126]. A group of six question marks 
indicates data which is not known or not available. In the Kabat ID column there are also flags indicating whether the sequence has a known pair (X), 
whether it was used in the analysis (!), and if it is defined as a psuedogene in the Kabat database (P). Where sequences did not match the sequences or 
names of members of any of the existing classes, the closest matching class was identified and a temporary class created with a name ending in a question 
mark. For example if a sequence was similar to GV5S1 the temporary class would be called GV5S?.
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